DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Flaviviridae are 2898

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0001	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	Brazilian strain ZKV2015	NA	Immunoflourescence assay	Decrease (50 %)	Approved	29150641
DrugRepV_0002	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	Brazilian strain ZKV2015	NA	NA	Decrease	Approved	29150641
DrugRepV_0003	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	Brazilian strain ZKV2015	NA	Real-time PCR	Decrease (20 Fold)	Approved	29150641
DrugRepV_0004	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	Brazilian strain ZKV2015	NA	Immunohistochemical assay	Decrease (10 %)	Approved	29150641
DrugRepV_0005	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (100 %)	Approved	29033372
DrugRepV_0006	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (100 %)	Approved	29033372
DrugRepV_0007	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (60 %)	Approved	29033372
DrugRepV_0008	Alverine Citrate	Alimentary Tract and Metabolism	Spasms of the stomach and intestines	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (60 %)	Approved	29033372
DrugRepV_0009	Sertraline Hydrochloride	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Decrease (50 %)	Approved	29033372
DrugRepV_0010	Tamoxifen	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (45 %)	Approved	29033372
DrugRepV_0011	Amiodarone	Cardiovascular agents	Anginal and Arrhythmia	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (45 %)	Approved	29033372
DrugRepV_0012	BHSA	NA	NA	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (45 %)	NA	29033372
DrugRepV_0013	Fluoxetine Hydrochloride	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (40 %)	Approved, Vet approved	29033372
DrugRepV_0014	Anthocyanidin	Plant extract	NA	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (20 %)	NA	29033372
DrugRepV_0015	Chlorogenic Acid	NA	Cancer	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (10 %)	Investigational	29033372
DrugRepV_0016	Tetrandrine	NA	Congestive circulatory disorder and inflammatory diseases	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (0 %)	Experimental	29033372
DrugRepV_0017	Mibefradil	Cardiovascular agents	Angina | High blood pressure	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	No significant effect (0 %)	Investigational, Withdrawn	29033372
DrugRepV_0018	Fluvastatin	Cardiovascular agents	Cardiovascular disease (Coronary heart disease (CHD))	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Increase (110 %)	Approved	29033372
DrugRepV_0019	Delphinidin Chloride	NA	NA	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Increase (110 %)	NA	29033372
DrugRepV_0020	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Increase (120 %)	Approved	29033372
DrugRepV_0021	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	Real-time PCR	Decrease (50 %)	Approved	29033372
DrugRepV_0022	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	Real-time PCR	Decrease (50 %)	Approved	29033372
DrugRepV_0023	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	FSS13025 strain (old Asian lineage)	NA	Real-time PCR	Decrease (50 %)	Approved	29033372
DrugRepV_0024	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	Real-time PCR	Decrease (2 Copies (10(6)/ml))	Approved	29033372
DrugRepV_0025	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	Real-time PCR	Decrease (1 Copies (10(6)/ml))	Approved	29033372
DrugRepV_0026	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	NA	Decrease	Approved	29033372
DrugRepV_0027	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	GZ01, a recent Asian lineage	NA	Immunohistochemical assay	Decrease (85 %)	Approved	29033372
DrugRepV_0046	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (50 %)	Approved	28912011
DrugRepV_0047	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28912011
DrugRepV_0048	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Plaque assay	Decrease (50 %)	Approved	28912011
DrugRepV_0049	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28912011
DrugRepV_0050	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0051	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0052	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0053	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0054	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0055	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0056	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0057	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0058	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0059	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0060	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0061	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0062	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0063	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0064	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0065	Mericitabine	Antiviral	Hepatitis C virus	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Investigational	28912011
DrugRepV_0066	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_0067	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	Approved	28240606
DrugRepV_0075	Bromocriptine	Nervous System	Parkinson disease	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0076	Bromocriptine	Nervous System	Parkinson disease	Zika virus	Puerto Rico strain PRVABC-59	NA	Real-time PCR	Decrease (4 Log viral titer (copies/ml))	Approved	28185815
DrugRepV_0077	Bromocriptine	Nervous System	Parkinson disease	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>99 %)	Approved	28185815
DrugRepV_0078	Intron A	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0079	Intron A	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Zika virus	Puerto Rico strain PRVABC-59	NA	Real-time PCR	Decrease (4 Log viral titer (copies/ml))	Approved	28185815
DrugRepV_0080	Intron A	Antineoplastic and Immunomodulating Agents	Hairy cell leukemia | Malignant melanoma | AIDS-related Kaposi's sarcoma	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>99 %)	Approved	28185815
DrugRepV_0081	Avonex	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0082	Avonex	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Real-time PCR	Decrease (5 Log viral titer (copies/ml))	Approved	28185815
DrugRepV_0083	Avonex	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>99 %)	Approved	28185815
DrugRepV_0084	Rebif	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0085	Rebif	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Real-time PCR	Decrease (>4 Log viral titer (copies/ml))	Approved	28185815
DrugRepV_0086	Rebif	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>99 %)	Approved	28185815
DrugRepV_0087	Betaferon	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28185815
DrugRepV_0088	Betaferon	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Real-time PCR	Decrease (5 Log viral titer (copies/ml))	Approved	28185815
DrugRepV_0089	Betaferon	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>90 %)	Approved	28185815
DrugRepV_0090	Imukin	NA	NA	Zika virus	Puerto Rico strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	28185815
DrugRepV_0091	Imukin	NA	NA	Zika virus	Puerto Rico strain PRVABC-59	NA	Real-time PCR	Decrease (>2 Log viral titer (copies/ml))	Approved, Investigational	28185815
DrugRepV_0092	Imukin	NA	NA	Zika virus	Puerto Rico strain PRVABC-59	NA	Plaque assay	Decrease (>90 %)	Approved, Investigational	28185815
DrugRepV_0093	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0094	BMS-777607	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	28099856
DrugRepV_0095	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	28099856
DrugRepV_0096	MGCD-265	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	28099856
DrugRepV_0097	Ki8751	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0098	Rebastinib	Anticancer	Chronic Myeloid Leukemia	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	28099856
DrugRepV_0099	OSU-03012	Anticancer	Brain cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0100	GSK2656157	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	NA	28099856
DrugRepV_0101	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0102	Flubendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Experimental, Withdrawn	28099856
DrugRepV_0103	Oxibendazole	Antiparasitic	Helminth intestinal infections	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Investigational, Vet approved	28099856
DrugRepV_0104	Albendazole	Antiparasitic products, Insectisides and Repellents	Parasitic infections	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	Approved	28099856
DrugRepV_0105	Thioguanine	Antineoplastic and Immunomodulating Agents	Acute leukemia	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0106	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0107	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0108	Cabazitaxel	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	Approved	28099856
DrugRepV_0109	Tenovin-1	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0110	RGFP966	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0111	Dioscin	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0112	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0113	Tenovin-1	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0114	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0115	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0116	Methotrexate	NA	Gestational choriocarcinoma | Chorioadenoma destruens | Hydatidiform mole | Meningeal leukemia | Breast cancer | Epidermoid cancers of the head and neck | Lung cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0117	PF-04691502	NA	Breast Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	Investigational	28099856
DrugRepV_0118	GDC-0980	Anticancer	Solid Cancer | Breast Cancer | Prostate Cancer | Renal Cell Carcinoma | Endometrial Carcinoma	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	Investigational	28099856
DrugRepV_0119	Albendazole	Antiparasitic products, Insectisides and Repellents	Parasitic infections	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0120	Navitoclax	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Investigational	28099856
DrugRepV_0121	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	Approved	28099856
DrugRepV_0122	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	28099856
DrugRepV_0123	GZD824	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (No significant effect No significant effect)	NA	28099856
DrugRepV_0124	VE-822	NA	Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (No significant effect No significant effect)	Investigational	28099856
DrugRepV_0125	Amuvatinib	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (No significant effect No significant effect)	Investigational	28099856
DrugRepV_0126	NVP-BHG712	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (No significant effect No significant effect)	NA	28099856
DrugRepV_0127	WAY-600	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0128	YM201636	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	NA	28099856
DrugRepV_0129	RGFP966	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0130	QNZ	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0131	Obatoclax Mesylate	Anticancer	Leukemia | Myelofibrosis | Hodgkin's Lymphoma | Mantle-Cell Lymphoma	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect	Investigational	28099856
DrugRepV_0132	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0133	STF-118804	NA	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	NA	28099856
DrugRepV_0134	Cetylpyridinium Chloride	Blood and Blood Forming Organs; Antiseptics And Disinfectants; Dermatologicals; Respiratory System	Bacterial infections	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0135	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (95 %)	NA	28099856
DrugRepV_0136	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (95 %)	NA	28099856
DrugRepV_0137	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (80 %)	NA	28099856
DrugRepV_0138	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (80 %)	Approved	28099856
DrugRepV_0139	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (90 %)	Approved	28099856
DrugRepV_0140	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (95 %)	Approved	28099856
DrugRepV_0141	Tenovin-1	Anticancer	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (80 %)	NA	28099856
DrugRepV_0142	Tenovin-1	Anticancer	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (70 %)	NA	28099856
DrugRepV_0143	Tenovin-1	Anticancer	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (70 %)	NA	28099856
DrugRepV_0144	AMG-458	NA	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (60 %)	NA	28099856
DrugRepV_0145	AMG-458	NA	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	No significant effect (20 %)	NA	28099856
DrugRepV_0146	AMG-458	NA	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	No significant effect (10 %)	NA	28099856
DrugRepV_0147	MGCD-265	Anticancer	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (60 %)	Investigational	28099856
DrugRepV_0148	MGCD-265	Anticancer	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	No significant effect (25 %)	Investigational	28099856
DrugRepV_0149	MGCD-265	Anticancer	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	No significant effect (20 %)	Investigational	28099856
DrugRepV_0150	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (70 %)	Approved	28099856
DrugRepV_0151	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	No significant effect (20 %)	Approved	28099856
DrugRepV_0152	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Immunoflourescence assay	No significant effect (20 %)	Approved	28099856
DrugRepV_0153	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (70 %)	Investigational	28099856
DrugRepV_0154	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Zika virus	MR766	NA	Immunoflourescence assay	No significant effect (20 %)	Investigational	28099856
DrugRepV_0155	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Zika virus	MR766	NA	Immunoflourescence assay	Increase (120 %)	Investigational	28099856
DrugRepV_0156	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (95 %)	NA	28099856
DrugRepV_0157	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (80 %)	NA	28099856
DrugRepV_0158	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (90 %)	NA	28099856
DrugRepV_0159	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (95 %)	Approved	28099856
DrugRepV_0160	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (90 %)	Approved	28099856
DrugRepV_0161	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (95 %)	Approved	28099856
DrugRepV_0162	Tenovin-1	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (95 %)	NA	28099856
DrugRepV_0163	Tenovin-1	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (95 %)	NA	28099856
DrugRepV_0164	Tenovin-1	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (40 %)	NA	28099856
DrugRepV_0165	AMG-458	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (60 %)	NA	28099856
DrugRepV_0166	AMG-458	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (70 %)	NA	28099856
DrugRepV_0167	AMG-458	NA	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (30 %)	NA	28099856
DrugRepV_0168	MGCD-265	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (70 %)	Investigational	28099856
DrugRepV_0169	MGCD-265	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (70 %)	Investigational	28099856
DrugRepV_0170	MGCD-265	Anticancer	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (40 %)	Investigational	28099856
DrugRepV_0171	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (50 %)	Approved	28099856
DrugRepV_0172	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (70 %)	Approved	28099856
DrugRepV_0173	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (40 %)	Approved	28099856
DrugRepV_0174	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (60 %)	Investigational	28099856
DrugRepV_0175	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	Decrease (60 %)	Investigational	28099856
DrugRepV_0176	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Zika virus	Mex2-81	NA	Immunoflourescence assay	No significant effect (0 %)	Investigational	28099856
DrugRepV_0177	Tenovin-1	Anticancer	Cancer	Zika virus	Mex2-81	NA	Real-time PCR	Decrease (80 %)	NA	28099856
DrugRepV_0178	Tenovin-1	Anticancer	Cancer	Zika virus	Mex2-81	NA	Real-time PCR	Decrease (85 %)	NA	28099856
DrugRepV_0179	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Zika virus	Mex2-81	NA	Real-time PCR	No significant effect (30 %)	Investigational	28099856
DrugRepV_0180	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Zika virus	Mex2-81	NA	Real-time PCR	No significant effect (0 %)	Investigational	28099856
DrugRepV_0181	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	Mex2-81	NA	Real-time PCR	Decrease (70 %)	Approved	28099856
DrugRepV_0182	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	Mex2-81	NA	Real-time PCR	No significant effect (20 %)	Approved	28099856
DrugRepV_0183	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	Mex2-81	NA	Real-time PCR	Decrease (95 %)	NA	28099856
DrugRepV_0184	Nanchangmycin	Antibacterial; Antiviral	NA	Zika virus	Mex2-81	NA	Real-time PCR	Decrease (95 %)	NA	28099856
DrugRepV_0186	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	Mex2-81	NA	TCID50 assay	Decrease (80 %)	Approved	28099856
DrugRepV_0187	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	Mex2-81	NA	TCID50 assay	Decrease (75 %)	Approved	28099856
DrugRepV_0188	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	Mex2-81	NA	TCID50 assay	Decrease (95 %)	Approved	28099856
DrugRepV_0189	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	Mex2-81	NA	TCID50 assay	No significant effect (30 %)	Approved	28099856
DrugRepV_0190	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	Mex2-81	NA	TCID50 assay	Decrease (75 %)	Approved	28099856
DrugRepV_0191	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	Mex2-81	NA	TCID50 assay	No significant effect (0 %)	Approved	28099856
DrugRepV_0195	Tenovin-1	Anticancer	Cancer	Zika virus	Mex2-81	NA	TCID50 assay	No significant effect (40 %)	NA	28099856
DrugRepV_0196	Tenovin-1	Anticancer	Cancer	Zika virus	Mex2-81	NA	TCID50 assay	No significant effect (50 %)	NA	28099856
DrugRepV_0197	Tenovin-1	Anticancer	Cancer	Zika virus	Mex2-81	NA	TCID50 assay	Decrease (75 %)	NA	28099856
DrugRepV_0760	Clofazimine	Antiinfectives For Systemic Use	Lepromatous leprosy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.665 %)	Approved	27476412
DrugRepV_0761	Digoxin	Cardiovascular agents	Cardiac insufficiency, arrhythmias and heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (100 %)	Approved	27476412
DrugRepV_0762	Gemcitabine Hydrochloride	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.955 %)	Approved	27476412
DrugRepV_0763	Idarubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Acute myeloid leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (100 %)	Approved	27476412
DrugRepV_0764	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.52 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0765	Mefloquine Hydrochloride	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.815 %)	Approved, Investigational	27476412
DrugRepV_0766	Mercaptopurine Hydrate	Antineoplastic and Immunomodulating Agents	Acute lymphatic leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.425 %)	Approved	27476412
DrugRepV_0767	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.845 %)	Approved	27476412
DrugRepV_0768	Tacrolimus	Antineoplastic and Immunomodulating Agents	Allogenic organ transplant (kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (100 %)	Approved	27476412
DrugRepV_0769	Epirubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.23 %)	Approved	27476412
DrugRepV_0770	Fingolimod	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.18 %)	Approved	27476412
DrugRepV_0771	Mycophenolate Mofetil	Immunosuppressant	Organ rejection (immunosuppressants)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.825 %)	Approved, Investigational	27476412
DrugRepV_0772	Dactinomycin	NA	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.435 %)	Approved	27476412
DrugRepV_0773	Methotrexate	NA	Gestational choriocarcinoma | Chorioadenoma destruens | Hydatidiform mole | Meningeal leukemia | Breast cancer | Epidermoid cancers of the head and neck | Lung cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (97.715 %)	Approved	27476412
DrugRepV_0774	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (98.03 %)	Approved	27476412
DrugRepV_0775	Chlorhexidine Dihydrochloride	Alimentary Tract and Metabolism	Disinfectant, oropharyngeal decontamination	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (97.965 %)	Approved	27476412
DrugRepV_0776	Methoxsalen	Dermatologicals	Psoriasis | Vitiligo	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (94.295 %)	Approved	27476412
DrugRepV_0777	Azathioprine	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis, renal transplant rejection, Crohn disease, and colitis.	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (96.385 %)	Approved	27476412
DrugRepV_0778	Thioguanine	Antineoplastic and Immunomodulating Agents	Acute leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (95.295 %)	Approved	27476412
DrugRepV_0779	Auranofin	Musculo-Skeletal System	Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (93.84 %)	Approved	27476412
DrugRepV_0780	Sertraline Hydrochloride	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (89 %)	Approved	27476412
DrugRepV_0781	Pyrimethamine	Antiparasitic products, Insectisides and Repellents	Toxoplasmosis | Acute malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (83.105 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0782	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (89.915 %)	Approved	27476412
DrugRepV_0783	Palonosetron Hydrochloride	Alimentary Tract and Metabolism	Nausea and vomiting associated with cancer chemotherapy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (87.615 %)	Approved, Investigational	27476412
DrugRepV_0784	Deferasirox	Various	Tansfusional hemosiderosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (87.47 %)	Approved	27476412
DrugRepV_0785	Micafungin	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (86.88 %)	Approved, Investigational	27476412
DrugRepV_0786	Trifluoperazine Hydrochloride	Nervous System	Schizophrenia and other psychotic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (70.37 %)	Approved	27476412
DrugRepV_0787	Nebivolol Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (72.455 %)	Approved, Investigational	27476412
DrugRepV_0788	Sorafenib Tosylate	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma | Renal cell carcinoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (82.225 %)	Approved, Investigational	27476412
DrugRepV_0789	Ethinyl estradiol	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (77.81 %)	Approved	27476412
DrugRepV_0790	Pimecrolimus	Dermatologicals	Atopic dermatitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (71.825 %)	Approved, Investigational	27476412
DrugRepV_0791	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (82.105 %)	Approved	27476412
DrugRepV_0792	Sunitinib Malate	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (73.145 %)	Approved, Investigational	27476412
DrugRepV_0793	Pimozide	Nervous System	Tourette Disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (72.91 %)	Approved	27476412
DrugRepV_0794	Thioridazine Hydrochloride	Nervous System	Schizophrenia | Anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (69.315 %)	Approved, Withdrawn	27476412
DrugRepV_0795	Paclitaxel	Antineoplastic and Immunomodulating Agents	Kaposi's sarcoma | Lung cancer | Ovarian cancer | Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (78.59 %)	Approved	27476412
DrugRepV_0796	Docetaxel	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (79.61 %)	Approved	27476412
DrugRepV_0797	Prazosin Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (79.755 %)	Approved	27476412
DrugRepV_0798	Tolvaptan	Cardiovascular agents	Hyponatremia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (71.575 %)	Approved	27476412
DrugRepV_0799	Hexachlorophene	Dermatologicals	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (73.95 %)	Approved, Withdrawn	27476412
DrugRepV_0800	Eplerenone	Cardiovascular agents	Left ventricular systolic dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (66.435 %)	Approved	27476412
DrugRepV_0801	Mebendazole	Antiparasitic products, Insectisides and Repellents	Helminthiasis (Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (71.81 %)	Approved, Vet approved	27476412
DrugRepV_0802	Cilostazol	Blood and Blood Forming Organs	Intermittent claudication	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (67.75 %)	Approved	27476412
DrugRepV_0803	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.34 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0804	Dutasteride	Genito Urinary System and Sex Hormones	Prostatic hyperplasia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (66.475 %)	Approved	27476412
DrugRepV_0805	Pazopanib Hydrochloride	Antineoplastic and Immunomodulating Agents	Advanced renal cell cancer | Advanced soft tissue sarcoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (70.75 %)	Approved	27476412
DrugRepV_0806	Paroxetine Hydrochloride	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.91 %)	Approved, Investigational	27476412
DrugRepV_0807	Vinorelbine	Antineoplastic and Immunomodulating Agents	Breast cancer and non-small cell lung cancer (NSCLC)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (67.24 %)	Approved	27476412
DrugRepV_0808	Vorinostat	Antineoplastic and Immunomodulating Agents	T-cell lymphoma (CTCL, a type of cancer)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (70.85 %)	Approved	27476412
DrugRepV_0809	Deferoxamine Mesylate	Various	Iron or aluminum toxicity	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (67.29 %)	Approved	27476412
DrugRepV_0810	Bexarotene	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (69.51 %)	Approved	27476412
DrugRepV_0811	Podofilox	Dermatologicals	External genital warts	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (63.735 %)	Approved	27476412
DrugRepV_0812	Colchicine	Musculo-Skeletal System	Gout	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (65.075 %)	Approved	27476412
DrugRepV_0813	Nilotinib	Antineoplastic and Immunomodulating Agents	Leukemias | Chronic myeloid leukemia (CML)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (63.05 %)	Approved, Investigational	27476412
DrugRepV_0814	Albendazole	Antiparasitic products, Insectisides and Repellents	Parasitic infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (68.09 %)	Approved	27476412
DrugRepV_0815	Ciclesonide	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (66.46 %)	Approved	27476412
DrugRepV_0816	Meclizine Dihydrochloride	Respiratory System	Nausea | Vomiting | Motion sickness | Vertigo	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.685 %)	Approved	27476412
DrugRepV_0817	Tazarotene	Dermatologicals	Psoriasis, acne and sun damaged skin	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.1 %)	Approved	27476412
DrugRepV_0818	Moexipril Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.935 %)	Approved	27476412
DrugRepV_0819	Vinblastine Sulfate	Antineoplastic and Immunomodulating Agents	Cancer (Hodgkin lymphoma | Non-Hodgkin's lymphoma |Testicular | Breast | Lung (Non-small cell lung cancer) | Head and neck | Bladder cancers | Melanoma | Soft tissue sarcoma |Kaposi's sarcoma | Mycosis fungoides (t-cell lymphoma) | Choriocarcinoma)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (66.755 %)	Approved	27476412
DrugRepV_0820	Trospium Chloride	Genito Urinary System and Sex Hormones	Overactive bladder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.11 %)	Approved	27476412
DrugRepV_0821	Econazole Nitrate	Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (69.6 %)	Approved	27476412
DrugRepV_0822	Prednisone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.325 %)	Approved, Vet approved	27476412
DrugRepV_0823	Calcipotriene	Dermatologicals	Psoriasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.795 %)	Approved	27476412
DrugRepV_0824	Rabeprazole Sodium	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) | Peptic ulcer disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.765 %)	Approved, Investigational	27476412
DrugRepV_0825	Pitavastatin Calcium	Cardiovascular agents	Dyslipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (62.655 %)	Approved	27476412
DrugRepV_0826	Risperidone	Nervous System	Schizophrenia | Mood disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (63.025 %)	Approved, Investigational	27476412
DrugRepV_0827	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (65.085 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0828	Irbesartan	Cardiovascular agents	Hypertension | Diabetic nephropathy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.84 %)	Approved, Investigational	27476412
DrugRepV_0829	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.145 %)	Approved	27476412
DrugRepV_0830	Triamterene	Cardiovascular agents	Edema associated with congestive heart failure | Cirrhosis of the liver | Nephrotic syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.03 %)	Approved	27476412
DrugRepV_0831	Mitomycin C	Antineoplastic and Immunomodulating Agents	Malignant neoplasm of lip, oral cavity, pharynx, digestive organs, peritoneum, female breast, and urinary bladder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (64.305 %)	Approved	27476412
DrugRepV_0832	Ciclopirox	Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (65.575 %)	Approved	27476412
DrugRepV_0833	Doxorubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (65.365 %)	Approved	27476412
DrugRepV_0834	Cisatracurium Besylate	Musculo-Skeletal System	Muscle spasms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.815 %)	Approved	27476412
DrugRepV_0835	Tolcapone	Nervous System	Parkinson's Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.86 %)	Approved, Withdrawn	27476412
DrugRepV_0836	Primaquine Phosphate	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.24 %)	Approved	27476412
DrugRepV_0837	Exemestane	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.61 %)	Approved	27476412
DrugRepV_0838	Pentamidine Isethionate	Antiparasitic products, Insectisides and Repellents	Pneumonia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.63 %)	Approved, Investigational	27476412
DrugRepV_0839	Isoniazid	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.29 %)	Approved, Investigational	27476412
DrugRepV_0840	Zaleplon	Nervous System	Insomnia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.615 %)	Approved	27476412
DrugRepV_0841	Pravastatin Sodium	Cardiovascular agents	Hypercholesterolemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.5 %)	Approved	27476412
DrugRepV_0842	Clofarabine	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (62.94 %)	Approved	27476412
DrugRepV_0843	Penicillin G Potassium	Antiinfectives For Systemic Use	Septicemia | Meningitis | Pericarditis | Endocarditis | Pneumonia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.15 %)	Approved	27476412
DrugRepV_0844	Etonogestrel	Genito Urinary System and Sex Hormones	Contraception	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.965 %)	Approved	27476412
DrugRepV_0845	Alitretinoin	Dermatologicals	Cutaneous lesions in patients with AIDS-related Kaposi sarcoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.94 %)	Approved	27476412
DrugRepV_0846	Cefuroxime Axetil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.5 %)	Approved	27476412
DrugRepV_0847	Mesna	Respiratory System; Various	Hemorrhagic cystitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.73 %)	Approved, Investigational	27476412
DrugRepV_0848	Levonorgestrel	Genito Urinary System and Sex Hormones	Menopausal and postmenopausal disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.52 %)	Approved, Investigational	27476412
DrugRepV_0849	Nystatin	Alimentary Tract And Metabolism; Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.71 %)	Approved	27476412
DrugRepV_0850	Olopatadine	Sensory Organ	Allergic conjunctivitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.77 %)	Approved	27476412
DrugRepV_0851	Acetylcysteine	Respiratory System; Sensory Organ; Various	Acetaminophen poisoning	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.525 %)	Approved	27476412
DrugRepV_0852	Linezolid	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.395 %)	Approved, Investigational	27476412
DrugRepV_0853	Vincristine Sulfate	Antineoplastic and Immunomodulating Agents	Cancer (Acute leukemia |Hodgkin's and non-Hodgkin's lymphoma |Neuroblastoma |Rhabdomyosarcoma |Ewing's sarcoma |Wilms' tumor | Multiple myeloma | Chronic leukemias | Thyroid cancer | Brain tumors)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (62.91 %)	Approved, Investigational	27476412
DrugRepV_0854	Metaraminol Bitartrate	Cardiovascular agents	Hypotension due to hemorrhage, spinal anesthesia, and shock associated with brain damage	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.365 %)	Approved, Investigational	27476412
DrugRepV_0855	Raloxifene Hydrochloride	Genito Urinary System and Sex Hormones	Osteoporosis | Corticosteroid-induced bone loss	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (66.245 %)	Approved, Investigational	27476412
DrugRepV_0856	Lincomycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.795 %)	Approved, Vet approved	27476412
DrugRepV_0857	Atorvastatin Calcium	Cardiovascular agents	Coronary heart disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.57 %)	Approved	27476412
DrugRepV_0858	Calcitriol	Alimentary Tract and Metabolism	Vitamin D resistant rickets	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.57 %)	Approved	27476412
DrugRepV_0859	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.53 %)	Approved	27476412
DrugRepV_0860	Megestrol Acetate	Genito Urinary System and Sex Hormones	Anorexia | Cachexia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.545 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0861	Pralidoxime Chloride	Various	Poisoning	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.51 %)	Approved, Vet approved	27476412
DrugRepV_0862	Chenodiol	Alimentary Tract and Metabolism	Radiolucent stones	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.095 %)	Approved	27476412
DrugRepV_0863	Tretinoin	Dermatologicals; Antineoplastic and Immunomodulating Agents	Acne | Photodamaged skin | Keratinization disorders such as ichthyosis and keratosis follicularis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.47 %)	Approved	27476412
DrugRepV_0864	Vancomycin Hydrochloride	Alimentary Tract And Metabolism; Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.91 %)	Approved	27476412
DrugRepV_0865	Prasugrel	Blood and Blood Forming Organs	Acute coronary syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.09 %)	Approved	27476412
DrugRepV_0866	Acrivastine	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.315 %)	Approved	27476412
DrugRepV_0867	Mequinol	Dermatologicals	Solar lentigines | Hyperpigmented lesions	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.96 %)	Approved	27476412
DrugRepV_0868	Bromocriptine Mesylate	Nervous System	Parkinson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.805 %)	Approved	27476412
DrugRepV_0869	Donepezil Hydrochloride	Nervous System	Dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.885 %)	Approved	27476412
DrugRepV_0870	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.1 %)	Approved	27476412
DrugRepV_0871	Methazolamide	Sensory Organ	Glaucoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.695 %)	Approved	27476412
DrugRepV_0872	Probenecid	Musculo-Skeletal System	Gout	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.465 %)	Approved, Investigational	27476412
DrugRepV_0873	Carbachol Chloride	Sensory Organ	Glaucoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.395 %)	Approved	27476412
DrugRepV_0874	Nortriptyline Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.8 %)	Approved	27476412
DrugRepV_0875	Colistimethate Sodium	Alimentary Tract And Metabolism; Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.695 %)	Approved	27476412
DrugRepV_0876	Norfloxacin	Antiinfectives For Systemic Use	Urinary tract infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.51 %)	Approved	27476412
DrugRepV_0877	Simvastatin	Cardiovascular agents	Hypercholesterolemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.405 %)	Approved	27476412
DrugRepV_0878	Amphotericin B	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.04 %)	Approved	27476412
DrugRepV_0879	Ziprasidone Hydrochloride	Nervous System	Schizophrenia and psychotic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.475 %)	Approved	27476412
DrugRepV_0880	Fluphenazine Hydrochloride	Nervous System	Psychosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.715 %)	Approved	27476412
DrugRepV_0881	Metoclopramide Hydrochloride	Alimentary Tract and Metabolism	Gastroesophageal reflux disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.405 %)	Approved, Investigational	27476412
DrugRepV_0882	Mepenzolate Bromide	Alimentary Tract and Metabolism	Peptic ulcer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.065 %)	Approved	27476412
DrugRepV_0883	Eptifibatide	Blood and Blood Forming Organs	Myocardial infarction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.02 %)	Approved	27476412
DrugRepV_0884	Oxtriphylline	Respiratory System	Asthma | Bronchospasm | Chronic Obstructive Pulmonary Disease (COPD)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.265 %)	Approved	27476412
DrugRepV_0885	Procarbazine Hydrochloride	Antineoplastic and Immunomodulating Agents	Hodgkin's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.4 %)	Approved	27476412
DrugRepV_0886	Ketoconazole	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.415 %)	Approved, Investigational	27476412
DrugRepV_0887	Trazodone Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.415 %)	Approved, Investigational	27476412
DrugRepV_0888	Ceftibuten	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.895 %)	Approved	27476412
DrugRepV_0889	Fluvastatin Sodium	Cardiovascular agents	Cardiovascular disease (Coronary heart disease (CHD))	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.69 %)	Approved	27476412
DrugRepV_0890	Acetazolamide	Sensory Organ	Edema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.035 %)	Approved	27476412
DrugRepV_0891	Chlorzoxazone	Musculo-Skeletal System	Pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.755 %)	Approved	27476412
DrugRepV_0892	Naltrexone Hydrochloride	Nervous System	Alcohol dependence	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.515 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0893	Perindopril Erbumine	Cardiovascular agents	Hypertension | Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.56 %)	Approved	27476412
DrugRepV_0894	Prednisolone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Congenital adrenal hyperplasia | Thyroiditis | Psoriatic arthritis | Rheumatoid arthritis | Ankylosing spondylitis | Bursitis | Acute gouty arthritis | Epicondylitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.415 %)	Approved, Vet approved	27476412
DrugRepV_0895	Nefazodone Hydrochloride	Nervous System	Depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.595 %)	Approved, Withdrawn	27476412
DrugRepV_0896	Prilocaine Hydrochloride	NA	Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.97 %)	Approved	27476412
DrugRepV_0897	Quinidine Hydrochloride Hydrate	Cardiovascular agents	Ventricular pre-excitation | Cardiac dysrhythmias	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.385 %)	Approved, Investigational	27476412
DrugRepV_0898	Acarbose	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.59 %)	Approved	27476412
DrugRepV_0899	Progesterone	Genito Urinary System and Sex Hormones	Infertility	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.635 %)	Approved, Vet approved	27476412
DrugRepV_0900	Tetrabenazine	Nervous System	Huntington disease | Hemiballismus | Senile chorea | Tourette syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.175 %)	Approved	27476412
DrugRepV_0901	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.92 %)	Approved	27476412
DrugRepV_0902	Danazol	Genito Urinary System and Sex Hormones	Endometriosis and fibrocystic breast disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.385 %)	Approved	27476412
DrugRepV_0903	Estropipate	Genito Urinary System and Sex Hormones	Vaginal atrophy associated with the menopause	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.39 %)	Approved	27476412
DrugRepV_0904	Clopidogrel Hydrogen Sulfate	Blood and Blood Forming Organs	Myocardial infarction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.555 %)	Approved	27476412
DrugRepV_0905	Lovastatin	Cardiovascular agents	Atherosclerotic vascular disease | Hypercholesterolemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.375 %)	Approved, Investigational	27476412
DrugRepV_0906	Sertaconazole	Dermatologicals; Genito Urinary System and Sex Hormones	Fungal infections (Tinea pedis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.215 %)	Approved, Investigational	27476412
DrugRepV_0907	Ofloxacin	Antiinfectives For Systemic Use	Respiratory tract infections | Kidney infection | Skin infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.695 %)	Approved	27476412
DrugRepV_0908	Acetohydroxamic Acid	Genito Urinary System and Sex Hormones	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.495 %)	Approved	27476412
DrugRepV_0909	Penciclovir	Antiinfectives For Systemic Use	Recurrent cold sores on the lips and face from Herpesvirus invections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.495 %)	Approved	27476412
DrugRepV_0910	Tacrine Hydrochloride	Nervous System	Dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.39 %)	Approved	27476412
DrugRepV_0911	L-Ascorbic Acid	Alimentary Tract and Metabolism	Vitamin C deficiency | Scurvy | Delayed wound and bone healing | Urine acidification	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.58 %)	Approved, Nutraceutical	27476412
DrugRepV_0912	Nepafenac	Sensory Organ	Inflammation associated with cataract surgery	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.565 %)	Approved	27476412
DrugRepV_0913	Ambrisentan	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.165 %)	Approved	27476412
DrugRepV_0914	Imiquimod	Dermatologicals	Genital and perianal warts/condyloma acuminata	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.785 %)	Approved, Investigational	27476412
DrugRepV_0915	Loperamide Hydrochloride	Alimentary Tract and Metabolism	Chronic diarrhea associated with inflammatory bowel disease or gastroenteritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.78 %)	Approved	27476412
DrugRepV_0916	Methyl Aminolevulinate Hydrochloride	Antineoplastic and Immunomodulating Agents	Non-hyperkeratotic actinic keratoses	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.34 %)	Approved	27476412
DrugRepV_0917	Etodolac	Musculo-Skeletal System	Osteoarthritis and rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.89 %)	Approved	27476412
DrugRepV_0918	Cephalexin Monohydrate	Antibiotics	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.225 %)	Approved	27476412
DrugRepV_0919	Metaproterenol Hemisulfate	Respiratory System	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.225 %)	Approved	27476412
DrugRepV_0920	Acitretin	Dermatologicals	Psoriasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.15 %)	Approved	27476412
DrugRepV_0921	Oxybutynin Chloride	Genito Urinary System and Sex Hormones	Overactive bladder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.105 %)	Approved, Investigational	27476412
DrugRepV_0922	Oxcarbazepine	Nervous System	Partial seizures	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.92 %)	Approved	27476412
DrugRepV_0923	Amikacin Disulfate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.975 %)	Approved	27476412
DrugRepV_0924	Ciprofloxacin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.87 %)	Approved	27476412
DrugRepV_0925	Duloxetine Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.7 %)	Approved	27476412
DrugRepV_0926	Spectinomycin Hydrochloride Pentahydrate	Antiinfectives For Systemic Use	Bacterial infections (Gonorrheal urethritis and proctitis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.825 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0927	Famotidine	Alimentary Tract and Metabolism	Peptic ulcer | Gastroesophageal reflux disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.495 %)	Approved	27476412
DrugRepV_0928	Triamcinolone Acetonide	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.745 %)	Approved, Vet approved	27476412
DrugRepV_0929	Methacholine Chloride	Nervous System	Bronchial hyperreactivity	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.51 %)	Approved, Investigational	27476412
DrugRepV_0930	Apomorphine Hydrochloride Hemihydrate	Nervous System	Parkinson's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.305 %)	Approved	27476412
DrugRepV_0931	Nilutamide	Antineoplastic and Immunomodulating Agents	Metastatic prostate cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.885 %)	Approved, Investigational	27476412
DrugRepV_0932	Almotriptan	Nervous System	Acute migraine	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.88 %)	Approved	27476412
DrugRepV_0933	Felbamate	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.745 %)	Approved	27476412
DrugRepV_0934	Pantoprazole	Alimentary Tract and Metabolism	Gastroesophageal reflux disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.82 %)	Approved	27476412
DrugRepV_0935	Lamotrigine	Nervous System	Epilepsy and bipolar disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.015 %)	Approved, Investigational	27476412
DrugRepV_0936	Chlorthalidone	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.405 %)	Approved	27476412
DrugRepV_0937	Penicillin V Potassium	Antiinfectives For Systemic Use	Mild to moderately severe infections due to penicillin G­-sensitive microorganisms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.165 %)	Approved	27476412
DrugRepV_0938	Ceftriaxone Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.04 %)	Approved	27476412
DrugRepV_0939	Scopolamine Hydrobromide	Alimentary Tract And Metabolism; Nervous System; Sensory Organ	Irritable bowel syndrome | Excessive salivation | Motion sickness	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.095 %)	Approved, Investigational	27476412
DrugRepV_0940	Acetaminophen	Nervous System	Fever, minor aches and pains	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.27 %)	Approved	27476412
DrugRepV_0941	Alosetron Hydrochloride	Alimentary Tract and Metabolism	Diarrhea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.005 %)	Approved	27476412
DrugRepV_0942	Meclofenamate Sodium	Musculo-Skeletal System	Pain | Primary dysmenorrhea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.11 %)	Approved, Vet approved	27476412
DrugRepV_0943	Varenicline Tartrate	Nervous System	Nicotine dependence	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.14 %)	Approved	27476412
DrugRepV_0944	Acetohexamide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.13 %)	Approved, Withdrawn	27476412
DrugRepV_0945	Crotamiton	Antipruritic agent	Scabies	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.21 %)	Approved	27476412
DrugRepV_0946	Sulindac	Musculo-Skeletal System	Osteoarthritis | Rheumatoid arthritis | Ankylosing spondylitis | Acute painful shoulder | Acute gouty arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.295 %)	Approved, Investigational	27476412
DrugRepV_0947	Rosiglitazone	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.78 %)	Approved	27476412
DrugRepV_0948	Acebutolol Hydrochloride	Cardiovascular agents	Hypertension and ventricular premature beats	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.335 %)	Approved	27476412
DrugRepV_0949	Procainamide Hydrochloride	Cardiovascular agents	Ventricular arrhythmias	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.96 %)	Approved	27476412
DrugRepV_0950	Atropine Sulfate Monohydrate	Sensory Organ	Cholinesterase	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.08 %)	Approved	27476412
DrugRepV_0951	Bupropion	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.045 %)	Approved	27476412
DrugRepV_0952	Febuxostat	Musculo-Skeletal System	Hyperuricemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.325 %)	Approved	27476412
DrugRepV_0953	Valsartan	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.425 %)	Approved	27476412
DrugRepV_0954	Nitisinone	Alimentary Tract and Metabolism	Hereditary tyrosinemia type 1	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.205 %)	Approved	27476412
DrugRepV_0955	Guanfacine Hydrochloride	NA	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.975 %)	Approved, Investigational	27476412
DrugRepV_0956	Valproate Sodium	Nervous System	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.71 %)	Approved	27476412
DrugRepV_0957	Primidone	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.36 %)	Approved, Vet approved	27476412
DrugRepV_0958	Halcinonide	Dermatologicals	Dermatoses	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.67 %)	Approved, Investigational, Withdrawn	27476412
DrugRepV_0959	Eszopiclone	Nervous System	Insomnia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.415 %)	Approved	27476412
DrugRepV_0960	Haloperidol	Nervous System	Schizophrenia | Psychotic disorders | Chemotherapy-induced nausea/vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.42 %)	Approved	27476412
DrugRepV_0961	Pioglitazone Hydrochloride	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.685 %)	Approved, Investigational	27476412
DrugRepV_0962	Epinephrine	Alimentary Tract And Metabolism; Blood and Blood Forming Organs; Cardiovascular agents; Respiratory	Anaphylaxis and sepsis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.39 %)	Approved	27476412
DrugRepV_0963	Zanamivir	Antiinfectives For Systemic Use	Influenza virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.235 %)	Approved	27476412
DrugRepV_0964	Pilocarpine Hydrochloride	Sensory Organ	Xerostomia | Glaucoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.575 %)	Approved, Investigational	27476412
DrugRepV_0965	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.69 %)	Approved	27476412
DrugRepV_0966	Chlorothiazide	Cardiovascular agents	Edema associated with congestive heart failure, hepatic cirrhosis and hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.72 %)	Approved	27476412
DrugRepV_0967	Chlorpropamide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.46 %)	Approved	27476412
DrugRepV_0968	Ethionamide	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.99 %)	Approved	27476412
DrugRepV_0969	Praziquantel	Antiparasitic products, Insectisides and Repellents	Schistosomiasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.16 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0970	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.93 %)	Approved	27476412
DrugRepV_0971	Iloperidone	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.515 %)	Approved	27476412
DrugRepV_0972	Etomidate	Nervous System	General anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.365 %)	Approved	27476412
DrugRepV_0973	Zonisamide	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.085 %)	Approved	27476412
DrugRepV_0974	Oxacillin Sodium salt Monohydrate	Antiinfectives For Systemic Use	Staphylococci infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.525 %)	Approved, Investigational	27476412
DrugRepV_0975	Fexofenadine Hydrochloride	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.055 %)	Approved	27476412
DrugRepV_0976	Phenytoin	Nervous System	Seizures	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.54 %)	Approved, Vet approved	27476412
DrugRepV_0977	Mirtazapine	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.19 %)	Approved	27476412
DrugRepV_0978	Formoterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.97 %)	Approved, Investigational	27476412
DrugRepV_0979	Ticlopidine Hydrochloride	Blood and Blood Forming Organs	Stroke	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.53 %)	Approved	27476412
DrugRepV_0980	Zoledronic Acid Monohydrate	Musculo-Skeletal System	Hypercalcemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.625 %)	Approved	27476412
DrugRepV_0981	Aminophylline	Respiratory System	Asthma, bronchospasm and Chronic Obstructive Pulmonary Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.325 %)	Approved	27476412
DrugRepV_0982	Cefixime	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.925 %)	Approved	27476412
DrugRepV_0983	Buspirone Hydrochloride	Nervous System	Anxiety and depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.19 %)	Approved	27476412
DrugRepV_0984	Warfarin Sodium	Blood and Blood Forming Organs	Coagulation disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.055 %)	Approved	27476412
DrugRepV_0985	Mestranol	NA	Contraception	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.56 %)	Approved	27476412
DrugRepV_0986	Pyrazinamide	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.975 %)	Approved, Investigational	27476412
DrugRepV_0987	Epinastine Hydrochloride	Sensory Organ	Allergy and conjunctivitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.33 %)	Approved	27476412
DrugRepV_0988	Pyridostigmine Bromide	Nervous System	Myasthenia gravis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.965 %)	Approved, Investigational	27476412
DrugRepV_0989	Ursodiol	NA	Gallstone and cholestatic forms of liver diseases including primary biliary cirrhosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.78 %)	Approved	27476412
DrugRepV_0990	Ibuprofen	Musculo-Skeletal System	Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.025 %)	Approved	27476412
DrugRepV_0991	Sodium Phenylbutyrate	Alimentary Tract and Metabolism	Chronic urea cycle disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.64 %)	Approved	27476412
DrugRepV_0992	Glycopyrrolate Iodide	Alimentary Tract And Metabolism; Respiratory System	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.585 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0993	Clotrimazole	Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.76 %)	Approved	27476412
DrugRepV_0994	Chlorpheniramine Maleate	Respiratory System	Rhinitis, urticaria, allergy, common cold, asthma and hay fever	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.605 %)	Approved	27476412
DrugRepV_0995	Trientine Dihydrochloride	Alimentary Tract and Metabolism	Wilson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.41 %)	Approved	27476412
DrugRepV_0996	Cinacalcet Hydrochloride	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hyperparathyroidism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.525 %)	Approved	27476412
DrugRepV_0997	Metaxalone	NA	Musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.445 %)	Approved	27476412
DrugRepV_0998	Carbamazepine	Nervous System	Epilepsy and pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.68 %)	Approved	27476412
DrugRepV_0999	Dofetilide	Cardiovascular agents	Atrial flutter	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.755 %)	Approved	27476412
DrugRepV_1000	Beclomethasone Dipropionate	NA	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.25 %)	Approved	27476412
DrugRepV_1001	Delavirdine Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.035 %)	Approved	27476412
DrugRepV_1002	Balsalazide	Alimentary Tract and Metabolism	Active ulcerative colitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.825 %)	Approved	27476412
DrugRepV_1003	Carvedilol	Cardiovascular agents	Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.625 %)	Approved	27476412
DrugRepV_1004	Estramustine phosphate Sodium	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.96 %)	Approved	27476412
DrugRepV_1005	Goserelin Acetate	Antineoplastic and Immunomodulating Agents	Prostate cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.315 %)	Approved	27476412
DrugRepV_1006	Bimatoprost	Sensory Organ	Ocular Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.62 %)	Approved	27476412
DrugRepV_1007	Phenelzine Sulfate	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.225 %)	Approved	27476412
DrugRepV_1008	Disulfiram	Nervous System	Chronic alcoholism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.105 %)	Approved	27476412
DrugRepV_1009	Olmesartan	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.095 %)	Approved, Investigational	27476412
DrugRepV_1010	Lidocaine Hydrochloride Hydrate	Cardiovascular agents	Anesthesia | Ventricular arrhythmias	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.62 %)	Approved, Vet approved	27476412
DrugRepV_1011	Pemetrexed Disodium	Antineoplastic and Immunomodulating Agents	Cancer (Chemotherapy drug) | Malignant pleural mesothelioma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.02 %)	Approved, Investigational	27476412
DrugRepV_1012	Cefaclor	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.11 %)	Approved	27476412
DrugRepV_1013	Vardenafil	Genito Urinary System and Sex Hormones	Erectile dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.67 %)	Approved	27476412
DrugRepV_1014	Fulvestrant	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.615 %)	Approved, Investigational	27476412
DrugRepV_1015	Chloramphenicol	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.08 %)	Approved	27476412
DrugRepV_1016	Spironolactone	Cardiovascular agents	Heart failure | Hyperaldosteronism | Adrenal hyperplasia | Hypertension | Nephrotic syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.965 %)	Approved	27476412
DrugRepV_1017	Ranitidine Hydrochloride	Alimentary Tract and Metabolism	Duodenal ulcer | Pathological hypersecretion of gastric acid | Gastric ulcer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.44 %)	Approved, Withdrawn	27476412
DrugRepV_1018	Caffeine	Nervous System	Fatigue, orthostatic hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.37 %)	Approved	27476412
DrugRepV_1019	Tolmetin Sodium Dihydrate	Musculo-Skeletal System	Rheumatoid arthritis and osteoarthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.77 %)	Approved	27476412
DrugRepV_1020	Cidofovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.06 %)	Approved	27476412
DrugRepV_1021	Levofloxacin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections (Conjunctivitis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.885 %)	Approved	27476412
DrugRepV_1022	Demeclocycline Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.41 %)	Approved	27476412
DrugRepV_1023	Tolbutamide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.45 %)	Approved, Investigational	27476412
DrugRepV_1024	Arsenic Trioxide	Antineoplastic and Immunomodulating Agents	Acute promyelocytic leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.425 %)	Approved	27476412
DrugRepV_1025	Pancuronium Dibromide	Musculo-Skeletal System	Muscle relaxant during anesthesia and surgical procedures	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.955 %)	Approved	27476412
DrugRepV_1026	Cefuroxime Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.005 %)	Approved	27476412
DrugRepV_1027	Ibutilide Fumarate	Cardiovascular agents	Atrial flutter	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.475 %)	Approved	27476412
DrugRepV_1028	Guanabenz Acetate	Cardiovascular agents	High blood pressure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.815 %)	Approved	27476412
DrugRepV_1029	Ethambutol Dihydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.32 %)	Approved	27476412
DrugRepV_1030	Bisacodyl	Alimentary Tract and Metabolism	Colon cleansing	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.3 %)	Approved	27476412
DrugRepV_1031	Thalidomide	Antineoplastic and Immunomodulating Agents	Erythema nodosum leprosum	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.365 %)	Approved, Investigational, Withdrawn	27476412
DrugRepV_1032	Alfuzosin	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.7 %)	Approved	27476412
DrugRepV_1033	Zileuton	NA	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.355 %)	Approved, Withdrawn	27476412
DrugRepV_1034	Lacosamide	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.055 %)	Approved	27476412
DrugRepV_1035	Doxycycline Monohydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.935 %)	Approved	27476412
DrugRepV_1036	Dacarbazine	Antineoplastic and Immunomodulating Agents	Hodgkin disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.515 %)	Approved	27476412
DrugRepV_1037	Dyphylline	Respiratory System	Chronic bronchitis and emphysema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.825 %)	Approved	27476412
DrugRepV_1038	Rasagiline Mesylate	Nervous System	Idiopathic Parkinson's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.31 %)	Approved	27476412
DrugRepV_1039	Tiludronate Disodium	NA	Paget disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.63 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1040	Chloroquine Diphosphate	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (59.115 %)	Approved	27476412
DrugRepV_1041	Floxuridine	Anticancer	Gastrointestinal adenocarcinomas	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.32 %)	Approved	27476412
DrugRepV_1042	Ergotamine Tartrate	Nervous System	Vascular headache	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (56.33 %)	Approved	27476412
DrugRepV_1043	Voriconazole	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.235 %)	Approved	27476412
DrugRepV_1044	Clonidine Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.37 %)	Approved	27476412
DrugRepV_1045	Dapsone	Antiinfectives For Systemic Use	Leprosy and dermatitis herpetiformis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.585 %)	Approved	27476412
DrugRepV_1046	Rivastigmine Tartrate	Nervous System	Dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.655 %)	Approved, Investigational	27476412
DrugRepV_1047	Ezetimibe	Cardiovascular agents	Hyperlipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.62 %)	Approved	27476412
DrugRepV_1048	Azelaic acid	Dermatologicals	Acne vulgaris	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.95 %)	Approved	27476412
DrugRepV_1049	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.075 %)	Approved	27476412
DrugRepV_1050	Aminohippurate Sodium	Various	Measure effective renal plasma flow	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.04 %)	Approved	27476412
DrugRepV_1051	Bupivacaine Hydrochloride	Nervous System	Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.995 %)	Approved	27476412
DrugRepV_1052	Dipyridamole	Blood and Blood Forming Organs	Coagulation disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.91 %)	Approved	27476412
DrugRepV_1053	Bacitracin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.205 %)	Approved	27476412
DrugRepV_1054	Dienogest	Genito Urinary System and Sex Hormones	Endometriosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.265 %)	Approved	27476412
DrugRepV_1055	Ceftizoxim Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.58 %)	Approved	27476412
DrugRepV_1056	Ethosuximide	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.245 %)	Approved	27476412
DrugRepV_1057	Estradiol	Genito Urinary System and Sex Hormones	Vulvar and vaginal atrophy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.74 %)	Approved	27476412
DrugRepV_1058	Proparacaine Hydrochloride	Sensory Organ	Ophthalmic anesthetic	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.315 %)	Approved, Vet approved	27476412
DrugRepV_1059	Mepivacaine Hydrochloride	Nervous System	Analgesia | Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.64 %)	Approved, Vet approved	27476412
DrugRepV_1060	Amiloride Hydrochloride Dihydrate	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.595 %)	Approved	27476412
DrugRepV_1061	Methsuximide	Anticonvulsant	Seizures	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.81 %)	Approved	27476412
DrugRepV_1062	Acamprosate	Nervous System	Alcohol dependence	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.895 %)	Approved	27476412
DrugRepV_1063	Estrone	Genito Urinary System and Sex Hormones	Perimenopausal and postmenopausal symptoms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.96 %)	Approved	27476412
DrugRepV_1064	Glipizide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.385 %)	Approved, Investigational	27476412
DrugRepV_1065	Nateglinide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.745 %)	Approved, Investigational	27476412
DrugRepV_1066	Lomustine	Antineoplastic and Immunomodulating Agents	Brain tumor	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.175 %)	Approved, Investigational	27476412
DrugRepV_1067	Midodrine Hydrochloride	NA	Orthostatic Hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.235 %)	Approved	27476412
DrugRepV_1068	Norepinephrine Bitartrate Monohydrate	Cardiovascular agents	Vasodilatory shock states such as septic shock and neurogenic shock | Vasopressor medication for patients with critical hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.87 %)	Approved	27476412
DrugRepV_1069	Aripiprazole	Nervous System	Schizophrenia and psychotic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.35 %)	Approved	27476412
DrugRepV_1070	Terazosin Hydrochloride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia | Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.235 %)	Approved	27476412
DrugRepV_1071	Fenoprofen Calcium	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.89 %)	Approved	27476412
DrugRepV_1072	Miglitol	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.84 %)	Approved	27476412
DrugRepV_1073	Methscopolamine Bromide	Alimentary Tract And Metabolism; Sensory Organ	Peptic ulcers | Nausea | Vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.49 %)	Approved	27476412
DrugRepV_1074	Riluzole Hydrochloride	Nervous System	Amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.545 %)	Approved, Investigational	27476412
DrugRepV_1075	Cefotaxime Acid	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.85 %)	Approved	27476412
DrugRepV_1076	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55 %)	Approved	27476412
DrugRepV_1077	Rosuvastatin Calcium	Cardiovascular agents	Hyperlipidemia | Dyslipidemia | Hypertriglyceridemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.215 %)	Approved	27476412
DrugRepV_1078	Clindamycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.415 %)	Approved	27476412
DrugRepV_1079	Sitagliptin Phosphate	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.02 %)	Approved, Investigational	27476412
DrugRepV_1080	Pentostatin	Antineoplastic and Immunomodulating Agents	Hairy cell leukaemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.995 %)	Approved, Investigational	27476412
DrugRepV_1081	Labetalol Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.74 %)	Approved	27476412
DrugRepV_1082	Tiopronin	Genito Urinary System and Sex Hormones	Kidney stone	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.93 %)	Approved	27476412
DrugRepV_1083	Eflornithine Hydrochloride	Dermatologicals	Facial hirsutism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.285 %)	Approved, Withdrawn	27476412
DrugRepV_1084	Gemifloxacin	Antiinfectives For Systemic Use	Bacterial infections (Chronic bronchitis and mild-to-moderate pneumonia)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.92 %)	Approved, Investigational	27476412
DrugRepV_1085	Adefovir dipivoxil	Antiinfectives For Systemic Use	Hepatitis B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.3 %)	Approved	27476412
DrugRepV_1086	Doxapram Hydrochloride Hydrate	Respiratory System	Obstructive pulmonary disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.45 %)	Approved	27476412
DrugRepV_1087	Cetirizine Hydrochloride	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.565 %)	Approved	27476412
DrugRepV_1088	Methyclothiazide	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.82 %)	Approved	27476412
DrugRepV_1089	Ceftazidime	Antibacterial	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.255 %)	Approved	27476412
DrugRepV_1090	Cefprozil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.765 %)	Approved	27476412
DrugRepV_1091	Ipratropium bromide	Respiratory System	Asthma | Chronic bronchitis | Emphysema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.345 %)	Approved, Experimental	27476412
DrugRepV_1092	Colistin Sulfate	Alimentary Tract and Metabolism	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.875 %)	Approved	27476412
DrugRepV_1093	Daunorubicin Hydrochloride	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (72.65 %)	Approved	27476412
DrugRepV_1094	Succinylcholine Chloride Dihydrate	Musculo-Skeletal System	Muscle spasms (Muscle Relaxant)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.005 %)	Approved	27476412
DrugRepV_1095	Emtricitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.065 %)	Approved	27476412
DrugRepV_1096	Cefdinir	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.845 %)	Approved	27476412
DrugRepV_1097	Tropicamide	Sensory Organ	Mydriasis and Cycloplegia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.195 %)	Approved	27476412
DrugRepV_1098	Entacapone	Nervous System	Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.01 %)	Approved	27476412
DrugRepV_1099	Cisplatin	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.65 %)	Approved	27476412
DrugRepV_1100	Acetylcholine Chloride	Sensory Organ	Ophthalmological Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.43 %)	Approved	27476412
DrugRepV_1101	Ketoprofen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Dysmenorrhea | Pain (sprains and strains, postoperative (including dental surgery) or postpartum pain)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.115 %)	Approved, Vet approved	27476412
DrugRepV_1102	Paromomycin Sulfate	Alimentary Tract and Metabolism	Intestinal Amebiasis | Hepatic coma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.015 %)	Approved	27476412
DrugRepV_1103	Cycloserine	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.77 %)	Approved	27476412
DrugRepV_1104	Norethindrone	Gynaecological-agents	Secondary amenorrhea | Endometriosis | Abnormal uterine bleeding	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.75 %)	Approved	27476412
DrugRepV_1105	Flumazenil	Various	Anesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.315 %)	Approved	27476412
DrugRepV_1106	Quetiapine Fumarate	Nervous System	Schizophrenia | Bipolar disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.45 %)	Approved	27476412
DrugRepV_1107	Finasteride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.37 %)	Approved	27476412
DrugRepV_1108	Trimethadione	Nervous System	Seizure | Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.375 %)	Approved	27476412
DrugRepV_1109	Tenofovir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.855 %)	Approved, Investigational	27476412
DrugRepV_1110	Pentoxifylline	Cardiovascular agents	Chronic occlusive arterial disease of the limbs	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.155 %)	Approved, Investigational	27476412
DrugRepV_1111	Moxifloxacin Hydrochloride	Antiinfectives For Systemic Use	Sinusitis | Pneumonia | Chronic bronchitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.71 %)	Approved, Investigational	27476412
DrugRepV_1112	Capsaicin	Nervous System	Neuropathic pain associated with post-herpetic neuralgia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.63 %)	Approved	27476412
DrugRepV_1113	Oxytetracycline Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.71 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1114	Zafirlukast	Respiratory System	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.94 %)	Approved	27476412
DrugRepV_1115	Niacin	NA	Hyperlipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.67 %)	Approved, Investigational, Nutraceutical	27476412
DrugRepV_1116	Valganciclovir Hydrochloride	Antiinfectives For Systemic Use	Herpes simplex and Zoster virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.32 %)	Approved	27476412
DrugRepV_1117	Losartan Potassium	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.79 %)	Approved	27476412
DrugRepV_1118	4-Aminosalicylic Acid	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.44 %)	Approved	27476412
DrugRepV_1119	Butenafine Hydrochloride	Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.54 %)	Approved	27476412
DrugRepV_1120	Nisoldipine	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.255 %)	Approved	27476412
DrugRepV_1121	Dobutamine Hydrochloride	Cardiovascular agents	Cardiovascular disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.705 %)	Approved	27476412
DrugRepV_1122	Vigabatrin	Nervous System	Epilepsy and Seizure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.795 %)	Approved	27476412
DrugRepV_1123	Flunisolide	Respiratory System	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.785 %)	Approved, Investigational	27476412
DrugRepV_1124	Mafenide Hydrochloride	Dermatologicals	Severe burns	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.525 %)	Approved, Vet approved	27476412
DrugRepV_1125	Levalbuterol Hydrochloride	Respiratory System	Chronic obstructive pulmonary disease | Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.305 %)	Approved, Investigational	27476412
DrugRepV_1126	Milnacipran Hydrochloride	Nervous System	Depressive disorder | Fibromyalgia pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.375 %)	Approved, Investigational	27476412
DrugRepV_1127	Droperidol	Nervous System	Nausea and vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.61 %)	Approved	27476412
DrugRepV_1128	Ramelteon	Nervous System	Insomnia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.02 %)	Approved, Investigational	27476412
DrugRepV_1129	Fluorometholone	Sensory Organ	Inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.275 %)	Approved, Investigational	27476412
DrugRepV_1130	Ketorolac Tromethamine	Musculo-Skeletal System	Osteoarthritis | Severe Pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.06 %)	Approved	27476412
DrugRepV_1131	Methenamine Hippurate	Antiinfectives For Systemic Use	Urinary tract infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.645 %)	Approved, Vet approved	27476412
DrugRepV_1132	Cloxacillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.82 %)	Approved	27476412
DrugRepV_1133	Candesartan	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.62 %)	Experimental	27476412
DrugRepV_1134	Disopyramide	Cardiovascular agents	Ventricular tachycardia and arrhythmias	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.605 %)	Approved	27476412
DrugRepV_1135	Fluocinonide	Dermatologicals	Eczema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.945 %)	Approved, Investigational	27476412
DrugRepV_1136	Sotalol Hydrochloride	Cardiovascular agents	Atrial flutter	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.965 %)	Approved	27476412
DrugRepV_1137	Fenofibrate	Cardiovascular agents	Hypercholesterolemia | Dyslipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.755 %)	Approved	27476412
DrugRepV_1138	Travoprost	Sensory Organ	Glaucoma or ocular hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.805 %)	Approved	27476412
DrugRepV_1139	Medroxyprogesterone Acetate	Genito Urinary System and Sex Hormones	Amenorrhea | Abnormal uterine bleeding	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.06 %)	Approved	27476412
DrugRepV_1140	Clozapine	Nervous System	Psychosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.96 %)	Approved	27476412
DrugRepV_1141	Torsemide	Cardiovascular agents	Edema and hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.19 %)	Approved	27476412
DrugRepV_1142	Decitabine	Antineoplastic and Immunomodulating Agents	Myelodysplastic syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.315 %)	Approved	27476412
DrugRepV_1143	Metoprolol Tartrate	Cardiovascular agents	Angina | Heart failure | Myocardial infarction | Atrial fibrillation | Atrial flutter | Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.545 %)	Approved, Investigational	27476412
DrugRepV_1144	Dexchlorpheniramine Maleate	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.11 %)	Approved	27476412
DrugRepV_1145	Fludrocortisone Acetate	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Addison disease and salt-losing adrenogenital syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.635 %)	Approved	27476412
DrugRepV_1146	Cyclopentolate	Sensory Organ	Mydriasis and cycloplegia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.525 %)	Approved	27476412
DrugRepV_1147	Tirofiban Hydrochloride	Blood and Blood Forming Organs	Acute coronary syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.245 %)	Approved	27476412
DrugRepV_1148	Piperacillin	Antiinfectives For Systemic Use	Polymicrobial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.9 %)	Approved	27476412
DrugRepV_1149	Rizatriptan Benzoate	NA	Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.98 %)	Approved	27476412
DrugRepV_1150	Diflunisal	Nervous System	Osteoarthritis and rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.05 %)	Approved	27476412
DrugRepV_1151	Famciclovir	Antiinfectives For Systemic Use	Herpes simplex virus | Zoster virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.62 %)	Approved, Investigational	27476412
DrugRepV_1152	Metyrapone	Various	Cushing syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.775 %)	Approved, Investigational	27476412
DrugRepV_1153	Naphazoline Hydrochloride	Respiratory System; Sensory Organ	Eyedrops for ocular vasoconstriction or as a nasal preparation for nasal congestion	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.32 %)	Approved, Investigational	27476412
DrugRepV_1154	Quinapril Hydrochloride	Cardiovascular agents	Hypertension | Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.015 %)	Approved, Investigational	27476412
DrugRepV_1155	Levobunolol Hydrochloride	Sensory Organ	Glaucoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.12 %)	Approved	27476412
DrugRepV_1156	Metolazone	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.57 %)	Approved	27476412
DrugRepV_1157	Amoxicillin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.335 %)	Approved	27476412
DrugRepV_1158	Testosterone Enanthate	Genito Urinary System and Sex Hormones	Primary hypogonadism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.075 %)	Approved	27476412
DrugRepV_1159	Esomeprazole Potassium	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.98 %)	Approved	27476412
DrugRepV_1160	Anastrozole	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.01 %)	Approved	27476412
DrugRepV_1161	Pemirolast Potassium	Respiratory-Tract-agents	Eye itching caused by allergies such as hay fever, and allergic conjunctivitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.52 %)	Approved	27476412
DrugRepV_1162	Flurandrenolide	Dermatologicals	Skin disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.98 %)	Approved	27476412
DrugRepV_1163	Sulfanilamide	Antiinfectives For Systemic Use	Vulvovaginitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.175 %)	Approved	27476412
DrugRepV_1164	Memantine Hydrochloride	Nervous System	Alzheimer's dementia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.785 %)	Approved, Investigational	27476412
DrugRepV_1165	Rifampin	Antiinfectives For Systemic Use	Tuberculosis and Tuberculosis-related mycobacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.505 %)	Approved	27476412
DrugRepV_1166	Repaglinide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.1 %)	Approved, Investigational	27476412
DrugRepV_1167	Cefepime Hydrochloride Hydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.89 %)	Approved	27476412
DrugRepV_1168	Ropivacaine Hydrochloride Monohydrate	Nervous System	Used in obstetric anesthesia and regional anesthesia for surgery	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.655 %)	Approved	27476412
DrugRepV_1169	Orlistat	Alimentary Tract and Metabolism	Obesity	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.835 %)	Approved, Investigational	27476412
DrugRepV_1170	Oxaprozin	Musculo-Skeletal System	Inflammation | Swelling | Stiffness | Joint pain associated with rheumatoid arthritis and osteoarthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.255 %)	Approved	27476412
DrugRepV_1171	Naftifine Hydrochloride	Dermatologicals	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.795 %)	Approved	27476412
DrugRepV_1172	Phenylephrine	Cardiovascular agents; Respiratory System; Sensory Organ	Nasal congestion | Hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.085 %)	Approved	27476412
DrugRepV_1173	Oxiconazole Nitrate	Dermatologicals	Dermal fungal infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.345 %)	Approved	27476412
DrugRepV_1174	Chlorpromazine Hydrochloride	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.955 %)	Approved	27476412
DrugRepV_1175	Nicotine	Nervous System	Nicotine dependence (Tobacco smoke)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.33 %)	Approved	27476412
DrugRepV_1176	Trandolapril	Cardiovascular agents	Hypertension and Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.025 %)	Approved	27476412
DrugRepV_1177	Doripenem	Antiinfectives For Systemic Use	Intra-abdominal infections and complicated urinary tract infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.47 %)	Approved	27476412
DrugRepV_1178	Phenoxybenzamine Hydrochloride	Cardiovascular agents	Phaeochromocytoma (malignant) | Benign prostatic hypertrophy | Malignant essential hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.895 %)	Approved	27476412
DrugRepV_1179	Amiodarone Hydrochloride	Cardiovascular agents	Anginal and Arrhythmia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.055 %)	Approved	27476412
DrugRepV_1180	Topiramate	Nervous System	Seizures (Epilepsy) | Migraine	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.995 %)	Approved	27476412
DrugRepV_1181	Brimonidine	Sensory Organ	Glaucoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.265 %)	Approved	27476412
DrugRepV_1182	Methylprednisolone	Dermatologicals; Dermatologicals; Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.3 %)	Approved, Vet approved	27476412
DrugRepV_1183	Flavoxate Hydrochloride	Genito Urinary System and Sex Hormones	Urinary syndromes	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.38 %)	Approved	27476412
DrugRepV_1184	Propofol	Nervous System	Anaesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.53 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1185	Isosorbide Dinitrate	Cardiovascular agents	Angina pectoris (Coronary artery disease)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.66 %)	Approved, Investigational	27476412
DrugRepV_1186	Mannitol	Alimentary Tract And Metabolism; Blood and Blood Forming Organs; and Respiratory System	Diuresis | Intracranial pressure | Cerebral edema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.355 %)	Approved, Investigational	27476412
DrugRepV_1187	Cefadroxil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.15 %)	Approved	27476412
DrugRepV_1188	Lindane	Antiparasitic products, Insectisides and Repellents	Scabies	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.465 %)	Approved, Withdrawn	27476412
DrugRepV_1189	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.03 %)	Approved	27476412
DrugRepV_1190	Ranolazine Dihydrochloride	Cardiovascular agents	Chronic angina | Ventricular tachycardia | Acute coronary syndrome | Microvascular coronary dysfunction | Arrhythmia | Glycemic control	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.88 %)	Approved	27476412
DrugRepV_1191	Dicloxacillin Sodium Salt Monohydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.765 %)	Approved	27476412
DrugRepV_1192	Etidronate Disodium	Musculo-Skeletal System	Paget disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.165 %)	Approved	27476412
DrugRepV_1193	Carbidopa	Neurologic-agent	Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.045 %)	Approved	27476412
DrugRepV_1194	Cimetidine	Alimentary Tract and Metabolism	Peptic ulcers, heartburn and acid indigestion	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.79 %)	Approved	27476412
DrugRepV_1195	Dalfampridine	Nervous System	Multiple sclerosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.235 %)	Approved	27476412
DrugRepV_1196	Ganciclovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.48 %)	Approved, Investigational	27476412
DrugRepV_1197	Tiagabine Hydrochloride	Nervous System	Panic disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.68 %)	Approved, Investigational	27476412
DrugRepV_1198	Trihexyphenidyl Hydrochloride	Nervous System	Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.61 %)	Approved	27476412
DrugRepV_1199	Rifaximin	Alimentary Tract and Metabolism	Traveller's Diarrhea | Irritable bowel syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.745 %)	Approved, Investigational	27476412
DrugRepV_1200	Fosphenytoin Sodium Pentahydrate	Nervous System	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.9 %)	Approved, Investigational	27476412
DrugRepV_1201	Aspirin	Alimentary Tract And Metabolism; Blood and Blood Forming Organs; and Nervous System	Rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.71 %)	Approved	27476412
DrugRepV_1202	Flutamide	Antineoplastic and Immunomodulating Agents	Prostate cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.23 %)	Approved, Investigational	27476412
DrugRepV_1203	Meloxicam	Musculo-Skeletal System	Arthritis | Osteoarthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.475 %)	Approved, Vet approved	27476412
DrugRepV_1204	Amlexanox	Respiratory System	Asthma and rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.71 %)	Approved	27476412
DrugRepV_1205	Naringenin	NA	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.34 %)	Experimental	27476412
DrugRepV_1206	Lansoprazole	Alimentary Tract and Metabolism	Gastric acid secretion | Gastric ulcers, active duodenal ulcers | Erosive reflux oesophagitis | Gastroesophageal reflux disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.545 %)	Approved, Investigational	27476412
DrugRepV_1207	(S)-Timolol Maleate	Cardiovascular agents; Sensory	Hypertension, heart disease and anginal pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.365 %)	Approved	27476412
DrugRepV_1208	Regadenoson	Cardiovascular agents	Myocardial perfusion imaging (MPI)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.46 %)	Approved	27476412
DrugRepV_1209	Maraviroc	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.18 %)	Approved, Investigational	27476412
DrugRepV_1210	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.73 %)	Approved	27476412
DrugRepV_1211	Ifosfamide	Antineoplastic and Immunomodulating Agents	Germ cell testicular cancer | Cervical cancer | Osteosarcoma | Bladder cancer | Ovarian cancer | Small cell lung cancer | Non-Hodgkin's lymphoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.825 %)	Approved	27476412
DrugRepV_1212	Zalcitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.06 %)	Approved	27476412
DrugRepV_1213	Cyclophosphamide Monohydrate	Antineoplastic and Immunomodulating Agents	Lymphoma and leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.745 %)	Approved	27476412
DrugRepV_1214	Sildenafil Citrate	Genito Urinary System and Sex Hormones	Erectile dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.095 %)	Approved, Investigational	27476412
DrugRepV_1215	Metronidazole	Antiparasitic products, Insectisides and Repellents	Amebiasis | Vaginitis | Trichomonas infections | Giardiasis | Anaerobic bacteria | Treponemal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.465 %)	Approved	27476412
DrugRepV_1216	Kanamycin Sulfate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.43 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1217	Clomipramine Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.19 %)	Approved	27476412
DrugRepV_1218	Methocarbamol	Musculo-Skeletal System	Muscle spasms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.16 %)	Approved, Vet approved	27476412
DrugRepV_1219	Methimazole	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hyperthyroidism | Goiter | Graves disease | Psoriasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.56 %)	Approved	27476412
DrugRepV_1220	Amcinonide	Dermatologicals	Inflammatory and pruritic	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.13 %)	Approved	27476412
DrugRepV_1221	Aminolevulinic Acid Hydrochloride	Antineoplastic and Immunomodulating Agents	Actinic keratosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.19 %)	Approved	27476412
DrugRepV_1222	Betaxolol Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.605 %)	Approved	27476412
DrugRepV_1223	Metformin Hydrochloride	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.215 %)	Approved	27476412
DrugRepV_1224	Galantamine Hydrobromide	NA	Alzheimer's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.96 %)	Approved	27476412
DrugRepV_1225	Nevirapine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.07 %)	Approved	27476412
DrugRepV_1226	Pindolol	Cardiovascular agents	Hypertension | Edema | Ventricular tachycardias | Atrial fibrillation	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.37 %)	Approved, Investigational	27476412
DrugRepV_1227	Darunavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.605 %)	Approved	27476412
DrugRepV_1228	Sulfacetamide Sodium	Dermatologicals	Bacterial infections (Vaginitis, keratitis, acute conjunctivitis, and blepharitis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.36 %)	Approved	27476412
DrugRepV_1229	Nalbuphine Hydrochloride Dihydrate	Nervous System	Pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.375 %)	Approved	27476412
DrugRepV_1230	Temozolomide	Antineoplastic and Immunomodulating Agents	Anaplastic astrocytoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.52 %)	Approved	27476412
DrugRepV_1231	Azelastine Hydrochloride	Respiratory System	Rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.96 %)	Approved	27476412
DrugRepV_1232	Busulfan	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.405 %)	Approved	27476412
DrugRepV_1233	Methylergonovine Maleate	Genito Urinary System and Sex Hormones	Postpartum hemorrhage	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.715 %)	Approved	27476412
DrugRepV_1234	Cefotetan Disodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.645 %)	Approved	27476412
DrugRepV_1235	Aztreonam	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.05 %)	Approved	27476412
DrugRepV_1236	Phentolamine Hydrochloride	Cardiovascular agents	Pheochromocytoma | Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.465 %)	Approved	27476412
DrugRepV_1237	Salbutamol Hemisulfate	Respiratory System	Bronchial asthma | Chronic bronchitis | Chronic bronchopulmonary disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.66 %)	Approved	27476412
DrugRepV_1238	Flucytosine	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.75 %)	Approved, Investigational	27476412
DrugRepV_1239	Clomiphene Citrate	Genito Urinary System and Sex Hormones	Female infertility	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.36 %)	Approved	27476412
DrugRepV_1240	Drospirenone	Genito Urinary System and Sex Hormones	Contraception	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.33 %)	Approved	27476412
DrugRepV_1241	Malathion	Antiparasitic products, Insectisides and Repellents	Pediculus humanus capitis of the scalp hair	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.575 %)	Approved, Investigational	27476412
DrugRepV_1242	Captopril	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.42 %)	Approved	27476412
DrugRepV_1243	Fluorouracil	Antineoplastic and Immunomodulating Agents	Multiple actinic or solar keratoses | Cancer, such as colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.195 %)	Approved	27476412
DrugRepV_1244	Propylthiouracil	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hyperthyroidism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.32 %)	Approved, Investigational	27476412
DrugRepV_1245	Terconazole	Genito Urinary System and Sex Hormones	Candidiasis (a yeast-like fungal infection) of the vulva and vagina	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.175 %)	Approved	27476412
DrugRepV_1246	Tranexamic Acid	Blood and Blood Forming Organs	Hemorrhage	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.975 %)	Approved	27476412
DrugRepV_1247	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.405 %)	Approved, Investigational	27476412
DrugRepV_1248	Atracurium Besylate	Musculo-Skeletal System	Endotracheal intubation	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.525 %)	Approved	27476412
DrugRepV_1249	Dorzolamide Hydrochloride	Sensory Organ	Open-angle glaucoma and ocular hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.595 %)	Approved	27476412
DrugRepV_1250	Cefoxitin Sodium	Antibiotics	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.11 %)	Approved	27476412
DrugRepV_1251	Isotretinoin	Dermatologicals	Acne	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.065 %)	Approved	27476412
DrugRepV_1252	Griseofulvin	Dermatologicals	Fungal infections (Ringworm infections of the skin, hair, and nails, namely: tinea corporis, tinea pedis, tinea cruris, tinea barbae, cradle cap)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.7 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1253	Dihydroergotamine Mesylate	Nervous System	Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.92 %)	Approved	27476412
DrugRepV_1254	Theophylline	Respiratory System	Chronic asthma | Chronic lung diseases, such as emphysema and chronic bronchitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.835 %)	Approved	27476412
DrugRepV_1255	Alprostadil	Genito Urinary System and Sex Hormones	Palliative and erectile dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.655 %)	Approved	27476412
DrugRepV_1256	Diatrizoate Meglumine	Various	X-ray contrast medium, gastrointestinal studies, angiography, and urography	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.205 %)	Approved	27476412
DrugRepV_1257	Streptozocin	Antineoplastic and Immunomodulating Agents	Malignant neoplasms of pancreas (metastatic islet cell carcinoma)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.225 %)	Approved, Investigational	27476412
DrugRepV_1258	Ropinirole Hydrochloride	Nervous System	Parkinson's disease | Restless legs syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.565 %)	Approved, Investigational	27476412
DrugRepV_1259	Nicardipine Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.09 %)	Approved, Investigational	27476412
DrugRepV_1260	Silver Sulfadiazine	Dermatologicals	Wound sepsis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.965 %)	Approved	27476412
DrugRepV_1261	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.915 %)	Approved, Investigational	27476412
DrugRepV_1262	Cefditoren Pivoxil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.4 %)	Approved	27476412
DrugRepV_1263	Disodium Cromoglycate	Alimentary Tract And Metabolism; Dermatologicals; Respiratory System; Respiratory System; Sensory Or	Allergy and asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.03 %)	Approved	27476412
DrugRepV_1264	Cefpodoxime Proxetil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.81 %)	Approved	27476412
DrugRepV_1265	Baclofen	Musculo-Skeletal System	Muscle spasms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.605 %)	Approved	27476412
DrugRepV_1266	Miglustat	Alimentary Tract and Metabolism	Gaucher's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.98 %)	Approved	27476412
DrugRepV_1267	Selegiline Hydrochloride	Nervous System	Parkinson's Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.86 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1268	Guanidine Hydrochloride	Musculo-Skeletal System	Muscle weakness | Myasthenic syndrome of Eaton-Lambert	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.91 %)	Approved	27476412
DrugRepV_1269	Carglumic Acid	NA	Hyperammonaemia in patients with N-acetylglutamate synthase (NAGS) deficiency	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.855 %)	Approved	27476412
DrugRepV_1270	Flecainide Acetate	Cardiovascular agents	Arrhythmia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.52 %)	Approved, Withdrawn	27476412
DrugRepV_1271	Meropenem	Antiinfectives For Systemic Use	Bacterial infections (Skin infection)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.025 %)	Approved, Investigational	27476412
DrugRepV_1272	Milrinone	Cardiovascular agents	Cardiotonic agent	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.26 %)	Approved	27476412
DrugRepV_1273	Bromfenac	Sensory Organ	Non-steroidal anti-inflammatory agent	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.755 %)	Approved	27476412
DrugRepV_1274	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.2 %)	Approved, Investigational	27476412
DrugRepV_1275	Citalopram Hydrobromide	Nervous System	Depressive disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.045 %)	Approved	27476412
DrugRepV_1276	Tigecycline	Antiinfectives For Systemic Use	Complicated skin and skin structure infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.4 %)	Approved	27476412
DrugRepV_1277	Naratriptan Hydrochloride	Nervous System	Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.13 %)	Approved, Investigational	27476412
DrugRepV_1278	Latanoprost	Sensory Organ	Glaucoma or ocular hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.57 %)	Approved, Investigational	27476412
DrugRepV_1279	Dopamine Hydrochloride	Cardiovascular agents	Arrythmias and arterial hypotension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.74 %)	Approved	27476412
DrugRepV_1280	Brompheniramine Maleate	Respiratory System	Allergies, rhinitis and urticaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.015 %)	Approved	27476412
DrugRepV_1281	Clarithromycin	Antiinfectives For Systemic Use	Microbial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.09 %)	Approved	27476412
DrugRepV_1282	Fosfomycin Calcium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.385 %)	Approved	27476412
DrugRepV_1283	Zolmitriptan	Nervous System	Migraine with or without auras	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.49 %)	Approved	27476412
DrugRepV_1284	Perphenazine	Nervous System	Psychosis | Nausea and vomiting in adults	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.76 %)	Approved	27476412
DrugRepV_1285	Carbinoxamine maleate	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.11 %)	Approved	27476412
DrugRepV_1286	Hydroxocobalamin Hydrochloride	Blood and Blood Forming Organs	Vitamin B12 deficiency	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.41 %)	Approved	27476412
DrugRepV_1287	Bicalutamide	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.37 %)	Approved	27476412
DrugRepV_1288	Trimethoprim	Antiinfectives For Systemic Use	Urinary tract infections | Uncomplicated pyelonephritis (with sulfamethoxazole) | Mild acute prostatitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.69 %)	Approved	27476412
DrugRepV_1289	Mefenamic Acid	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Dysmenorrhea, and mild to moderate pain, inflammation, and fever	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.43 %)	Approved	27476412
DrugRepV_1290	Gentamycin Sulfate	NA	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.715 %)	Approved	27476412
DrugRepV_1291	Olanzapine	Nervous System	Schizophrenia | Bipolar I disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.535 %)	Approved, Investigational	27476412
DrugRepV_1292	Argatroban	Blood and Blood Forming Organs	Coagulation disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.59 %)	Approved	27476412
DrugRepV_1293	Trimethobenzamide Hydrochloride	Respiratory System	Nausea | Vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.125 %)	Approved, Investigational	27476412
DrugRepV_1294	Pramipexole Dihydrochloride Monohydrate	Nervous System	Parkinson's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.46 %)	Approved, Investigational	27476412
DrugRepV_1295	Cilastatin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.065 %)	Approved	27476412
DrugRepV_1296	Levocetirizine Dihydrochloride	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.885 %)	Approved	27476412
DrugRepV_1297	Naloxone Hydrochloride	Alimentary Tract And Metabolism; Various	Narcotic depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.38 %)	Approved, Vet approved	27476412
DrugRepV_1298	Hydroxyurea	Antineoplastic and Immunomodulating Agents	Melanoma | Chronic myelocytic leukemia | Ovary carcinoma | Sickle-cell anemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.375 %)	Approved	27476412
DrugRepV_1299	Vecuronium bromide	Musculo-Skeletal System	Non-depolarizing neuromuscular blocking agent	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.6 %)	Approved	27476412
DrugRepV_1300	Paliperidone	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.455 %)	Approved	27476412
DrugRepV_1301	Glimepiride	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.29 %)	Approved	27476412
DrugRepV_1302	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.29 %)	Approved, Investigational	27476412
DrugRepV_1303	Piroxicam	Musculo-Skeletal System	Osteoarthritis | Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.81 %)	Approved, Investigational	27476412
DrugRepV_1304	Ramipril	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.37 %)	Approved	27476412
DrugRepV_1305	Bisoprolol Fumarate	Cardiovascular agents	Cardiovascular disease, angina pectoris and myocardial infarction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.34 %)	Approved	27476412
DrugRepV_1306	Dinoprostone	Genito Urinary System and Sex Hormones	Gestational trophoblastic disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.46 %)	Approved	27476412
DrugRepV_1307	Neomycin Sulfate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.33 %)	Approved	27476412
DrugRepV_1308	Penicillamine	Musculo-Skeletal System	Wilson disease | Cystinuria | Active rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.665 %)	Approved	27476412
DrugRepV_1309	Nafcillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.57 %)	Approved, Investigational	27476412
DrugRepV_1310	Capreomycin Disulfate	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.425 %)	Approved	27476412
DrugRepV_1311	Mupirocin	Dermatologicals and Respiratory System	Impetigo | Skin lesions (Staphylococci infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.04 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1312	Cefazolin Sodium	Antibiotics	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.205 %)	Approved	27476412
DrugRepV_1313	Carmustine	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.895 %)	Approved	27476412
DrugRepV_1314	Gemfibrozil	Cardiovascular agents	Hyperlipidemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.965 %)	Approved	27476412
DrugRepV_1315	Flurbiprofen	Musculo-Skeletal System	Rheumatoid arthritis | Osteorarthritis | Anklosing spondylitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.215 %)	Approved, Investigational	27476412
DrugRepV_1316	Dexamethasone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Dermatologicals; Systemic H	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.47 %)	Approved	27476412
DrugRepV_1317	Esmolol	Cardiovascular agents	Cardiovascular disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.035 %)	Approved	27476412
DrugRepV_1318	Carboplatin	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.525 %)	Approved	27476412
DrugRepV_1319	Gefitinib	Antineoplastic and Immunomodulating Agents	Non-small cell lung cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.195 %)	Approved, Investigational	27476412
DrugRepV_1320	Hydroxychloroquine Sulfate	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.595 %)	Approved	27476412
DrugRepV_1321	Sulfamethoxazole	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, prostatitis and urinary tract infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.87 %)	Approved	27476412
DrugRepV_1322	Misoprostol	Alimentary Tract and Metabolism	Gastric ulcer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.33 %)	Approved	27476412
DrugRepV_1323	Eprosartan Mesylate	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.265 %)	Approved	27476412
DrugRepV_1324	Maprotiline Hydrochloride	Nervous System	Bipolar depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.58 %)	Approved, Investigational	27476412
DrugRepV_1325	Tetracycline	Antiinfectives For Systemic Use	Bacterial infections (Rocky Mountain spotted fever | Typhus fever | Tick fevers | Q fever | Rickettsialpox | Brill-Zinsser disease)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.51 %)	Approved	27476412
DrugRepV_1326	Sulfadiazine	Antiinfectives For Systemic Use	Rheumatic fever | Meningococcal meningitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.975 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1327	Azacitidine	Antineoplastic and Immunomodulating Agents	French-American-British myelodysplastic syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.81 %)	Approved	27476412
DrugRepV_1328	Liothyronine Sodium	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hypothyroidism | Thyroid cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.935 %)	Approved, Vet approved	27476412
DrugRepV_1329	Mesalamine	Alimentary Tract and Metabolism	Ulcerative colitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.935 %)	Approved	27476412
DrugRepV_1330	Methyldopa Sesquihydrate	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.48 %)	Approved	27476412
DrugRepV_1331	Propafenone Hydrochloride	Cardiovascular agents	Paroxysmal atrial fibrillation/flutter	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.065 %)	Approved	27476412
DrugRepV_1332	Mometasone Furoate	Dermatologicals and Respiratory System	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.31 %)	Approved, Vet approved	27476412
DrugRepV_1333	Minoxidil	Cardiovascular agents; Dermatologicals	Hypertension | Alopecia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.195 %)	Approved, Investigational	27476412
DrugRepV_1334	Pamidronic Acid	Musculo-Skeletal System	Hypercalcemia associated with malignancy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48 %)	Approved	27476412
DrugRepV_1335	Promethazine Hydrochloride	Respiratory System	Allergic disorders | Nausea/vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.26 %)	Approved, Investigational	27476412
DrugRepV_1336	Ibandronate Sodium Monohydrate	Musculo-Skeletal System	Osteoporosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.185 %)	Approved	27476412
DrugRepV_1337	Phytonadione	NA	Haemorrhagic conditions in infants | Antidote for coumarin anticoagulants in hypoprothrombinaemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.655 %)	Approved, Investigational	27476412
DrugRepV_1338	Lenalidomide	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.155 %)	Approved	27476412
DrugRepV_1339	Bleomycin Sulfate	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.675 %)	Approved	27476412
DrugRepV_1340	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.185 %)	Approved, Investigational	27476412
DrugRepV_1341	Miconazole	Alimentary Tract And Metabolism; Dermatologicals; Genito Urinary System; Sex Hormones; Antiinfective	Fungal infections (Tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment o	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.55 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1342	Hydroflumethiazide	Cardiovascular agents	Edema | Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.285 %)	Approved, Investigational	27476412
DrugRepV_1343	Articaine Hydrochloride	Nervous System	Anaesthesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.825 %)	Approved	27476412
DrugRepV_1344	Amantadine Hydrochloride	Nervous System	Influenza and Parkinson Disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.43 %)	Approved	27476412
DrugRepV_1345	Anagrelide	Antineoplastic and Immunomodulating Agents	Thrombocytosis and chronic myeloid leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.7 %)	Approved	27476412
DrugRepV_1346	Dolasetron	Alimentary Tract and Metabolism	Nausea and vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.42 %)	Approved	27476412
DrugRepV_1347	Hydrocortisone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Dermatoses | Immune and allergic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.325 %)	Approved, Vet approved	27476412
DrugRepV_1348	Hydrocortisone Acetate	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Dermatoses | Immune and allergic disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.6 %)	Approved	27476412
DrugRepV_1349	Tolazamide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.11 %)	Approved	27476412
DrugRepV_1350	Tobramycin	Antiinfectives For Systemic Use; Sensory Organ	Pseudomonas Aeruginosa (Bacteria) lung infections | Sinus infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.055 %)	Approved, Investigational	27476412
DrugRepV_1351	Sulfasalazine	Alimentary Tract and Metabolism	Inflammatory bowel diseases | Crohn disease | Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.285 %)	Approved	27476412
DrugRepV_1352	Gatifloxacin	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, sinusitis, Community-acquired pneumonia, and Skin infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.98 %)	Approved, Investigational	27476412
DrugRepV_1353	Tetrahydrozoline Hydrochloride	NA	Discomfort and redness of the eye due to minor eye irritations	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.315 %)	Approved	27476412
DrugRepV_1354	Desoximetasone	Dermatologicals	Dermatoses, skin allergies and psoriasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.515 %)	Approved	27476412
DrugRepV_1355	Isoproterenol Hydrochloride	Cardiovascular agents; Respiratory System	Heart block	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.86 %)	Approved, Investigational	27476412
DrugRepV_1356	Fomepizole	Various	Ethylene glycol poisoning	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.72 %)	Approved, Vet approved	27476412
DrugRepV_1357	Desvenlafaxine Succinate Hydrate	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.305 %)	Approved	27476412
DrugRepV_1358	Levocarnitine	Alimentary Tract and Metabolism	Carnitine deficiency | Hyperlipoproteinemias	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.09 %)	Approved, Investigational	27476412
DrugRepV_1359	Lactulose	Alimentary Tract and Metabolism	Constipation | Hepatic encephalopathy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.74 %)	Approved	27476412
DrugRepV_1360	Bumetanide	Cardiovascular agents	Edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.355 %)	Approved	27476412
DrugRepV_1361	Fenoldopam Mesylate	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.23 %)	Approved	27476412
DrugRepV_1362	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.965 %)	Approved	27476412
DrugRepV_1363	Montelukast Sodium	Respiratory System	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.9 %)	Approved	27476412
DrugRepV_1364	Telbivudine	Antiinfectives For Systemic Use	Hepatitis B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.765 %)	Approved	27476412
DrugRepV_1365	Budesonide	Alimentary Tract And Metabolism; Dermatologicals; Respiratory System; Respiratory System	Crohn disease, asthma and rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.745 %)	Approved	27476412
DrugRepV_1366	Granisetron Hydrochloride	Alimentary Tract and Metabolism	Nausea | Vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.96 %)	Approved, Investigational	27476412
DrugRepV_1367	Dexmedetomidine Hydrochloride	Nervous System	Sedative therapy, pain relief , anxiety reduction and analgesia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.065 %)	Approved	27476412
DrugRepV_1368	Quinine Hydrochloride Hydrate	Antiparasitic products, Insectisides and Repellents	Malaria | Leg cramps	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.065 %)	Approved	27476412
DrugRepV_1369	Fluconazole	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.98 %)	Approved, Investigational	27476412
DrugRepV_1370	Sumatriptan Succinate	Nervous System	Migraine disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.465 %)	Approved, Investigational	27476412
DrugRepV_1371	Azithromycin	Antiinfectives For Systemic Use	Microbial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.07 %)	Approved	27476412
DrugRepV_1372	Tranylcypromine Hemisulfate	Nervous System	Depressive episode without melancholia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.615 %)	Approved, Investigational	27476412
DrugRepV_1373	Olsalazine Sodium	Alimentary Tract and Metabolism	Inflammatory Bowel Disease | Ulcerative Colitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.435 %)	Approved	27476412
DrugRepV_1374	Gabapentin	Nervous System	Epilepsy (seizure)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.8 %)	Approved	27476412
DrugRepV_1375	Cysteamine Hydrochloride	Sensory Organ	Radiation sickness, cystinosis and cystinurea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.955 %)	Approved	27476412
DrugRepV_1376	Betaine	Alimentary Tract and Metabolism	NA	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.565 %)	Approved, Nutraceutical	27476412
DrugRepV_1377	Halobetasol Propionate	Dermatologicals	Dermatoses	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.565 %)	Approved	27476412
DrugRepV_1378	Tizanidine Hydrochloride	Musculo-Skeletal System	Muscle spasms | Multiple sclerosis | Stroke | Acquired brain injury or a Spinal cord injury	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.39 %)	Approved, Investigational	27476412
DrugRepV_1379	Risedronic Acid	Musculo-Skeletal System	Paget's disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.505 %)	Approved	27476412
DrugRepV_1380	Ampicillin Trihydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.895 %)	Approved	27476412
DrugRepV_1381	Amifostine	Various	Nephrotoxicity and Xerostomia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.31 %)	Approved	27476412
DrugRepV_1382	Foscarnet Sodium	Antiinfectives For Systemic Use	Cytomegalovirus retinitis | Herpesviruses | Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.945 %)	Approved	27476412
DrugRepV_1383	Altretamine	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.56 %)	Approved	27476412
DrugRepV_1384	Hydroxyzine Dihydrochloride	Nervous System	Anxiety | Tension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.005 %)	Approved	27476412
DrugRepV_1385	Enalapril	Cardiovascular agents	Hypertension and Diabetic nephropathies	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.605 %)	Approved	27476412
DrugRepV_1386	Dantrolene Sodium	Musculo-Skeletal System	Malignant hyperthermia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.04 %)	Approved	27476412
DrugRepV_1387	Indapamide	Cardiovascular agents	Hypertension | Edema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.8 %)	Approved	27476412
DrugRepV_1388	Tiotropium Bromide	Respiratory System	Chronic obstructive pulmonary disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.135 %)	Approved	27476412
DrugRepV_1389	Diazoxide	Cardiovascular agents	Hypertension, hyperinsulinemic and hypoglycemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.04 %)	Approved	27476412
DrugRepV_1390	Mexiletine Hydrochloride	Cardiovascular agents	Ventricular tachycardia | Symptomatic premature ventricular beats	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.255 %)	Approved, Investigational	27476412
DrugRepV_1391	Nitrofurantoin	Antiinfectives For Systemic Use	Urinary tract infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.26 %)	Approved	27476412
DrugRepV_1392	Abacavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.76 %)	Approved	27476412
DrugRepV_1393	Sulconazole Nitrate	Dermatologicals	Fungal infections (Tinea cruris and Tinea corporis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.21 %)	Approved	27476412
DrugRepV_1394	Tinidazole	NA	Trichomonasis | Amebiasis | Giardiasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.3 %)	Approved	27476412
DrugRepV_1395	Dicyclomine Hydrochloride	Alimentary Tract and Metabolism	Bowel/irritable bowel syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.09 %)	Approved	27476412
DrugRepV_1396	Diclofenac Sodium salt	Dermatologicals; Musculo-Skeletal System and Sensory Organ	Fever and pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.66 %)	Approved	27476412
DrugRepV_1397	Atenolol	Cardiovascular agents	Hypertension and angina pectoris	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.835 %)	Approved	27476412
DrugRepV_1398	Trimipramine Maleate	Nervous System	Anxiety, Agitation or Sleep disturbance	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.4 %)	Approved	27476412
DrugRepV_1399	Ondansetron	Alimentary Tract and Metabolism	Nausea | Vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.655 %)	Approved	27476412
DrugRepV_1400	Betamethasone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Edocrine disorders, rheumatic disorders, collagen diseases	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.4 %)	Approved	27476412
DrugRepV_1401	Cortisone Acetate	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Allergies, skin problems, asthma and arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.925 %)	Approved	27476412
DrugRepV_1402	Loteprednol Etabonate	Sensory Organ	Allergic conjunctivitis | Uveitis | Acne rosacea | Superficial punctate keratitis | Herpes zoster keratitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.55 %)	Approved	27476412
DrugRepV_1403	Tamsulosin Hydrochloride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.555 %)	Approved, Investigational	27476412
DrugRepV_1404	Ketotifen Fumarate	Respiratory System	Atopic asthma | Conjunctivitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.43 %)	Approved	27476412
DrugRepV_1405	Glyburide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.39 %)	Approved	27476412
DrugRepV_1406	Permethrin	Antiparasitic products, Insectisides and Repellents	Scabies	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.93 %)	Approved, Investigational	27476412
DrugRepV_1407	Amrinone	Cardiovascular agents	Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.125 %)	Approved	27476412
DrugRepV_1408	Clobetasol Propionate	Dermatologicals	Psoriasis and dermatosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.13 %)	Approved	27476412
DrugRepV_1409	Artemether	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.96 %)	Approved	27476412
DrugRepV_1410	Hydralazine Hydrochloride	Cardiovascular agents	Hypertension | Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.67 %)	Approved	27476412
DrugRepV_1411	Topotecan Hydrochloride	Antineoplastic and Immunomodulating Agents	Ovarian cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.14 %)	Approved, Investigational	27476412
DrugRepV_1412	Nifedipine	Cardiovascular agents	Vasospastic angina | Chronic stable angina | Hypertension | Raynaud's phenomenon	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.03 %)	Approved	27476412
DrugRepV_1413	Dexrazoxane	Various	Cardiomyopathy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.42 %)	Approved	27476412
DrugRepV_1414	Fosinopril Sodium	Cardiovascular agents	Hypertension | Congestive heart failure | Renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.225 %)	Approved	27476412
DrugRepV_1415	Capecitabine	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.405 %)	Approved	27476412
DrugRepV_1416	Rifapentine	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.79 %)	Approved, Investigational	27476412
DrugRepV_1417	Difluprednate	NA	Anterior uveitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.575 %)	Approved	27476412
DrugRepV_1418	Letrozole	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.705 %)	Approved, Investigational	27476412
DrugRepV_1419	Clavulanate Potassium	Antibacterial	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.97 %)	Approved	27476412
DrugRepV_1420	Nadolol	Cardiovascular agents	Arrhythmias | Angina pectoris | Hypertension | Migraine disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.93 %)	Approved	27476412
DrugRepV_1421	Tramadol Hydrochloride	Nervous System	Pain	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.36 %)	Approved, Investigational	27476412
DrugRepV_1422	Allopurinol	Musculo-Skeletal System	Hyperuricemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.775 %)	Approved	27476412
DrugRepV_1423	Leucovorin Calcium Pentahydrate	Various	Osteosarcoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.875 %)	Approved	27476412
DrugRepV_1424	Levetiracetam	Nervous System	Epilepsy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.66 %)	Approved, Investigational	27476412
DrugRepV_1425	Fluticasone propionate	Respiratory System	Asthma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.92 %)	Approved	27476412
DrugRepV_1426	Terbutaline Hemisulfate	Respiratory System	Bronchospasm	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.52 %)	Approved	27476412
DrugRepV_1427	Furosemide	Cardiovascular agents	Edema and Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.555 %)	Approved, Vet approved	27476412
DrugRepV_1428	Rufinamide	Nervous System	Seizure disorder :- Lennox-Gastuat syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.69 %)	Approved	27476412
DrugRepV_1429	Nizatidine	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) | Peptic ulcer disease | Active benign gastric ulcer | Active duodenal ulcer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.075 %)	Approved	27476412
DrugRepV_1430	Darifenacin Hydrobromide	Genito Urinary System and Sex Hormones	Overactive bladder with symptoms of urge urinary incontinence, urgency and frequency	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.55 %)	Approved	27476412
DrugRepV_1431	Biperiden Hydrochloride	Nervous System	Parkinson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.17 %)	Approved	27476412
DrugRepV_1432	Bendroflumethiazide	Cardiovascular agents	Familial hyperkalemia, hypertension, edema, and urinary tract disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.345 %)	Approved	27476412
DrugRepV_1433	Idoxuridine	Antiinfectives For Systemic Use	Keratoconjunctivitis and Keratitis caused by herpes simplex virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.78 %)	Approved, Investigational	27476412
DrugRepV_1434	Leflunomide	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.89 %)	Approved, Investigational	27476412
DrugRepV_1435	Imipramine Hydrochloride	Nervous System	Depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.665 %)	Approved	27476412
DrugRepV_1436	Telmisartan	Cardiovascular agents	Hypertension | Type 2 diabetes mellitus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.505 %)	Approved, Investigational	27476412
DrugRepV_1437	Bendamustine Hydrochloride	Antineoplastic and Immunomodulating Agents	Chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.125 %)	Approved	27476412
DrugRepV_1438	Rocuronium Bromide	Musculo-Skeletal System	Muscle fasciculation caused by succinylcholine	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.025 %)	Approved	27476412
DrugRepV_1439	Triptorelin Acetate	Antineoplastic and Immunomodulating Agents	Advanced prostate cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.535 %)	Approved	27476412
DrugRepV_1440	Levothyroxine Sodium	Systemic Hormonal Preparations, Excl. Sex Hormones And Insulins	Hypothyroidism	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.275 %)	Approved	27476412
DrugRepV_1441	Diltiazem Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.9 %)	Approved	27476412
DrugRepV_1442	Lisinopril dihydrate	Cardiovascular agents	Hypertension | Congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.825 %)	Approved, Investigational	27476412
DrugRepV_1443	Amoxapine	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.49 %)	Approved	27476412
DrugRepV_1444	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.21 %)	Approved	27476412
DrugRepV_1445	Ethacrynic Acid	Cardiovascular agents	Edema, hypertension and congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.32 %)	Approved	27476412
DrugRepV_1446	Orphenadrine Citrate	Musculo-Skeletal System	Parkinson's disease | Muscle spasm	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.71 %)	Approved	27476412
DrugRepV_1447	Escitalopram	Nervous System	Major depressive disorder and generalized anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.27 %)	Approved	27476412
DrugRepV_1448	Chlorambucil	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.315 %)	Approved	27476412
DrugRepV_1449	Bethanechol Chloride	Nervous System	Neurogenic bladder dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.03 %)	Approved	27476412
DrugRepV_1450	Valacyclovir Hydrochloride	Antiinfectives For Systemic Use	Herpes simplex and Zoster virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.35 %)	Approved	27476412
DrugRepV_1451	Nelarabine	Antineoplastic and Immunomodulating Agents	T-cell acute lymphoblastic leukemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.83 %)	Approved, Investigational	27476412
DrugRepV_1452	Doxepin Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.49 %)	Approved	27476412
DrugRepV_1453	Verapamil Hydrochloride	Cardiovascular agents	Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders).	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.75 %)	Approved	27476412
DrugRepV_1454	Didanosine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.17 %)	Approved	27476412
DrugRepV_1455	Fluocinolone Acetonide	Cardiovascular agents; Dermatologicals; Sensory Organ; Sensory Organ	Chronic non-infectious uveitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.16 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1456	Mifepristone	Genito Urinary System and Sex Hormones	Hypercortisolism | Nonpituitary cushing syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.56 %)	Approved	27476412
DrugRepV_1457	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.8 %)	Approved	27476412
DrugRepV_1458	Mechlorethamine Hydrochloride	Antineoplastic and Immunomodulating Agents	Hodgkin's disease | Lymphosarcoma | Chronic myelocytic or chronic lymphocytic leukemia | Polycythemia vera | Mycosis fungoides | Bronchogenic carcinoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.89 %)	Approved, Investigational	27476412
DrugRepV_1459	Asenapine Maleate	Nervous System	Psychosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.345 %)	Approved	27476412
DrugRepV_1460	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.985 %)	Approved	27476412
DrugRepV_1461	Benztropine Mesylate	Nervous System	Parkinson disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.365 %)	Approved	27476412
DrugRepV_1462	Nabumetone	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.66 %)	Approved	27476412
DrugRepV_1463	Dextromethorphan	Respiratory System	Cough	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.605 %)	Approved	27476412
DrugRepV_1464	Diphenhydramine Hydrochloride	Dermatologicals and Respiratory System	Vertigo/Meniere disease, nausea and vomiting, motion sickness and insect bite	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.965 %)	Approved	27476412
DrugRepV_1465	Protriptyline Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.31 %)	Approved	27476412
DrugRepV_1466	Hydrochlorothiazide	Cardiovascular agents	High blood pressure | Edema	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.61 %)	Approved, Vet approved	27476412
DrugRepV_1467	Bosentan	Cardiovascular agents	Pulmonary artery hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.61 %)	Approved	27476412
DrugRepV_1468	Isradipine	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.02 %)	Approved, Investigational	27476412
DrugRepV_1469	Thiotepa	Antineoplastic and Immunomodulating Agents	Breast cancer | Ovarian cancer | Bladder cancer | Bone marrow transplantation	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.125 %)	Approved, Investigational	27476412
DrugRepV_1470	Enalaprilat Maleate	Cardiovascular agents	Hypertension and symptomatic congestive heart failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.67 %)	Approved	27476412
DrugRepV_1471	Cytarabine	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.14 %)	Approved	27476412
DrugRepV_1472	Terbinafine Hydrochloride	Dermatologicals	Toenail or Fingernail infections (Fungal) | Tinea capitis (scalp ringworm) | Tinea corporis (body ringworm) or tinea cruris (jock itch)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.665 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1473	Tolterodine Tartrate	Genito Urinary System and Sex Hormones	Overactive bladder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.97 %)	Approved, Investigational	27476412
DrugRepV_1474	Isocarboxazid	Nervous System	Depression	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.14 %)	Approved	27476412
DrugRepV_1475	Imatinib Mesylate	Antineoplastic and Immunomodulating Agents	Leukemia | Myelodysplastic/myeloproliferative disease | Gastrointestinal stromal tumors	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.475 %)	Approved	27476412
DrugRepV_1476	Benazepril Hydrochloride	Cardiovascular agents	Hypertension, congestive heart failure and chronic renal failure	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.975 %)	Approved	27476412
DrugRepV_1477	Alendronate Sodium trihydrate	Musculo-Skeletal System	Paget disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.805 %)	Approved	27476412
DrugRepV_1478	Atazanavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.68 %)	Approved	27476412
DrugRepV_1479	Etoposide	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.21 %)	Approved	27476412
DrugRepV_1480	Clemastine Fumarate	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.7 %)	Approved	27476412
DrugRepV_1481	Cyclobenzaprine Hydrochloride	Musculo-Skeletal System	Muscle spasms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.705 %)	Approved	27476412
DrugRepV_1482	Rifabutin	Antiinfectives For Systemic Use	Mycobacterium avium complex (MAC) disease in patients with advanced Acquired immunodeficiency syndrome infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (35.56 %)	Approved, Investigational	27476412
DrugRepV_1483	Adenosine	Cardiovascular agents	Arrhythmia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.51 %)	Approved	27476412
DrugRepV_1484	Fluvoxamine Maleate	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.14 %)	Approved, Investigational	27476412
DrugRepV_1485	Tadalafil	Genito Urinary System and Sex Hormones	Erectile dysfunction	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.655 %)	Approved	27476412
DrugRepV_1486	Oseltamivir Phosphate	Antiinfectives For Systemic Use	Influenza A/B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.305 %)	Approved	27476412
DrugRepV_1487	Mitotane	Antineoplastic and Immunomodulating Agents	Adrenocortical tumours | Cushing's syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.98 %)	Approved	27476412
DrugRepV_1488	Venlafaxine Hydrochloride	Nervous System	Depression | General anxiety disorder | Social phobia | Panic disorder | vasomotor symptoms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.34 %)	Approved	27476412
DrugRepV_1489	Atomoxetine Hydrochloride	Nervous System	Attention-deficit hyperactivity disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.265 %)	Approved	27476412
DrugRepV_1490	Desonide	Dermatologicals	Inflammatory disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.765 %)	Approved	27476412
DrugRepV_1491	Propranolol Hydrochloride	Cardiovascular agents	Migraine | Acute myocardial infarction | Arrhythmias | Angina pectoris | Hypertension | Hypertensive emergencies | Hyperthyroidism | Pheochromocytoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.09 %)	Approved, Investigational	27476412
DrugRepV_1492	Desipramine Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.2 %)	Approved	27476412
DrugRepV_1493	Sirolimus	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressant)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.38 %)	Approved, Investigational	27476412
DrugRepV_1494	Melphalan	Antineoplastic and Immunomodulating Agents	Multiple myeloma | Palliation of non-resectable epithelial carcinoma of the ovary	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.86 %)	Approved	27476412
DrugRepV_1495	Homatropine Methylbromide	Sensory Organ	Peptic ulcer | Gastric ulcer | Duodenal ulcer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.29 %)	Approved	27476412
DrugRepV_1496	Cabergoline	Genito Urinary System and Sex Hormones; Nervous System	Hyperprolactinemic disorders and Parkinsonian Syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (33.37 %)	Approved	27476412
DrugRepV_1497	Aminocaproic Acid	Blood and Blood Forming Organs	Antifibrinolytic agent	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.285 %)	Approved	27476412
DrugRepV_1498	Desloratadine	Respiratory System	Allergic rhinitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.02 %)	Approved	27476412
DrugRepV_1499	Lapatinib Ditosylate	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.875 %)	Approved, Investigational	27476412
DrugRepV_1500	Doxazosin Mesylate	Cardiovascular agents	Hypertension and Hyperplasia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.835 %)	Approved	27476412
DrugRepV_1501	Rimantadine Hydrochloride	Antiinfectives For Systemic Use	Influenza A virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.755 %)	Approved, Investigational	27476412
DrugRepV_1502	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (36.42 %)	Approved	27476412
DrugRepV_1503	Everolimus	Antineoplastic and Immunomodulating Agents	Immune disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (33.77 %)	Approved	27476412
DrugRepV_1504	Oxaliplatin	Antineoplastic and Immunomodulating Agents	Colon Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.1 %)	Approved, Investigational	27476412
DrugRepV_1505	Dimenhydrinate	Respiratory System; Dermatologicals	Antimuscarinic, and motion sickness	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (36.59 %)	Approved	27476412
DrugRepV_1506	Nimodipine	Cardiovascular agents	Subarachnoid hemorrhage (SAH)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.835 %)	Approved, Investigational	27476412
DrugRepV_1507	Loratadine	Respiratory System	Rhinitis | Urticaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.655 %)	Approved, Investigational	27476412
DrugRepV_1508	Butoconazole Nitrate	Genito Urinary System and Sex Hormones	Vulvovaginal candidiasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.275 %)	Approved	27476412
DrugRepV_1509	Fluoxetine Hydrochloride	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (31.79 %)	Approved, Vet approved	27476412
DrugRepV_1510	Amitriptyline Hydrochloride	Nervous System	Depressive disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.4 %)	Approved	27476412
DrugRepV_1511	Acyclovir Zovirax	NA	Viral infections (Herpes simplex, Zoster and varicella zoster)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.46 %)	Approved	27476412
DrugRepV_1512	Fludarabine phosphate	Antineoplastic and Immunomodulating Agents	Hematological malignancies	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (37.445 %)	Approved	27476412
DrugRepV_1513	Loxapine succinate	Nervous System	Schizophrenia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.465 %)	Approved	27476412
DrugRepV_1514	Reserpine	Cardiovascular agents	Hypertension | Psychotic disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.15 %)	Approved, Investigational	27476412
DrugRepV_1515	Adapalene	Dermatologicals	Acne vulgaris	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.305 %)	Approved	27476412
DrugRepV_1516	Saquinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (32.635 %)	Approved, Investigational	27476412
DrugRepV_1517	Telithromycin	Antiinfectives For Systemic Use	Pneumococcal infection | Acute sinusitis | Acute bacterial tonsillitis | Acute bronchitis and bronchiolitis | Lower respiratory tract infection and lobar (pneumococcal) pneumonia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (31.37 %)	Approved	27476412
DrugRepV_1518	Amlodipine	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (26.615 %)	Approved	27476412
DrugRepV_1519	Cladribine	Antineoplastic and Immunomodulating Agents	Lymphoproliferative diseases	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (31.775 %)	Approved	27476412
DrugRepV_1520	Cyproheptadine Hydrochloride Sesquihydrate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (34.41 %)	Approved	27476412
DrugRepV_1521	Irinotecan Hydrochloride	Antineoplastic and Immunomodulating Agents	Colorectal cancer | Small cell lung cancer | Cervical cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (30.47 %)	Approved, Investigational	27476412
DrugRepV_1522	Streptomycin Sulfate	Antiinfectives For Systemic Use	Tuberculosis | Tularemia | Plague | Brucellosis | Endocarditis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (28.56 %)	Approved, Vet approved	27476412
DrugRepV_1523	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (29.485 %)	Approved, Investigational	27476412
DrugRepV_1524	Teniposide	Antineoplastic and Immunomodulating Agents	Acute lymphoblastic leukaemia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (26.615 %)	Approved	27476412
DrugRepV_1525	Tamoxifen Citrate	Antineoplastic and Immunomodulating Agents	Breast cancer	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (27.085 %)	Approved	27476412
DrugRepV_1526	Celecoxib	Musculo-Skeletal System	Osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (29.635 %)	Approved	27476412
DrugRepV_1527	Indomethacin	Cardiovascular agents; Musculo-Skeletal System; Musculo-Skeletal System	Rheumatoid arthritis | Ankylosing spondylitis | Osteoarthritis | Acute painful shoulder (bursitis and/or tendinitis) | Acute gouty arthritis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.73 %)	Approved, Investigational	27476412
DrugRepV_1528	Temsirolimus	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (20.73 %)	Approved	27476412
DrugRepV_1529	Desogestrel	Genito Urinary System and Sex Hormones	Contraception	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (21.195 %)	Approved	27476412
DrugRepV_1530	Clindamycin Palmitate Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (22.29 %)	Approved	27476412
DrugRepV_1531	Felodipine	Cardiovascular agents	Hypertension	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (25.83 %)	Approved, Investigational	27476412
DrugRepV_1532	Aprepitant	Alimentary Tract and Metabolism	Nausea and vomiting	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (19.16 %)	Approved	27476412
DrugRepV_1533	Mitoxantrone Hydrochloride	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (0.635 %)	Approved, Investigational	27476412
DrugRepV_1534	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Flow cytometry	Decrease (50 %)	Approved	27476412
DrugRepV_1535	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Zika virus	MEX_I_7	NA	Flow cytometry	Decrease (50 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1536	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Flow cytometry	Decrease (50 %)	Approved, Investigational	27476412
DrugRepV_1537	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	MEX_I_7	NA	Flow cytometry	Decrease (50 %)	Approved	27476412
DrugRepV_1538	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	MEX_I_7	NA	Flow cytometry	No significant effect (50 %)	Approved	27476412
DrugRepV_1539	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	MEX_I_7	NA	Flow cytometry	No significant effect (50 %)	Approved	27476412
DrugRepV_1540	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	MEX_I_7	NA	Flow cytometry	Decrease (50 %)	Approved	27476412
DrugRepV_1541	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Flow cytometry	No significant effect (50 %)	Approved	27476412
DrugRepV_1542	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	MEX_I_7	NA	Flow cytometry	Increase (>200 %)	Approved	27476412
DrugRepV_1543	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	MEX_I_7	NA	Flow cytometry	Decrease (50 %)	Approved	27476412
DrugRepV_1544	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Zika virus	MEX_I_7	NA	Flow cytometry	No significant effect (50 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1545	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Flow cytometry	Increase (120 %)	Approved	27476412
DrugRepV_1546	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Flow cytometry	Increase (200 %)	Approved, Investigational	27476412
DrugRepV_1547	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	DAK_41525	NA	Flow cytometry	Increase (140 %)	Approved	27476412
DrugRepV_1548	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	DAK_41525	NA	Flow cytometry	Decrease (60 %)	Approved	27476412
DrugRepV_1549	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Zika virus	DAK_41525	NA	Flow cytometry	Decrease (60 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1550	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	DAK_41525	NA	Flow cytometry	No significant effect	Approved	27476412
DrugRepV_1551	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	DAK_41525	NA	Flow cytometry	Increase (120 %)	Approved, Investigational	27476412
DrugRepV_1552	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	DAK_41525	NA	Flow cytometry	Increase (120 %)	Approved	27476412
DrugRepV_1553	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Zika virus	DAK_41525	NA	Flow cytometry	Decrease (>80 %)	Approved	27476412
DrugRepV_1554	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1555	Pyrimethamine	Antiparasitic products, Insectisides and Repellents	Toxoplasmosis | Acute malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	No significant effect	Approved, Investigational, Vet approved	27476412
DrugRepV_1556	Azathioprine	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis, renal transplant rejection, Crohn disease, and colitis.	Zika virus	MEX_I_7	NA	Fluorescence-based assay	No significant effect	Approved	27476412
DrugRepV_1557	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved	27476412
DrugRepV_1558	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved	27476412
DrugRepV_1559	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Zika virus	MEX_I_7	NA	Fluorescence-based assay	No significant effect	Approved	27476412
DrugRepV_1560	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	27476412
DrugRepV_1561	Sertraline	Nervous System	Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved	27476412
DrugRepV_1649	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	MR766	NA	Cell viability assay	Decrease (98.7 %)	Investigational	27571349
DrugRepV_1650	Teriflunomide	Antineoplastic and Immunomodulating Agents	Multiple sclerosis (MS)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1651	Hydroxocobalamin	Blood and Blood Forming Organs	Vitamin B12 deficiency	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1652	Ensulizole	NA	Sunburn	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1653	Tenonitrozole	Antiparasitic products, Insectisides and Repellents	Protozoal infections	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1654	Isoliquirtigenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1655	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	MR766	NA	Cell viability assay	Decrease (53.6 %)	Approved, Investigational, Vet approved	27571349
DrugRepV_1656	Febuxostat	Musculo-Skeletal System	Hyperuricemia	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1657	Leflunomide	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Investigational	27571349
DrugRepV_1658	Vidofludimus	NA	Crohn disease; Inflammatory bowel diseases and Rheumatoid arthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1659	SB-366791	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1660	Emodin	NA	Polycystic Kidney	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1661	Diphenyl isophthalate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1662	Benzoylpas	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1663	Fenobam	NA	Fragile X Syndrome	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1664	Indobufen	Blood and Blood Forming Organs	Atrial Fibrillation	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1665	Drometrizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1666	PHA-690509	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	Decrease (81.9 %)	NA	27571349
DrugRepV_1667	Tiaprofenic Acid	Musculo-Skeletal System	Arthritic pain	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1668	Flufenamic Acid	Musculo-Skeletal System	Musculoskeletal | Joint disorders	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1669	Vitamin B12	Blood and Blood Forming Organs	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1670	Cinanserin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1671	5-Nitro-2-(3-phenylpropylamino)benzoic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1672	Veliflapon	NA	Myocardial infarction (Heart attack)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Phase III	27571349
DrugRepV_1673	Thiabendazole	Dermatologicals; Antiparasitic products, Insectisides and Repellents	Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1674	SIB 1893	Neurologic-agent	Epilepsy	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1675	Anethole Trithione	Alimentary Tract and Metabolism	Xerostomia and salivary gland hypofunction	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1676	Naringenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1677	Phenazopyridine Hydrochloride	Genito Urinary System and Sex Hormones	Urinary tract infection	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1678	Fanetizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1679	Terazosin Hydrochloride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia | Hypertension	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1680	Diacerein	Musculo-Skeletal System	Osteoarthritis	Zika virus	MR766	NA	Cell viability assay	Decrease (35.2 %)	Approved	27571349
DrugRepV_1681	CAY10505	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1682	Hesperetin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1683	Suprofen	Musculo-Skeletal System	Miosis (pupil constriction)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Withdrawn	27571349
DrugRepV_1684	Ketorolac Tromethamine	Musculo-Skeletal System	Osteoarthritis | Severe Pain	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1685	Piperine	Anticancer	Multiple Myeloma | Deglutition Disorders	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1686	Pirarubicin	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1687	Piraxostat	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (34.7 %)	NA	27571349
DrugRepV_1688	Albendazole oxide	NA	Parasitic infections	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1689	Tyrphostin AG 494	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1690	Genistin	Antineoplastic and Antitumor agent	Prostate cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1691	Fenbufen	Musculo-Skeletal System	Inflammatory disorders (in osteoarthritis, ankylosing spondylitis, and tendinitis)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1692	Apatinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1693	RITA	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	Decrease (81.7 %)	NA	27571349
DrugRepV_1694	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	MR766	NA	Cell viability assay	Decrease (51.2 %)	Approved	27571349
DrugRepV_1695	BF-170-hydrochloride	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (65.8 %)	NA	27571349
DrugRepV_1696	OSI-930	Anticancer	Solid tumors	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1697	Tribromsalan	NA	Bacterial infections	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1698	Pifexole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1699	Formononetin	NA	Postmenopausal Osteopenia	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1700	Ebselen	Anti-diabetic	Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1701	Tranilast	NA	Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1702	Benzylparaben	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Experimental	27571349
DrugRepV_1703	2-Ethoxylethyl-p-methoxycinnamate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1704	Baicalein	Plant extract	Influenza	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Phase II	27571349
DrugRepV_1705	Nemorubicin	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease	NA	27571349
DrugRepV_1706	Rutaecarpine	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1707	MPEP	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1708	5,7-Dihydroxyflavone	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1709	Pipofezine	Antidepressant	Depressive disorders	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1710	Flurbiprofen Axetil	Musculo-Skeletal System	Hyperalgesia	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1711	2 Amino-6-nitrobenzothiazole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1712	Malachite green oxalate	Antibacterial	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1713	Enfenamic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1714	Fenaminosulf	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1715	AS-252424	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1716	Phenserine	NA	Alzheimer's disease	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1717	Epalrestat	Anti-diabetic	Diabetic neuropathy	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1718	Alizarin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1719	Dalcetrapib	Cardiovascular agents	Acute Coronary Syndrome	Zika virus	MR766	NA	Cell viability assay	Decrease (45.7 %)	Investigational	27571349
DrugRepV_1720	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	MR766	NA	Cell viability assay	Decrease	Investigational	27571349
DrugRepV_1721	Teriflunomide	Antineoplastic and Immunomodulating Agents	Multiple sclerosis (MS)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1722	Hydroxocobalamin	Blood and Blood Forming Organs	Vitamin B12 deficiency	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1723	Ensulizole	NA	Sunburn	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1724	Tenonitrozole	Antiparasitic products, Insectisides and Repellents	Protozoal infections	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1725	Isoliquirtigenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (36.3 %)	Experimental	27571349
DrugRepV_1726	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	MR766	NA	Cell viability assay	Decrease (62.1 %)	Approved, Investigational, Vet approved	27571349
DrugRepV_1727	Febuxostat	Musculo-Skeletal System	Hyperuricemia	Zika virus	MR766	NA	Cell viability assay	Decrease (68.4 %)	Approved	27571349
DrugRepV_1728	Leflunomide	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Investigational	27571349
DrugRepV_1729	Vidofludimus	NA	Crohn disease; Inflammatory bowel diseases and Rheumatoid arthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1730	SB-366791	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1731	Emodin	NA	Polycystic Kidney	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1732	Diphenyl isophthalate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1733	Benzoylpas	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1734	Fenobam	NA	Fragile X Syndrome	Zika virus	MR766	NA	Cell viability assay	Decrease (60.5 %)	Investigational	27571349
DrugRepV_1735	Indobufen	Blood and Blood Forming Organs	Atrial Fibrillation	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1736	Drometrizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1737	PHA-690509	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	Decrease	NA	27571349
DrugRepV_1738	Tiaprofenic Acid	Musculo-Skeletal System	Arthritic pain	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1739	Flufenamic Acid	Musculo-Skeletal System	Musculoskeletal | Joint disorders	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1740	Vitamin B12	Blood and Blood Forming Organs	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1741	Cinanserin	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (56.9 %)	NA	27571349
DrugRepV_1742	5-Nitro-2-(3-phenylpropylamino)benzoic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1743	Veliflapon	NA	Myocardial infarction (Heart attack)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Phase III	27571349
DrugRepV_1744	Thiabendazole	Dermatologicals; Antiparasitic products, Insectisides and Repellents	Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1745	SIB 1893	Neurologic-agent	Epilepsy	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1746	Anethole Trithione	Alimentary Tract and Metabolism	Xerostomia and salivary gland hypofunction	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1747	Naringenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1748	Phenazopyridine Hydrochloride	Genito Urinary System and Sex Hormones	Urinary tract infection	Zika virus	MR766	NA	Cell viability assay	Decrease (35.3 %)	Approved	27571349
DrugRepV_1749	Fanetizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1750	Terazosin Hydrochloride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia | Hypertension	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1751	Diacerein	Musculo-Skeletal System	Osteoarthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1752	CAY10505	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1753	Hesperetin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1754	Suprofen	Musculo-Skeletal System	Miosis (pupil constriction)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Withdrawn	27571349
DrugRepV_1755	Ketorolac Tromethamine	Musculo-Skeletal System	Osteoarthritis | Severe Pain	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1756	Piperine	Anticancer	Multiple Myeloma | Deglutition Disorders	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1757	Pirarubicin	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1758	Piraxostat	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (60.3 %)	NA	27571349
DrugRepV_1759	Albendazole oxide	NA	Parasitic infections	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1760	Tyrphostin AG 494	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (45.6 %)	NA	27571349
DrugRepV_1761	Genistin	Antineoplastic and Antitumor agent	Prostate cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1762	Fenbufen	Musculo-Skeletal System	Inflammatory disorders (in osteoarthritis, ankylosing spondylitis, and tendinitis)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1763	Apatinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1764	RITA	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1765	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	MR766	NA	Cell viability assay	Decrease (97.3 %)	Approved	27571349
DrugRepV_1766	BF-170-hydrochloride	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1767	OSI-930	Anticancer	Solid tumors	Zika virus	MR766	NA	Cell viability assay	Decrease (71.2 %)	Investigational	27571349
DrugRepV_1768	Tribromsalan	NA	Bacterial infections	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1769	Pifexole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1770	Formononetin	NA	Postmenopausal Osteopenia	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1771	Ebselen	Anti-diabetic	Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1772	Tranilast	NA	Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1773	Benzylparaben	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Experimental	27571349
DrugRepV_1774	2-Ethoxylethyl-p-methoxycinnamate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1775	Baicalein	Plant extract	Influenza	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Phase II	27571349
DrugRepV_1776	Nemorubicin	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease	NA	27571349
DrugRepV_1777	Rutaecarpine	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1778	MPEP	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1779	5,7-Dihydroxyflavone	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1780	Pipofezine	Antidepressant	Depressive disorders	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1781	Flurbiprofen Axetil	Musculo-Skeletal System	Hyperalgesia	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1782	2 Amino-6-nitrobenzothiazole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1783	Malachite green oxalate	Antibacterial	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Experimental	27571349
DrugRepV_1784	Enfenamic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1785	Fenaminosulf	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (36.7 %)	NA	27571349
DrugRepV_1786	AS-252424	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1787	Phenserine	NA	Alzheimer's disease	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1788	Epalrestat	Anti-diabetic	Diabetic neuropathy	Zika virus	MR766	NA	Cell viability assay	Decrease (82.1 %)	Investigational	27571349
DrugRepV_1789	Alizarin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1790	Dalcetrapib	Cardiovascular agents	Acute Coronary Syndrome	Zika virus	MR766	NA	Cell viability assay	Decrease	Investigational	27571349
DrugRepV_1791	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	MR766	NA	Cell viability assay	Decrease (54.4 %)	Investigational	27571349
DrugRepV_1792	Teriflunomide	Antineoplastic and Immunomodulating Agents	Multiple sclerosis (MS)	Zika virus	MR766	NA	Cell viability assay	No significant effect	Approved	27571349
DrugRepV_1793	Hydroxocobalamin	Blood and Blood Forming Organs	Vitamin B12 deficiency	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1794	Ensulizole	NA	Sunburn	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1795	Tenonitrozole	Antiparasitic products, Insectisides and Repellents	Protozoal infections	Zika virus	MR766	NA	Cell viability assay	No significant effect	Experimental	27571349
DrugRepV_1796	Isoliquirtigenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	Experimental	27571349
DrugRepV_1797	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	MR766	NA	Cell viability assay	No significant effect	Approved, Investigational, Vet approved	27571349
DrugRepV_1798	Febuxostat	Musculo-Skeletal System	Hyperuricemia	Zika virus	MR766	NA	Cell viability assay	No significant effect	Approved	27571349
DrugRepV_1799	Leflunomide	Antineoplastic and Immunomodulating Agents	Rheumatoid arthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect	Approved, Investigational	27571349
DrugRepV_1800	Vidofludimus	NA	Crohn disease; Inflammatory bowel diseases and Rheumatoid arthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1801	SB-366791	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1802	Emodin	NA	Polycystic Kidney	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1803	Diphenyl isophthalate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1804	Benzoylpas	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1805	Fenobam	NA	Fragile X Syndrome	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1806	Indobufen	Blood and Blood Forming Organs	Atrial Fibrillation	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1807	Drometrizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1808	PHA-690509	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1809	Tiaprofenic Acid	Musculo-Skeletal System	Arthritic pain	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1810	Flufenamic Acid	Musculo-Skeletal System	Musculoskeletal | Joint disorders	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1811	Vitamin B12	Blood and Blood Forming Organs	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1812	Cinanserin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1813	5-Nitro-2-(3-phenylpropylamino)benzoic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1814	Veliflapon	NA	Myocardial infarction (Heart attack)	Zika virus	MR766	NA	Cell viability assay	No significant effect	Phase III	27571349
DrugRepV_1815	Thiabendazole	Dermatologicals; Antiparasitic products, Insectisides and Repellents	Strongyloidiasis (threadworm) | Cutaneous larva migrans (creeping eruption) | Visceral larva migrans | Trichinosis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1816	SIB 1893	Neurologic-agent	Epilepsy	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1817	Anethole Trithione	Alimentary Tract and Metabolism	Xerostomia and salivary gland hypofunction	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1818	Naringenin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	Experimental	27571349
DrugRepV_1819	Phenazopyridine Hydrochloride	Genito Urinary System and Sex Hormones	Urinary tract infection	Zika virus	MR766	NA	Cell viability assay	No significant effect	Approved	27571349
DrugRepV_1820	Fanetizole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1821	Terazosin Hydrochloride	Genito Urinary System and Sex Hormones	Benign prostatic hyperplasia | Hypertension	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1822	Diacerein	Musculo-Skeletal System	Osteoarthritis	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1823	CAY10505	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1824	Hesperetin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	Experimental	27571349
DrugRepV_1825	Suprofen	Musculo-Skeletal System	Miosis (pupil constriction)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Withdrawn	27571349
DrugRepV_1826	Ketorolac Tromethamine	Musculo-Skeletal System	Osteoarthritis | Severe Pain	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1827	Piperine	Anticancer	Multiple Myeloma | Deglutition Disorders	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1828	Pirarubicin	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1829	Piraxostat	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1830	Albendazole oxide	NA	Parasitic infections	Zika virus	MR766	NA	Cell viability assay	No significant effect	Experimental	27571349
DrugRepV_1831	Tyrphostin AG 494	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1832	Genistin	Antineoplastic and Antitumor agent	Prostate cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1833	Fenbufen	Musculo-Skeletal System	Inflammatory disorders (in osteoarthritis, ankylosing spondylitis, and tendinitis)	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved	27571349
DrugRepV_1834	Apatinib	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1835	RITA	NA	Cancer	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1836	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	MR766	NA	Cell viability assay	No significant effect	Approved	27571349
DrugRepV_1837	BF-170-hydrochloride	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1838	OSI-930	Anticancer	Solid tumors	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1839	Tribromsalan	NA	Bacterial infections	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1840	Pifexole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1841	Formononetin	NA	Postmenopausal Osteopenia	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1842	Ebselen	Anti-diabetic	Meniere Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1843	Tranilast	NA	Bronchial asthma | Keloid and hypertrophic scar | Allergic disorders such as asthma, allergic rhinitis | Atopic dermatitis	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1844	Benzylparaben	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Approved, Experimental	27571349
DrugRepV_1845	2-Ethoxylethyl-p-methoxycinnamate	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1846	Baicalein	Plant extract	Influenza	Zika virus	MR766	NA	Cell viability assay	No significant effect	Phase II	27571349
DrugRepV_1847	Nemorubicin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1848	Rutaecarpine	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1849	MPEP	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1850	5,7-Dihydroxyflavone	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1851	Pipofezine	Antidepressant	Depressive disorders	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1852	Flurbiprofen Axetil	Musculo-Skeletal System	Hyperalgesia	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	Investigational	27571349
DrugRepV_1853	2 Amino-6-nitrobenzothiazole	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1854	Malachite green oxalate	Antibacterial	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	Experimental	27571349
DrugRepV_1855	Enfenamic Acid	NA	NA	Zika virus	MR766	NA	Cell viability assay	Decrease (58.5 %)	NA	27571349
DrugRepV_1856	Fenaminosulf	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect	NA	27571349
DrugRepV_1857	AS-252424	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1858	Phenserine	NA	Alzheimer's disease	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1859	Epalrestat	Anti-diabetic	Diabetic neuropathy	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1860	Alizarin	NA	NA	Zika virus	MR766	NA	Cell viability assay	No significant effect (0 %)	NA	27571349
DrugRepV_1861	Dalcetrapib	Cardiovascular agents	Acute Coronary Syndrome	Zika virus	MR766	NA	Cell viability assay	No significant effect	Investigational	27571349
DrugRepV_1862	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	MR766 (1947 Ugandan strain)	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1863	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	FSS13025 (2010 Cambodian strain)	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1864	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1865	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1866	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1867	Emricasan	NA	Antiapoptotic and anti-inflammatory	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	Investigational	27571349
DrugRepV_1868	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	Approved	27571349
DrugRepV_1869	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	Approved	27571349
DrugRepV_1870	PHA-690509	NA	Cancer	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	NA	27571349
DrugRepV_1871	PHA-690509	NA	Cancer	Zika virus	NA	NA	Cell viability assay	Decrease (50 %)	NA	27571349
DrugRepV_1872	PHA-690509	NA	Cancer	Zika virus	MR766 (1947 Ugandan strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1873	PHA-690509	NA	Cancer	Zika virus	FSS13025 (2010 Cambodian strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1874	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1875	PHA-690509	NA	Cancer	Zika virus	MR766 (1947 Ugandan strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1876	PHA-690509	NA	Cancer	Zika virus	FSS13025 (2010 Cambodian strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1877	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1878	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	Approved	27571349
DrugRepV_1879	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	Approved	27571349
DrugRepV_1880	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Enzyme-linked immunosorbent assay	Decrease	NA	27571349
DrugRepV_1881	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Enzyme-linked immunosorbent assay	Decrease	Approved	27571349
DrugRepV_1882	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Plaque assay	Decrease (50 %)	NA	27571349
DrugRepV_1883	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Plaque assay	Decrease (50 %)	Approved	27571349
DrugRepV_1884	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	FSS13025	NA	Real-time PCR	Decrease (50 %)	Approved	27571349
DrugRepV_1885	PHA-690509	NA	Cancer	Zika virus	FSS13026	NA	Real-time PCR	Decrease (50 %)	NA	27571349
DrugRepV_1886	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	FSS13025	NA	Real-time PCR	Decrease	Approved	27571349
DrugRepV_1887	PHA-690509	NA	Cancer	Zika virus	FSS13026	NA	Real-time PCR	Decrease	NA	27571349
DrugRepV_1888	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	Approved	27571349
DrugRepV_1889	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	Approved	27571349
DrugRepV_1890	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1891	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1892	Seliciclib	Anticancer	Breast cancer | Lung cancer | Lymphoma | Multiple myeloma | Leukemia	Zika virus	FSS13026	NA	NA	Decrease (50 %)	Investigational	27571349
DrugRepV_1893	SNS-032	NA	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	Investigational	27571349
DrugRepV_1894	PHA-793887	Anticancer	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	NA	27571349
DrugRepV_1895	AT7519	NA	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	NA	27571349
DrugRepV_1896	BS-194	Anticancer	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	NA	27571349
DrugRepV_1897	RGB-286147	NA	NA	Zika virus	FSS13026	NA	NA	Decrease (50 %)	NA	27571349
DrugRepV_1898	Dinaciclib	Anticancer	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	Investigational	27571349
DrugRepV_1899	Alvocidib	NA	Cancer	Zika virus	FSS13026	NA	NA	Decrease (50 %)	Experimental	27571349
DrugRepV_1900	PHA-690509	NA	Cancer	Zika virus	FSS13026	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1901	Alvocidib	NA	Cancer	Zika virus	FSS13026	NA	Western blot	Decrease (Decrease Band intensity)	Experimental	27571349
DrugRepV_1902	PHA-793887	Anticancer	Cancer	Zika virus	FSS13026	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1903	Dinaciclib	Anticancer	Cancer	Zika virus	FSS13026	NA	Western blot	Decrease (Decrease Band intensity)	Investigational	27571349
DrugRepV_1904	Seliciclib	Anticancer	Breast cancer | Lung cancer | Lymphoma | Multiple myeloma | Leukemia	Zika virus	FSS13026	NA	Western blot	Decrease (Decrease Band intensity)	Investigational	27571349
DrugRepV_1905	PHA-690509	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1906	Alvocidib	NA	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	Experimental	27571349
DrugRepV_1907	PHA-793887	Anticancer	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	NA	27571349
DrugRepV_1908	Dinaciclib	Anticancer	Cancer	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	Investigational	27571349
DrugRepV_1909	Seliciclib	Anticancer	Breast cancer | Lung cancer | Lymphoma | Multiple myeloma | Leukemia	Zika virus	PRVABC-59 (2015 Puerto Rican strain)	NA	Western blot	Decrease (Decrease Band intensity)	Investigational	27571349
DrugRepV_1910	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	Approved	29315671
DrugRepV_1911	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	Approved	29315671
DrugRepV_1912	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	Approved	29315671
DrugRepV_1913	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	Plaque assay	Decrease (50 %)	Approved	29315671
DrugRepV_1914	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	Plaque assay	Decrease (50 %)	Approved	29315671
DrugRepV_1915	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	PLCal_ZV	NA	Plaque assay	Decrease (50 %)	Approved	29315671
DrugRepV_1916	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	Time of addition assay	Decrease (50 %)	Approved	29315671
DrugRepV_1917	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	Time of addition assay	Decrease (62.5 %)	Approved	29315671
DrugRepV_1918	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	PLCal_ZV	NA	Time of addition assay	Decrease (90 %)	Approved	29315671
DrugRepV_1919	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	Real-time PCR	Decrease (85.7 %)	Approved	29315671
DrugRepV_1920	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	Real-time PCR	Decrease (99 %)	Approved	29315671
DrugRepV_1921	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	PLCal_ZV	NA	Real-time PCR	Decrease (85.7 %)	Approved	29315671
DrugRepV_1922	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (65 %)	Approved	29315671
DrugRepV_1923	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (70 %)	Approved	29315671
DrugRepV_1924	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (62.5 %)	Approved	29315671
DrugRepV_1926	Manidipine	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (100 %)	Approved, Investigational	28814523
DrugRepV_1927	Cilnidipine	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (100 %)	Approved	28814523
DrugRepV_1928	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (3 Logs)	Approved	28814523
DrugRepV_1929	Pimecrolimus	Dermatologicals	Atopic dermatitis	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (2 Logs)	Approved, Investigational	28814523
DrugRepV_1930	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (2 Logs)	Approved	28814523
DrugRepV_1931	Manidipine	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Real-time PCR	Decrease (0 %)	Approved, Investigational	28814523
DrugRepV_1932	Cilnidipine	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Real-time PCR	Decrease (0.01 %)	Approved	28814523
DrugRepV_1933	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Real-time PCR	Decrease (0.03 %)	Approved	28814523
DrugRepV_1934	Pimecrolimus	Dermatologicals	Atopic dermatitis	Zika virus	H/PF/2013	NA	Real-time PCR	Decrease (0.2 %)	Approved, Investigational	28814523
DrugRepV_1935	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Real-time PCR	Decrease (0 %)	Approved	28814523
DrugRepV_1936	Manidipine	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Immunoflourescence assay	Decrease (100 %)	Approved, Investigational	28814523
DrugRepV_1937	Cilnidipine	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Immunoflourescence assay	Decrease (100 %)	Approved	28814523
DrugRepV_1938	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Zika virus	H/PF/2013	NA	Immunoflourescence assay	Decrease	Approved	28814523
DrugRepV_1939	Pimecrolimus	Dermatologicals	Atopic dermatitis	Zika virus	H/PF/2013	NA	Immunoflourescence assay	Decrease	Approved, Investigational	28814523
DrugRepV_1940	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Immunoflourescence assay	Decrease	Approved	28814523
DrugRepV_1941	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Plaque assay	Decrease (>100 Fold)	Approved, Investigational, Vet approved	28480282
DrugRepV_1942	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Immunoflourescence assay	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1943	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Western blot	Decrease (100 Band Intensity)	Approved, Investigational, Vet approved	28480282
DrugRepV_1944	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (98 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1945	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease	Approved, Investigational, Vet approved	28480282
DrugRepV_1946	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1947	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease	Approved, Investigational, Vet approved	28480282
DrugRepV_1948	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1949	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1950	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (98 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1951	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1952	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Plaque assay	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1953	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Immunoflourescence assay	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1954	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Western blot	Decrease (100 Band Intensity)	Approved, Investigational, Vet approved	28480282
DrugRepV_1955	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (98 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1956	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease	Approved, Investigational, Vet approved	28480282
DrugRepV_1957	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease	Approved, Investigational, Vet approved	28480282
DrugRepV_1958	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease	Approved, Investigational, Vet approved	28480282
DrugRepV_1959	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease	Approved, Investigational, Vet approved	28480282
DrugRepV_1960	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1961	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1962	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (98 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_1963	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Zika virus	SZ-WIV01	NA	Real-time PCR	Decrease (100 %)	Approved, Investigational, Vet approved	28480282
DrugRepV_2107	NITD008	Antiviral	NA	Zika virus	GZ01/2016	NA	Plaque assay	Decrease (50 %)	NA	27747251
DrugRepV_2108	NITD008	Antiviral	NA	Zika virus	FSS13025/2010	NA	Plaque assay	Decrease (50 %)	NA	27747251
DrugRepV_2109	NITD008	Antiviral	NA	Zika virus	GZ01/2016	NA	Real-time PCR	Decrease (50 %)	NA	27747251
DrugRepV_2110	NITD008	Antiviral	NA	Zika virus	FSS13025/2010	NA	Real-time PCR	Decrease (50 %)	NA	27747251
DrugRepV_2111	NITD008	Antiviral	NA	Zika virus	GZ01/2016	NA	Survival assay	Increase	NA	27747251
DrugRepV_2112	NITD008	Antiviral	NA	Zika virus	GZ01/2016	NA	Real-time PCR	Decrease (2.6 Fold)	NA	27747251
DrugRepV_2113	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	PRVABC-59	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2114	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	PRVABC-59	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2115	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2116	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2117	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Dakar	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2118	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Dakar	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2119	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	PRVABC-59	NA	Real-time PCR	Decrease (>1 Log10 (GE/ml))	Approved	27902933
DrugRepV_2120	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	PRVABC-59	NA	Real-time PCR	Decrease (2 Log10 (GE/ml))	Approved	27902933
DrugRepV_2121	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Real-time PCR	Decrease (>1 Log10 (GE/ml))	Approved	27902933
DrugRepV_2122	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Real-time PCR	Decrease (2 Log10 (GE/ml))	Approved	27902933
DrugRepV_2123	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Dakar	NA	Real-time PCR	Decrease (>1 Log10 (GE/ml))	Approved	27902933
DrugRepV_2124	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Dakar	NA	Real-time PCR	Decrease (>2 Log10 (GE/ml))	Approved	27902933
DrugRepV_2125	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Flow cytometry	Decrease (50 %)	Approved	27902933
DrugRepV_2126	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Flow cytometry	Decrease (50 %)	Approved	27902933
DrugRepV_2127	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Dakar/41519	NA	Survival assay	Increase	Approved	27902933
DrugRepV_2128	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27163257
DrugRepV_2129	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MR766	NA	Virus yield reduction assay	Decrease (50 %)	Approved	27163257
DrugRepV_2130	Favipiravir	Antiviral	Influenza virus	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27163257
DrugRepV_2131	Favipiravir	Antiviral	Influenza virus	Zika virus	MR766	NA	Virus yield reduction assay	Decrease (50 %)	Investigational	27163257
DrugRepV_2132	2-C-Methylcytidine	NA	Hepatitis C virus	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Experimental	27163257
DrugRepV_2133	2-C-Methylcytidine	NA	Hepatitis C virus	Zika virus	MR766	NA	Virus yield reduction assay	Decrease (50 %)	Experimental	27163257
DrugRepV_2134	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	NA	27163257
DrugRepV_2135	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Virus yield reduction assay	Decrease (50 %)	NA	27163257
DrugRepV_2136	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	NA	27163257
DrugRepV_2137	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Immunoflourescence assay	Decrease (50 %)	NA	27163257
DrugRepV_2138	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Survival assay	Increase	NA	27163257
DrugRepV_2139	7-deaza-2-C-methyl-D-adenosine	NA	Viral infection	Zika virus	MR766	NA	Real-time PCR	Decrease	NA	27163257
DrugRepV_2140	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2141	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2142	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2143	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2144	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2145	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Puerto Rican strain PRVABC-59	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2146	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2147	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2148	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2149	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2150	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2151	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2152	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2153	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_2154	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Phase I	27838352
DrugRepV_2155	BCX4430 Dihydrochloride	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Virus yield reduction assay	Decrease (90 %)	Phase I	27838352
DrugRepV_3009	Imipramine	Nervous System	Depression	Zika virus	Pf13	NA	Real-time PCR	Decrease (100 %)	Approved	28600536
DrugRepV_3010	Imipramine	Nervous System	Depression	Zika virus	Pf13	NA	Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_3011	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Plaque assay	Decrease (75 %)	Approved	28343845
DrugRepV_3012	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Real-time PCR	Decrease	Approved	28343845
DrugRepV_3013	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Real-time PCR	Decrease (0.8 log)	Approved	28343845
DrugRepV_3015	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Real-time PCR	Decrease (1 log)	Approved	28343845
DrugRepV_3016	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Real-time PCR	Decrease (1 log)	Approved	28343845
DrugRepV_3020	Demethoxycurcumin	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	Phase II	28343845
DrugRepV_3021	Bisdemethoxycurcumin	Plant extract	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	Early Phase I	28343845
DrugRepV_3022	EF-24	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3023	FLLL31	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease	NA	28343845
DrugRepV_3028	Demethoxycurcumin	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	Phase II	28343845
DrugRepV_3029	Bisdemethoxycurcumin	Plant extract	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	Early Phase I	28343845
DrugRepV_3030	EF-24	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3031	FLLL31	NA	NA	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	NA	28343845
DrugRepV_3032	Curcumin	NA	Cancer, mucositis, chronic schizophrenia and mild cognitive impairment	Zika virus	HD78788	NA	Plaque assay	Decrease (50 %)	Approved	28343845
DrugRepV_3626	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Zika virus	Zika-016	NA	qRT-PCR	Decrease (50 %)	Approved, Investigational	27654301
DrugRepV_3867	BCX4430	NA	Ebola virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3868	BCX4430	NA	Ebola virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3869	BCX4430	NA	Ebola virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3870	BCX4430	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3871	BCX4430	NA	Ebola virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3872	BCX4430	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3873	BCX4430	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3874	BCX4430	NA	Ebola virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27838352
DrugRepV_3875	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3876	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3877	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3878	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3879	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3880	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3881	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3882	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3933	IHVR-19029	NA	NA	Zika virus	PRVABC-59	NA	qRT-PCR	Decrease (50 %)	NA	29253498
DrugRepV_4648	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Approved	28098253
DrugRepV_4649	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Approved	28098253
DrugRepV_4650	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Investigational	28098253
DrugRepV_4651	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	NA	NA	Plaque assay	Decrease (1.00E+02 pfu/ml)	Approved	28098253
DrugRepV_4652	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	NA	NA	Plaque assay	Decrease (5.00E+07 pfu/ml)	Approved	28098253
DrugRepV_4653	Palonosetron	Alimentary Tract and Metabolism	Nausea and vomiting associated with cancer chemotherapy	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27909576
DrugRepV_4654	6-Azauridine	NA	Cancer	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4655	5-Fluorouracil	Antineoplastic and Immunomodulating Agents	Cancer	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27909576
DrugRepV_4656	Lovastatin	Cardiovascular agents	Atherosclerotic vascular disease | Hypercholesterolemia	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational	27909576
DrugRepV_4657	Kitasamycin	NA	Bacterial infections	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	Experimental	27909576
DrugRepV_4658	SAM002589981	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4659	SAM002564206	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4660	SAM002564189	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4661	SAM002554886	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4662	SAM002548975	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4663	SAM002548938	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4664	SAM002264636	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4665	SAM001247107	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4666	SAM001247103	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4667	SAM001247083	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4668	SAM001247075	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4669	SAM001247056	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4670	SAM001247054	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4671	SAM001247052	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4672	SAM001247038	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4673	SAM001246989	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4674	SAM001246979	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4675	SAM001246977	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4676	SAM001246883	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4677	SAM001246690	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4678	SAM001246644	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4679	SAM001246622	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4680	SAM001246545	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease (50 %)	NA	27909576
DrugRepV_4681	N-(4-hydroxyphenyl) retinamide	NA	NA	Zika virus	MR766	NA	Plaque assay	Decrease (90 %)	Investigational	29051080
DrugRepV_4682	Arbidol	NA	Viral infection	Zika virus	MR766	NA	NA	Decrease (50 %)	Investigational	29895962
DrugRepV_4683	NITD008	Antiviral	NA	Zika virus	NA	NA	Luciferase assay	Decrease (50 %)	NA	29288699
DrugRepV_4684	2-C-Methylcytidine	NA	Hepatitis C virus	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Experimental	30061280
DrugRepV_4685	2-C-Methyladenosine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4686	2-C-Methylguanosine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4687	2-C-Methyluridine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4688	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Approved	30061280
DrugRepV_4689	5-Fluoro-2-deoxyuridine	NA	Cancer	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Approved	30061280
DrugRepV_4690	5-Fluorouridine	NA	Cancer	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Experimental	30061280
DrugRepV_4691	5-Fluorocytidine	NA	Breast Cancer	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Phase IV	30061280
DrugRepV_4692	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Approved	30061280
DrugRepV_4693	2-O-Methylcytidine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4694	3-Deoxyadenosine	NA	Leukemia	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Investigational	30061280
DrugRepV_4695	3-Deoxycytidine	NA	Cancer	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Phase I	30061280
DrugRepV_4696	3-O-Methylguanosine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4697	3-O-Methyluridine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4698	9-(beta-D-Arabinofuranosyl)guanine	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4699	2-C-Methylcytidine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4700	2-C-Methyluridine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4701	2-C-Methyladenosine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4702	3-Deoxyadenosine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4703	5-Fluorocytidine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4704	3-O-Methyluridine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4705	2-O-Methylcytidine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4706	3-Deoxycytidine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4707	3-Deoxy-3-fluoroguanosine ProTide	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4708	2,4-dichloro-6-(3,4-dibromo-5-fluoro-1H-pyrrole-2-carbonyl)phenol	NA	NA	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	NA	30061280
DrugRepV_4709	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	Immunoflourescence assay	Decrease	Approved	30061280
DrugRepV_4710	2,4-dichloro-6-(3,4-dibromo-5-fluoro-1H-pyrrole-2-carbonyl)phenol	NA	NA	Zika virus	NA	NA	Immunoflourescence assay	Decrease	NA	30061280
DrugRepV_4711	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	Investigational	27889529
DrugRepV_4712	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	27889529
DrugRepV_4713	GSK369796	NA	NA	Zika virus	MR766	NA	Plaque assay	Decrease (50 %)	NA	27889529
DrugRepV_5071	Brefeldin A	Antibiotics	Bacterial infections	Zika virus	NA	NA	Virus titration assay	Decrease (50 %)	Experimental	29093640
DrugRepV_5261	Delphinidin Chloride	NA	NA	Zika virus	MR766	NA	Plaque assay	Decrease (102 Log)	NA	28744282
DrugRepV_5262	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	Zika virus	MR766	NA	Plaque assay	Decrease (4.3 x 104 Log)	Investigational	28744282
DrugRepV_5263	Delphinidin Chloride	NA	NA	Zika virus	PA259459	NA	Plaque assay	Decrease	NA	28744282
DrugRepV_5264	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	Zika virus	PA259459	NA	Plaque assay	Decrease	Investigational	28744282
DrugRepV_5265	Tetra-O-methyl nordihydroguaiaretic acid (M4N)	NA	Brain and Central Nervous System Tumors	Zika virus	PA259459	NA	Plaque assay	Decrease (50 %)	Investigational	28507114
DrugRepV_5266	Tetra-O-methyl nordihydroguaiaretic acid (M4N)	NA	Brain and Central Nervous System Tumors	Zika virus	PA259459	NA	Plaque assay	Decrease (50 %)	Investigational	28507114
DrugRepV_5392	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Zika virus	NA	NA	NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5409	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	Approved	30801742
DrugRepV_5410	Desethylamodiaquine	NA	NA	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5411	Desethylchloroquine	NA	NA	Zika virus	PLCal_ZV	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5412	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MR 766	NA	MTT assay	Decrease (50 %)	Approved	30801742
DrugRepV_5413	Desethylamodiaquine	NA	NA	Zika virus	MR 766	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5414	Desethylchloroquine	NA	NA	Zika virus	MR 766	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5415	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PRVABC59	NA	MTT assay	Decrease (50 %)	Approved	30801742
DrugRepV_5416	Desethylamodiaquine	NA	NA	Zika virus	PRVABC59	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5417	Desethylchloroquine	NA	NA	Zika virus	PRVABC59	NA	MTT assay	Decrease (50 %)	NA	30801742
DrugRepV_5454	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MR766	NA	Plaque assay	Decrease (2 log10PFU/ml)	Approved	30894466
DrugRepV_5455	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MR766	NA	Plaque assay	Decrease (5.5 log10PFU/ml)	Approved	30894466
DrugRepV_5456	Atovaquone	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	MR766	NA	Plaque assay	Decrease (2 log10PFU/ml)	Approved	30894466
DrugRepV_5480	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Zika virus	(Asian/Cook Islands/2014	NA	Plaque assay	Decrease (50 %)	Approved, Investigational, Vet approved	32135219
DrugRepV_5481	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Zika virus	(Asian/Cook Islands/2014	NA	RT-qPCR	Decrease (50 %)	Approved, Investigational, Vet approved	32135219
DrugRepV_5482	RK-33	NA	NA	Zika virus	Asian/Cook Islands/2014	NA	Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_5483	RK-33	NA	NA	Zika virus	Asian/Cook Islands/2014	NA	qRT-PCR	Decrease (50 %)	NA	31936642
DrugRepV_5484	Chlorcyclizine	Respiratory System	Allergic rhinitis	Zika virus	NA	NA	MTT assay	Decrease (50 %)	Approved	31850756
DrugRepV_5485	Pranlukast	Respiratory System	Allergic reaction	Zika virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved	31786251
DrugRepV_5486	Conivaptan	Cardiovascular agents	Hypervolemic hyponatremia	Zika virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved, Investigational	31786251
DrugRepV_5487	Novobiocin	NA	Staphylococci infections	Zika virus	NA	NA	Flow cytometry	Decrease (50 %)	Approved, Investigational, Vet approved	31786251
DrugRepV_5488	Candesartan cilexetil	Cardiovascular agents	Hypertension	Zika virus	PRVABC59	NA	Cell viability assay	Decrease (50 %)	Approved	31669333
DrugRepV_5489	Calcifediol	Alimentary Tract and Metabolism	Bone pain, constipation (especially in children or adolescents), diarrhea, drowsiness, headache (continuing), increased thirst, increase in frequency of urination, irregular heartbeat, itching skin, loss of appetite, muscle pain, nausea or vomiting (	Zika virus	PRVABC59	NA	Cell viability assay	Decrease (50 %)	Approved, Nutraceutical	31669333
DrugRepV_5490	Primaquine Diphosphate	Antiparasitic products, Insectisides and Repellents	Malaria	Zika virus	PRVABC59	NA	Cell viability assay	Decrease (50 %)	Approved	31669333
DrugRepV_5594	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Dengue virus	276RKI, PRS41393		Plaque assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_5595	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	276RKI, PRS41393		Plaque assay	Decrease (50 %)	Approved	28240606
DrugRepV_5596	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Dengue virus	TSV01, 429557, New Guinea C		Plaque/ Luciferase assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_5597	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	TSV01, 429557, New Guinea C		Plaque/ Luciferase assay	Decrease (50 %)	Approved	28240606
DrugRepV_5598	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Dengue virus	Philippines/H87/1956		Plaque assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_5599	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	Philippines/H87/1956		Plaque assay	Decrease (50 %)	Approved	28240606
DrugRepV_5600	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Dengue virus	BC287/97, H241		Plaque assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_5601	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	BC287/97, H241		Plaque assay	Decrease (50 %)	Approved	28240606
DrugRepV_5602	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Dengue virus	N124D/K128E		Real-time PCR	No significant effect	Approved, Investigational	28240606
DrugRepV_5603	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	N124D/K128E		Real-time PCR	No significant effect	Approved	28240606
DrugRepV_5604	Sunitinib-Erlotinib	NA	NA	Dengue virus	N124D/K128E		NA	Increase	NA	28240606
DrugRepV_5605	Sunitinib-Erlotinib	NA	NA	Dengue virus	N124D/K128E		Real-time PCR	Decrease (11 Fold)	NA	28240606
DrugRepV_5606	Nanchangmycin	Antibacterial; Antiviral	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (95 %)	NA	28099856
DrugRepV_5607	Nanchangmycin	Antibacterial; Antiviral	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (95 %)	NA	28099856
DrugRepV_5608	Nanchangmycin	Antibacterial; Antiviral	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (80 %)	NA	28099856
DrugRepV_5609	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (70 %)	Approved	28099856
DrugRepV_5610	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (90 %)	Approved	28099856
DrugRepV_5611	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (80 %)	Approved	28099856
DrugRepV_5612	Tenovin-1	Anticancer	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (90 %)	NA	28099856
DrugRepV_5613	Tenovin-1	Anticancer	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (95 %)	NA	28099856
DrugRepV_5614	Tenovin-1	Anticancer	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	No significant effect (10 %)	NA	28099856
DrugRepV_5615	AMG-458	NA	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (60 %)	NA	28099856
DrugRepV_5616	AMG-458	NA	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	No significant effect (40 %)	NA	28099856
DrugRepV_5617	AMG-458	NA	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	No significant effect (5 %)	NA	28099856
DrugRepV_5618	MGCD-265	Anticancer	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (70 %)	Investigational	28099856
DrugRepV_5619	MGCD-265	Anticancer	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	No significant effect (25 %)	Investigational	28099856
DrugRepV_5620	MGCD-265	Anticancer	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	No significant effect (20 %)	Investigational	28099856
DrugRepV_5621	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (60 %)	Approved	28099856
DrugRepV_5622	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	No significant effect (30 %)	Approved	28099856
DrugRepV_5623	Cabozantinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	No significant effect (10 %)	Approved	28099856
DrugRepV_5624	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (80 %)	Investigational	28099856
DrugRepV_5625	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	No significant effect (25 %)	Investigational	28099856
DrugRepV_5626	Foretinib	Anticancer	Breast Cancer | Renal Cell Carcinoma | Breast Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Increase (120 %)	Investigational	28099856
DrugRepV_5627	Nanchangmycin	Antibacterial; Antiviral	NA	Dengue virus	New Guinea C		Real-time PCR	Decrease (95 %)	NA	28099856
DrugRepV_5628	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	16681		Enzyme-linked immunosorbent assay	Decrease (20 %)	Approved, Investigational	27396621
DrugRepV_5629	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	Hawaii		Enzyme-linked immunosorbent assay	Decrease (20 %)	Approved, Investigational	27396621
DrugRepV_5630	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	H87		Enzyme-linked immunosorbent assay	Decrease (30 %)	Approved, Investigational	27396621
DrugRepV_5631	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	H241		Enzyme-linked immunosorbent assay	Decrease (30 %)	Approved, Investigational	27396621
DrugRepV_5632	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	16681		Real-time PCR	Decrease (50 %)	Approved, Investigational	27396621
DrugRepV_5633	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	16681		Focus forming assay	Decrease (1 Log10 (FFU/ml))	Approved, Investigational	27396621
DrugRepV_5634	Lomefloxacin	Antiinfectives For Systemic Use	Bacterial infections (respiratory tract (chronic bronchitis) and urinary tract)	Dengue virus	16681		Enzyme-linked immunosorbent assay	No significant effect (5 %)	Approved, Investigational	27396621
DrugRepV_5635	Netilmicin	Antiinfectives For Systemic Use	Bacteremia | Septicaemia | Respiratory tract infections | Skin and soft-tissue infection | Burns | Wounds | Peri-operative infections caused by susceptible strains	Dengue virus	16681		Enzyme-linked immunosorbent assay	No significant effect (0 %)	Approved, Investigational	27396621
DrugRepV_5636	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5637	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5638	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5639	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5640	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5641	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5642	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5643	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5644	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5645	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5646	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5647	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (50 %)	Phase II	26794905
DrugRepV_5648	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		NA	Increase	Phase II	26794905
DrugRepV_5649	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		NA	Increase	Phase II	26794905
DrugRepV_5650	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		NA	Increase	Phase II	26794905
DrugRepV_5651	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Real-time PCR	Decrease (4.3 Fold)	Phase II	26794905
DrugRepV_5652	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Real-time PCR	Decrease (16.5 Fold)	Phase II	26794905
DrugRepV_5653	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Real-time PCR	Decrease (2.4 Fold)	Phase II	26794905
DrugRepV_5654	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV1-2402		Real-time PCR	Decrease (0.5 Log (copies/ml))	Phase II	26794905
DrugRepV_5655	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	DENV2-3295		Real-time PCR	Decrease (2 Log (copies/ml))	Phase II	26794905
DrugRepV_5656	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 872		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5657	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 2402		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5658	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	PVP41		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5659	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN3300		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5660	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN2928		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5661	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	ST		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5662	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 3295		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5663	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	PR8545		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5664	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	PR2167		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5665	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	PVP110		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5666	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 863		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5667	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 2930		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5668	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 2270		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5669	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EHI 69273		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5670	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EHI 16693		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_5671	Epoxomicin	Anti-inflammatory	Hypertension	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	26565697
DrugRepV_5672	Epoxomicin	Anti-inflammatory	Hypertension	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	26565697
DrugRepV_5673	Epoxomicin	Anti-inflammatory	Hypertension	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	26565697
DrugRepV_5674	Epoxomicin	Anti-inflammatory	Hypertension	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	26565697
DrugRepV_5675	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 3295		Immunohistochemical assay	Decrease (50 %)	Approved	26565697
DrugRepV_5676	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Dengue virus	EDEN 3295		Real-time PCR	Decrease	Approved	26565697
DrugRepV_5677	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	Thsman		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5678	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	FR37 -clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5679	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	FR42-clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5680	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	FR28 -clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5681	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	FR34 -clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5682	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	Th36		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5683	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	32/0140 --clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5684	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	32/0102--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5685	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0178--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5686	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0051--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5687	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	H87		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5688	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0072--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5689	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0253--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5690	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0177--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5691	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	33/0096--clinical isolate from Vietnamese dengue patients		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5692	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	H241		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5693	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	Phili/1567- patient strain as gift		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5694	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	Venz/JQ - patient strain as gift		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5695	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	Senga/DA - patient strain as gift		Real-time PCR	Decrease (50 %)	Phase II failed	22807519
DrugRepV_5696	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	NA		Real-time PCR	Increase (0.2 Log10 Copies/ml)	Phase II failed	22807519
DrugRepV_5697	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	NA		Real-time PCR	Increase (0.5 Log10 Copies/ml)	Phase II failed	22807519
DrugRepV_5698	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	NA		Real-time PCR	No significant effect (0.7 Log10 Copies/ml)	Phase II failed	22807519
DrugRepV_5699	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	NA		Real-time PCR	Increase (0.3 Log10 Copies/ml)	Phase II failed	22807519
DrugRepV_5700	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	16681		Flow cytometry	Decrease (50 %)	Approved	12504563
DrugRepV_5701	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	16681		Flow cytometry	Decrease (51 %)	Approved	12504563
DrugRepV_5702	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	16681		Flow cytometry	Decrease (52 %)	Approved	12504563
DrugRepV_5703	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	16681		Flow cytometry	Decrease (50 %)	Approved	12504563
DrugRepV_5704	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	16681		Plaque assay	Decrease (>1.0 + E3 pfu/ml)	Approved	12504563
DrugRepV_5705	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	16681		Real-time PCR	Decrease (>100 Fold)	Approved	12504563
DrugRepV_5706	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	N1047		Flow cytometry	Decrease (97 %)	Approved	12504563
DrugRepV_5707	Balapiravir	Antiviral	Hepatitis C virus	Dengue virus	TSV01		Plaque assay	No significant effect (<0.5 Log10 PFU/ml)	Phase II failed	24257621
DrugRepV_5708	R1479	NA	NA	Dengue virus	MY-10340		Plaque assay	Decrease (50 %)	NA	24257621
DrugRepV_5709	Sunitinib-Erlotinib	NA	NA	Dengue virus	NA		Survival assay	Increase	NA	29753658
DrugRepV_5710	Sunitinib-Erlotinib	NA	NA	Dengue virus	NA		Plaque assay	Decrease (>5 Log (pfu/g))	NA	29753658
DrugRepV_5711	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	Dengue virus	NA		Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	29753658
DrugRepV_5712	Erlotinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	NA		Luciferase reporter assay	Decrease (50 %)	Approved	29753658
DrugRepV_5713	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5714	Carrageenan	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5715	Tannic Acid	NA	Cold sores | Diaper rash | Fever blisters | Poison ivy	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5716	Tannic Acid	NA	Cold sores | Diaper rash | Fever blisters | Poison ivy	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5717	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Investigational	20973722
DrugRepV_5718	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Investigational	20973722
DrugRepV_5719	Antimycin A	Antifungal	Fungal infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5720	Antimycin A	Antifungal	Fungal infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5721	BIBU 1361	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5722	BIBU 1361	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5723	Acetylspiramycin	Antiinfectives For Systemic Use	Microbial infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5724	3-[(4-chloro-phenyl)-phenyl-methoxy]-tropane	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5725	3-[(4-chloro-phenyl)-phenyl-methoxy]-tropane	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5726	Bebeerine	Antiparasitic	Malaria	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5727	H-89	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5728	H-89	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5729	MPP	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5730	MPP	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5731	Benzethonium	Respiratory System	Topical microbial infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5732	Benzethonium	Respiratory System	Topical microbial infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5733	Selamectin	Antiparasitic	Vet-Antihelminthic	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Vet approved	20973722
DrugRepV_5734	W-9	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5735	W-9	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5736	AZ 10417808	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5737	AZ 10417808	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5738	Niguldipine	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Experimental	20973722
DrugRepV_5739	Niguldipine	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Experimental	20973722
DrugRepV_5740	3a-bis-(4-fluorophenyl) Methoxytropane	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5741	LE 135	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5742	LE 135	NA	NA	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5743	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Plaque assay	Decrease (50 %)	Approved	29297305
DrugRepV_5744	Asunaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Plaque assay	Decrease (50 %)	Phase III	29297305
DrugRepV_5745	Boceprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Real-time PCR	No significant effect	Phase II	29297305
DrugRepV_5746	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Real-time PCR	Decrease (2 Logs)	Approved	29297305
DrugRepV_5747	Asunaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Real-time PCR	Decrease (5 Logs)	Phase III	29297305
DrugRepV_5748	Manidipine	Cardiovascular agents	Hypertension	Dengue virus	DENV-2 replicon		Luciferase reporter assay	Decrease (75 %)	Approved, Investigational	28814523
DrugRepV_5749	Cilnidipine	Cardiovascular agents	Hypertension	Dengue virus	DENV-2 replicon		Luciferase reporter assay	Decrease (90 %)	Approved	28814523
DrugRepV_5750	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Dengue virus	DENV-2 replicon		Luciferase reporter assay	Decrease (100 %)	Approved	28814523
DrugRepV_5751	Pimecrolimus	Dermatologicals	Atopic dermatitis	Dengue virus	DENV-2 replicon		Luciferase reporter assay	Decrease (100 %)	Approved, Investigational	28814523
DrugRepV_5752	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Dengue virus	DENV-2 replicon		Luciferase reporter assay	No significant effect (0 %)	NA	28814523
DrugRepV_5753	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (1000 Fold)	Investigational	25313218
DrugRepV_5754	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Dengue virus	NGC		Western blot	Decrease (100 %)	Investigational	25313218
DrugRepV_5755	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Dengue virus	NGC		Western blot	Decrease (100 %)	Investigational	25313218
DrugRepV_5756	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (50 %)	Investigational	25313218
DrugRepV_5757	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (3.2 Logs)	Investigational	25313218
DrugRepV_5758	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (1 Logs)	Investigational	25313218
DrugRepV_5759	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (1 Logs)	Investigational	25313218
DrugRepV_5760	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Dengue virus	NGC		Plaque assay	Decrease (0 Logs)	Investigational	25313218
DrugRepV_5761	Myriocin	NA	Bacterial infections	Dengue virus	NGC		Plaque assay	No significant effect	NA	25313218
DrugRepV_5762	Fenretinide-Myriocin	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (4 Logs)	NA	25313218
DrugRepV_5763	Butylated Hydroxyanisole	NA	Antioxidant	Dengue virus	NGC		Plaque assay	No significant effect	NA	25313218
DrugRepV_5764	Fenretinide-Butylated Hydroxyanisole	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (1.5 Logs)	NA	25313218
DrugRepV_5765	Vitamin C	Alimentary Tract and Metabolism	Vitamin C deficiency, scurvy, delayed wound and bone healing, urine acidification	Dengue virus	NGC		Plaque assay	No significant effect	Approved	25313218
DrugRepV_5766	Fenretinide-Vitamin C	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (3 Logs)	NA	25313218
DrugRepV_5767	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Dengue virus	D2Y98P		Plaque assay	Decrease (1.73 Logs)	Investigational	25313218
DrugRepV_5768	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (89 %)	Experimental	25251726
DrugRepV_5769	Digitoxin	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (94 %)	Approved	25251726
DrugRepV_5770	Digoxin	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (92 %)	Approved	25251726
DrugRepV_5771	Hycanthone	Antischistosomal	Parasitic infections	Dengue virus	Singapore isolates		Plaque assay	Decrease (90 %)	Experimental	25251726
DrugRepV_5772	Cetrimonium Bromide	Dermatologicals	Sepsis	Dengue virus	Singapore isolates		Plaque assay	Decrease (90 %)	Approved	25251726
DrugRepV_5773	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Dengue virus	Singapore isolates		Plaque assay	Decrease (82 %)	Approved	25251726
DrugRepV_5774	Paroxetine Hydrochloride	Nervous System	Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD)	Dengue virus	Singapore isolates		Plaque assay	Decrease (78 %)	NA	25251726
DrugRepV_5775	Allantoin	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (78 %)	Approved	25251726
DrugRepV_5776	Mephentermine sulphate	Cardiovascular agents	Hypotension	Dengue virus	Singapore isolates		Plaque assay	Decrease (75 %)	Approved	25251726
DrugRepV_5777	Brucine	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (75 %)	NA	25251726
DrugRepV_5778	Dicloxacillium Sodium	NA	Bacterial infections	Dengue virus	Singapore isolates		Plaque assay	Decrease (72 %)	Approved	25251726
DrugRepV_5779	Clarithromycin	Antiinfectives For Systemic Use	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (72 %)	NA	25251726
DrugRepV_5780	Acrisorcin	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (72 %)	NA	25251726
DrugRepV_5781	Loxapine succinate	Nervous System	Schizophrenia	Dengue virus	Singapore isolates		Plaque assay	Decrease (68 %)	Approved	25251726
DrugRepV_5782	Oxantel Pamoate	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (68 %)	NA	25251726
DrugRepV_5783	Dioxybenzone	Dermatologicals	Sunburn	Dengue virus	Singapore isolates		Plaque assay	Decrease (65 %)	Approved	25251726
DrugRepV_5784	Mexiletine Hydrochloride	Cardiovascular agents	Ventricular tachycardia | Symptomatic premature ventricular beats	Dengue virus	Singapore isolates		Plaque assay	Decrease (65 %)	NA	25251726
DrugRepV_5785	Chlormadinone Acetate	Genito Urinary System and Sex Hormones	Atrophic vaginitis and estrogen deficiency	Dengue virus	Singapore isolates		Plaque assay	Decrease (65 %)	NA	25251726
DrugRepV_5786	Candesartan cilexetil	Cardiovascular agents	Hypertension	Dengue virus	Singapore isolates		Plaque assay	Decrease (63 %)	Approved	25251726
DrugRepV_5787	Lasalocid Sodium	NA	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (62 %)	NA	25251726
DrugRepV_5788	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (50 %)	Experimental	25251726
DrugRepV_5789	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (50 %)	Experimental	25251726
DrugRepV_5790	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (50 %)	Experimental	25251726
DrugRepV_5791	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (90 %)	Experimental	25251726
DrugRepV_5792	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates (+)		Real-time PCR	Decrease (2 Logs)	Experimental	25251726
DrugRepV_5793	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates (-)		Real-time PCR	Decrease (2 Logs)	Experimental	25251726
DrugRepV_5794	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Western blot	Decrease (6.7 Fold)	Experimental	25251726
DrugRepV_5795	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Western blot	Decrease (6.3 Fold)	Experimental	25251726
DrugRepV_5796	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (86.4 %)	Experimental	25251726
DrugRepV_5797	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (95.14 %)	Experimental	25251726
DrugRepV_5798	Lanatoside C	Cardiovascular agents	Arrhythmia	Dengue virus	Singapore isolates		Plaque assay	Decrease (73.79 %)	Experimental	25251726
DrugRepV_5799	Geneticin	Antibacterial	Bacterial infections	Dengue virus	NA		Almar Blue assay	Decrease (50 %)	Experimental	19501253
DrugRepV_5800	Geneticin	Antibacterial	Bacterial infections	Dengue virus	NA		Real-time PCR	Decrease (90 %)	Experimental	19501253
DrugRepV_5801	Geneticin	Antibacterial	Bacterial infections	Dengue virus	NA		Western blot	Decrease (100 %)	Experimental	19501253
DrugRepV_5802	Geneticin	Antibacterial	Bacterial infections	Dengue virus	NA		Western blot	Decrease (80 %)	Experimental	19501253
DrugRepV_5803	Lapachaone Alpha	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (98.84 %)	NA	22155902
DrugRepV_5804	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	NA		Immunoflourescence assay	Decrease (92.38 %)	Approved	22155902
DrugRepV_5805	Lycorine Hydrochloride	Antiviral, Antimalarial, Anticancer and Antiinflammatory	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (86.86 %)	NA	22155902
DrugRepV_5806	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Dengue virus	NA		Immunoflourescence assay	Decrease (84.62 %)	Approved, Investigational, Vet approved	22155902
DrugRepV_5807	C6 Ceramide	Dermatologicals	Skin disorder	Dengue virus	NA		Immunoflourescence assay	Decrease (84.06 %)	Approved	22155902
DrugRepV_5808	Anisomycin	Antibacterial	Bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (82.49 %)	Experimental	22155902
DrugRepV_5809	Shikonin	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (78.94 %)	NA	22155902
DrugRepV_5810	Cycloheximide	Antibacterial	Bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (78.71 %)	NA	22155902
DrugRepV_5811	Chelerythrine Chloride	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (73.36 %)	NA	22155902
DrugRepV_5812	Skimmianine	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (61.96 %)	NA	22155902
DrugRepV_5813	Actinomycin D	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	NA		Immunoflourescence assay	Decrease (59.6 %)	Approved	22155902
DrugRepV_5814	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (55.89 %)	Experimental	22155902
DrugRepV_5815	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Dengue virus	NA		Immunoflourescence assay	Decrease (55.12 %)	Approved, Investigational	22155902
DrugRepV_5816	Tunicamycin B	NA	Bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (55.01 %)	Experimental	22155902
DrugRepV_5817	Acivicin	NA	Cancer	Dengue virus	NA		Immunoflourescence assay	Decrease (54.32 %)	Phase I	22155902
DrugRepV_5818	Cotinine	Nervous System	Psychosis	Dengue virus	NA		Immunoflourescence assay	Decrease (52.71 %)	Withdrawn	22155902
DrugRepV_5819	Cantharidin	Dermatologicals	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (51.87 %)	Approved	22155902
DrugRepV_5820	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	Dengue virus	NA		Immunoflourescence assay	Decrease (50.92 %)	Phase I	22155902
DrugRepV_5821	Gitoxigenin	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (49.01 %)	NA	22155902
DrugRepV_5822	Kainic Acid	NA	Neuroexcitatory	Dengue virus	NA		Immunoflourescence assay	Decrease (48.87 %)	NA	22155902
DrugRepV_5823	Brefeldin A	Antibiotics	Bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (47.12 %)	Experimental	22155902
DrugRepV_5824	Dicoumarol	Blood and Blood Forming Organs	Coagulation disorders	Dengue virus	NA		Immunoflourescence assay	Decrease (45.99 %)	Approved	22155902
DrugRepV_5825	Diacetoxyscirpenol	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (45.55 %)	NA	22155902
DrugRepV_5826	Austricin	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (45.01 %)	NA	22155902
DrugRepV_5827	Valinomycin	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (43.34 %)	Experimental	22155902
DrugRepV_5828	Thapsigargin	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (42.9 %)	NA	22155902
DrugRepV_5829	Strophanthidin Acetate	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (41.96 %)	NA	22155902
DrugRepV_5830	Trimethylpsoralen,4,5,8-	Dermatologicals	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (41.86 %)	NA	22155902
DrugRepV_5831	Echinomycin	NA	Bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (41.52 %)	NA	22155902
DrugRepV_5832	Chromomycin A3	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (40.87 %)	NA	22155902
DrugRepV_5833	Anisomycin	Antibacterial	Bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (50 %)	Experimental	22155902
DrugRepV_5834	Lycorine Hydrochloride	Antiviral, Antimalarial, Anticancer and Antiinflammatory	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (50 %)	NA	22155902
DrugRepV_5835	Strophanthidin Acetate	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (50 %)	NA	22155902
DrugRepV_5836	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (50 %)	Experimental	22155902
DrugRepV_5837	Anisomycin	Antibacterial	Bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (100 %)	Experimental	22155902
DrugRepV_5838	Lycorine Hydrochloride	Antiviral, Antimalarial, Anticancer and Antiinflammatory	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (98 %)	NA	22155902
DrugRepV_5839	Strophanthidin Acetate	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease (98 %)	NA	22155902
DrugRepV_5840	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (80 %)	Experimental	22155902
DrugRepV_5841	Anisomycin	Antibacterial	Bacterial infections	Dengue virus	NA		Plaque assay	Decrease (5 Logs reduction)	Experimental	22155902
DrugRepV_5842	Lycorine Hydrochloride	Antiviral, Antimalarial, Anticancer and Antiinflammatory	NA	Dengue virus	NA		Plaque assay	Decrease (2 Logs reduction)	NA	22155902
DrugRepV_5843	Strophanthidin Acetate	NA	NA	Dengue virus	NA		Plaque assay	Decrease (5 Logs reduction)	NA	22155902
DrugRepV_5844	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (5 Logs reduction)	Experimental	22155902
DrugRepV_5845	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	22155902
DrugRepV_5846	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	22155902
DrugRepV_5847	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	22155902
DrugRepV_5848	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	22155902
DrugRepV_5849	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Immunoflourescence assay	No significant effect (0 %)	Experimental	22155902
DrugRepV_5850	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease	Experimental	22155902
DrugRepV_5851	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease	Experimental	22155902
DrugRepV_5852	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	No significant effect	Experimental	22155902
DrugRepV_5853	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (3.8 Logs reduction)	Experimental	22155902
DrugRepV_5854	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Plaque assay	Decrease (5 Logs reduction)	Experimental	22155902
DrugRepV_5855	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Immunoflourescence assay	No significant effect (0 %)	Experimental	22155902
DrugRepV_5856	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Immunoflourescence assay	Decrease (90 %)	Experimental	22155902
DrugRepV_5857	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Real-time PCR	No significant effect (0 Copies number)	Experimental	22155902
DrugRepV_5858	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Western blot	Decrease	Experimental	22155902
DrugRepV_5859	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	NA		Western blot	Decrease	Experimental	22155902
DrugRepV_5860	N-Desmethylclozapine	Antipsychotic	Schizophrenia | Schizoaffective disorders	Dengue virus	NA		Plaque assay	Decrease (50 %)	Investigational	27572397
DrugRepV_5861	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved, Vet approved	27572397
DrugRepV_5862	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved	27572397
DrugRepV_5863	N-Desmethylclozapine	Antipsychotic	Schizophrenia | Schizoaffective disorders	Dengue virus	NA		Western blot	Decrease (Decrease Band intensity)	Investigational	27572397
DrugRepV_5864	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Western blot	Decrease (Decrease Band intensity)	Approved, Vet approved	27572397
DrugRepV_5865	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Dengue virus	NA		Western blot	Decrease (Decrease Band intensity)	Approved	27572397
DrugRepV_5866	N-Desmethylclozapine	Antipsychotic	Schizophrenia | Schizoaffective disorders	Dengue virus	NA		Real-time PCR	Decrease (10 Fold)	Investigational	27572397
DrugRepV_5867	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Real-time PCR	Decrease (4.5 Fold)	Approved, Vet approved	27572397
DrugRepV_5868	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Dengue virus	NA		Real-time PCR	Decrease (99 Fold)	Approved	27572397
DrugRepV_5869	N-Desmethylclozapine	Antipsychotic	Schizophrenia | Schizoaffective disorders	Dengue virus	NA		Immunoflourescence assay	Decrease (0 %)	Investigational	27572397
DrugRepV_5870	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Immunoflourescence assay	Decrease (0 %)	Approved, Vet approved	27572397
DrugRepV_5871	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Dengue virus	NA		Immunoflourescence assay	Decrease (0 %)	Approved	27572397
DrugRepV_5872	N-Desmethylclozapine	Antipsychotic	Schizophrenia | Schizoaffective disorders	Dengue virus	NA		Real-time PCR	Decrease (>75 Fold)	Investigational	27572397
DrugRepV_5873	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Real-time PCR	Decrease (<10 Fold)	Approved, Vet approved	27572397
DrugRepV_5874	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Dengue virus	NA		Real-time PCR	Decrease (<10 Fold)	Approved	27572397
DrugRepV_5875	N-Desmethylclozapine	Antipsychotic	Schizophrenia | Schizoaffective disorders	Dengue virus	NA		Plaque assay	Decrease (1.5 Fold)	Investigational	27572397
DrugRepV_5876	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Plaque assay	Decrease (2 Fold)	Approved, Vet approved	27572397
DrugRepV_5877	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Dengue virus	NA		Plaque assay	Decrease (2.5 Fold)	Approved	27572397
DrugRepV_5878	N-Desmethylclozapine	Antipsychotic	Schizophrenia | Schizoaffective disorders	Dengue virus	NA		Real-time PCR	Decrease (> 90 %)	Investigational	27572397
DrugRepV_5879	Fluoxetine	Nervous System	Major depressive disorder | Bulimia nervosa | Obsessive-compulsive disorder | Premenstrual dysphoric disorder | Panic disorder with or without agoraphobia	Dengue virus	NA		Real-time PCR	Decrease (> 80 %)	Approved, Vet approved	27572397
DrugRepV_5880	Salmeterol	Respiratory System	Asthma | Chronic obstructive pulmonary disease	Dengue virus	NA		Real-time PCR	Decrease (> 95 %)	Approved	27572397
DrugRepV_5881	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (78 %)	Approved	24680954
DrugRepV_5882	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (58 %)	Approved	24680954
DrugRepV_5883	Chloroquine ethyl phenyl Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (> 99 %)	NA	24680954
DrugRepV_5884	Chloroquine Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (> 99 %)	NA	24680954
DrugRepV_5885	Chloroquine Pamoate	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5886	Chloroquine Sulfate	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (30 %)	NA	24680954
DrugRepV_5887	Apoquinine	Antiparasitic	Malaria	Dengue virus	NA		Plaque assay	Decrease (38 %)	NA	24680954
DrugRepV_5888	Primaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	No significant effect (0 %)	Approved	24680954
DrugRepV_5889	Quinine Hydrobromide Hydrate	Antiparasitic products, Insectisides and Repellents	Malaria | Leg cramps	Dengue virus	NA		Plaque assay	Decrease (38 %)	NA	24680954
DrugRepV_5890	Quinacrine Mustard	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	NA		Plaque assay	Decrease (> 99 %)	Experimental	24680954
DrugRepV_5891	Amodiaquine derivative (AQD1)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	NA	24680954
DrugRepV_5892	Amodiaquine derivative (AQD2)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (70 %)	NA	24680954
DrugRepV_5893	Amodiaquine derivative (AQD3)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_5894	Amodiaquine derivative (AQD4)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_5895	Amodiaquine derivative (AQD5)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (20 %)	NA	24680954
DrugRepV_5896	Amodiaquine derivative (AQD6)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_5897	Amodiaquine derivative (AQD7)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (97 %)	NA	24680954
DrugRepV_5898	Amodiaquine derivative (AQD8)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	No significant effect (0 %)	NA	24680954
DrugRepV_5899	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved	24680954
DrugRepV_5900	Amodiaquine derivative (AQD1)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5901	Amodiaquine derivative (AQD2)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5902	Amodiaquine derivative (AQD3)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5903	Amodiaquine derivative (AQD4)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5904	Amodiaquine derivative (AQD5)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5905	Amodiaquine derivative (AQD6)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5906	Amodiaquine derivative (AQD7)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5907	Amodiaquine derivative (AQD8)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5908	Quinacrine Mustard	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	NA		Plaque assay	Decrease (50 %)	Experimental	24680954
DrugRepV_5909	Chloroquine Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5910	Chloroquine ethyl phenyl Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_5911	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved	24680954
DrugRepV_5912	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved	24680954
DrugRepV_5913	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved	24680954
DrugRepV_5914	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Real-time PCR	Decrease (90 %)	Approved	24680954
DrugRepV_5915	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Real-time PCR	Decrease (90 %)	Approved	24680954
DrugRepV_5916	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (98 %)	Approved	24680954
DrugRepV_5917	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	Approved	24680954
DrugRepV_5918	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	Approved	24680954
DrugRepV_5919	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (100 %)	Approved	24680954
DrugRepV_5920	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (80 %)	Approved	24680954
DrugRepV_5921	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (100 %)	Approved	24680954
DrugRepV_5922	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	No significant effect	Approved	24680954
DrugRepV_5923	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (2 Fold)	Approved	24680954
DrugRepV_5924	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (3 Fold)	Approved	24680954
DrugRepV_5925	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	Approved	24680954
DrugRepV_5926	Amodiaquine derivative (AQD8)	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	NA	24680954
DrugRepV_5927	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	Approved	24680954
DrugRepV_5928	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (90 %)	Approved	24680954
DrugRepV_5929	Prochlorperazine	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease	Approved	25028694
DrugRepV_5930	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (50 %)	Approved	25028694
DrugRepV_5931	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (50 %)	Approved	25028694
DrugRepV_5932	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Western blot	Decrease (100 %)	Approved	25028694
DrugRepV_5933	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Western blot	Decrease (100 %)	Approved	25028694
DrugRepV_5934	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (2 Fold)	Approved	25028694
DrugRepV_5935	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (2.5 Fold)	Approved	25028694
DrugRepV_5936	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (9 Fold)	Approved	25028694
DrugRepV_5937	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease (2 Fold)	Approved	25028694
DrugRepV_5938	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5939	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5940	Prochlorperazine Dimaleate	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5941	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5942	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5943	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5944	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5945	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Survival assay	Increase	Approved	25028694
DrugRepV_5946	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease	Approved	25028694
DrugRepV_5947	Prochlorperazine Novamin	Nervous System	Nausea | Vomiting | Schizophrenia	Dengue virus	New Guinea C		Plaque assay	Decrease	Approved	25028694
DrugRepV_5948	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_5949	NITD008	Antiviral	NA	Dengue virus	Hawaii		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5950	NITD008	Antiviral	NA	Dengue virus	MY10245		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5951	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5952	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_5953	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19918064
DrugRepV_5954	NITD008	Antiviral	NA	Dengue virus	MY21531		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5955	NITD008	Antiviral	NA	Dengue virus	MY22366		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5956	NITD008	Antiviral	NA	Dengue virus	MY22713		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5957	NITD008	Antiviral	NA	Dengue virus	MY10245		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5958	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5959	NITD008	Antiviral	NA	Dengue virus	MY10340		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5960	NITD008	Antiviral	NA	Dengue virus	MY21531		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5961	NITD008	Antiviral	NA	Dengue virus	MY22366		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5962	NITD008	Antiviral	NA	Dengue virus	MY22713		Immunodetection assay	Decrease (50 %)	NA	19918064
DrugRepV_5963	NITD008	Antiviral	NA	Dengue virus	New Guinea C		Cytopathic effect (CPE) assay	Decrease (50 %)	NA	19918064
DrugRepV_5964	NITD008	Antiviral	NA	Dengue virus	MY10245		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_5965	NITD008	Antiviral	NA	Dengue virus	D2S10		Survival assay	Increase	NA	19918064
DrugRepV_5966	NITD008	Antiviral	NA	Dengue virus	D2S10		Plaque assay	Decrease (6.4 Fold)	NA	19918064
DrugRepV_5967	NITD008	Antiviral	NA	Dengue virus	TS01		Plaque assay	Decrease (10 Fold)	NA	19918064
DrugRepV_5968	NITD008	Antiviral	NA	Dengue virus	TS01		Enzyme-linked immunosorbent assay	Decrease (6 Fold)	NA	19918064
DrugRepV_5969	ZX-2401	NA	Rhinovirus 1A | Rhinovirus 30 | Rhinovirus 13 | Rhinovirus 8 | Rhinovirus 2	Dengue virus	New Guinea		Cytopathic effect (CPE) assay	Decrease (50 %)	NA	16199098
DrugRepV_5970	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	New Guinea		Plaque assay	Decrease	Approved	24773578
DrugRepV_5971	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	New Guinea		Real-time PCR	Decrease	Approved	24773578
DrugRepV_5972	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	New Guinea		Immunoflourescence assay	Decrease	Approved	24773578
DrugRepV_5973	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	New Guinea		Plaque assay	Decrease	Approved	25664975
DrugRepV_5974	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	FGA/89		Focus immunoassay	Decrease (95 %)	Experimental	10590151
DrugRepV_5975	Deoxynojirimycin	NA	NA	Dengue virus	FGA/89		Focus immunoassay	Decrease (80 %)	NA	10590151
DrugRepV_5976	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	16681		Plaque assay	Decrease (50 %)	Experimental	15994763
DrugRepV_5977	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	16681		Plaque assay	Decrease (50 %)	Experimental	15994763
DrugRepV_5978	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	16681		Western blot	Decrease	Experimental	15994763
DrugRepV_5979	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5980	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5981	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5982	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Plaque assay	Decrease	Experimental	15994763
DrugRepV_5983	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Flow cytometry	Decrease	Experimental	15994763
DrugRepV_5984	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Flow cytometry	Decrease	Experimental	15994763
DrugRepV_5985	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Flow cytometry	Decrease	Experimental	15994763
DrugRepV_5986	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	NA		Flow cytometry	Decrease	Experimental	15994763
DrugRepV_5987	Castanospermine	Antiviral	Dengue and Parainfluenza	Dengue virus	16681-Replicon		Renilla luciferase assay	Decrease	Experimental	15994763
DrugRepV_5988	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Plaque assay	Decrease (>50 %)	Phase II	22867971
DrugRepV_5989	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	S221		Survival assay	Decrease	Phase II	22867971
DrugRepV_5990	Celgosivir	Antiviral	Hepatitis C virus	Dengue virus	NA		Plaque assay	No significant difference	Phase II	27509020
DrugRepV_5991	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (>2 Log (pfu/ml))	Approved	17360676
DrugRepV_5992	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (>2 Log (pfu/ml))	Approved	17360676
DrugRepV_5993	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (>2 Log (pfu/ml))	Approved	17360676
DrugRepV_5994	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	Clone		Immunoflourescence assay	Decrease (>70 %)	Approved	17360676
DrugRepV_5995	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	Clone		Immunoflourescence assay	Decrease (>70 %)	Approved	17360676
DrugRepV_5996	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	Clone		Immunoflourescence assay	Decrease (>70 %)	Approved	17360676
DrugRepV_5997	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	Clone		Immunoflourescence assay	Decrease (>70 %)	Approved	17360676
DrugRepV_5998	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (2 Log (pfu/ml))	Investigational	17360676
DrugRepV_5999	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (2 Log (pfu/ml))	Investigational	17360676
DrugRepV_6000	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea		Plaque assay	Decrease (2 Log (pfu/ml))	Investigational	17360676
DrugRepV_6001	U18666A	NA	NA	Dengue virus	New Guinea		Plaque assay	Decrease (3 Log (pfu/ml))	NA	22146564
DrugRepV_6002	U18666A	NA	NA	Dengue virus	Replicon systen		Luciferase reporter assay	Decrease (50 %)	NA	22146564
DrugRepV_6003	U18666A	NA	NA	Dengue virus	Replicon systen		Luciferase reporter assay	Decrease (50 %)	NA	22146564
DrugRepV_6004	Imipramine	Nervous System	Depression	Dengue virus	16681		Real-time PCR	Decrease (100 %)	Approved	28600536
DrugRepV_6005	Imipramine	Nervous System	Depression	Dengue virus	16681		Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_6006	Chebulagic Acid	NA	Immunosuppressive and hepatoprotective	Dengue virus	16681		Plaque assay	Decrease (50 %)	NA	23924316
DrugRepV_6007	Punicalagin	Plant pigment	NA	Dengue virus	16681		Plaque assay	Decrease (50 %)	NA	23924316
DrugRepV_6008	Chebulagic Acid	NA	Immunosuppressive and hepatoprotective	Dengue virus	16681		Plaque assay	Decrease (100 %)	NA	23924316
DrugRepV_6009	Punicalagin	Plant pigment	NA	Dengue virus	16681		Plaque assay	Decrease (100 %)	NA	23924316
DrugRepV_6010	Prednisolone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Congenital adrenal hyperplasia | Thyroiditis | Psoriatic arthritis | Rheumatoid arthritis | Ankylosing spondylitis | Bursitis | Acute gouty arthritis | Epicondylitis	Dengue virus	NA		Plasma viremia	Decrease (3.2 Log)	Approved, Vet approved	22865871
DrugRepV_6011	Prednisolone	Alimentary Tract And Metabolism; Cardiovascular agents; Dermatologicals; Systemic Hormonal Preparati	Congenital adrenal hyperplasia | Thyroiditis | Psoriatic arthritis | Rheumatoid arthritis | Ankylosing spondylitis | Bursitis | Acute gouty arthritis | Epicondylitis	Dengue virus	NA		Plasma viremia	Decrease (3.2 Log)	Approved, Vet approved	22865871
DrugRepV_6012	Cromolyn	Respiratory System	Allergies and Asthma	Dengue virus	Eden2		Plaque assay	Increase	Approved	23638300
DrugRepV_6013	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		FITC- assay	Decrease (98 %)	NA	11907199
DrugRepV_6014	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Plaque assay	Decrease (4 Log)	NA	11907199
DrugRepV_6015	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Western blot	Decrease (Decrease Band Intensity)	NA	11907199
DrugRepV_6016	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Western blot	Decrease (Decrease Band Intensity)	NA	11907199
DrugRepV_6017	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Real-time PCR	Decrease (Decrease Ct Value)	NA	11907199
DrugRepV_6018	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	PL046		Real-time PCR	Decrease (Decrease Ct Value)	NA	11907199
DrugRepV_6019	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea C		Focus forming assay	Decrease (90 %)	Investigational	23616652
DrugRepV_6020	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Focus forming assay	Decrease (90 %)	Approved	23616652
DrugRepV_6021	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Focus forming assay	Decrease (1 Log)	Approved	23616652
DrugRepV_6022	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea C		Northern blot	Decrease (60 AU (Arbitrary units))	Investigational	23616652
DrugRepV_6023	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Northern blot	Decrease (65 AU (Arbitrary units))	Approved	23616652
DrugRepV_6024	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea C		Northern blot	Decrease (65 AU (Arbitrary units))	Investigational	23616652
DrugRepV_6025	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Northern blot	Decrease (75 AU (Arbitrary units))	Approved	23616652
DrugRepV_6026	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea C		Western blot	Decrease (Decrease expression of C protein Band Intensity)	Investigational	23616652
DrugRepV_6027	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea C		Western blot	Decrease (Decrease expression of E protein Band Intensity)	Investigational	23616652
DrugRepV_6028	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea C		Western blot	Decrease (Decrease expression of NS3 and NS5 protein Band Intensity)	Investigational	23616652
DrugRepV_6029	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Western blot	Decrease (Decrease expression of C protein Band Intensity)	Approved	23616652
DrugRepV_6030	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Western blot	Decrease (Decrease expression of E protein Band Intensity)	Approved	23616652
DrugRepV_6031	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Western blot	Decrease (Decrease expression of NS3 and NS5 protein Band Intensity)	Approved	23616652
DrugRepV_6032	Saracatinib	Anticancer	Cancer	Dengue virus	New Guinea C		Luciferase reporter assay	Decrease (1 Log)	Investigational	23616652
DrugRepV_6033	Dasatinib	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Luciferase reporter assay	No significant effect (0.4 Log)	Approved	23616652
DrugRepV_6034	Aminolevullic acid	Antineoplastic and Immunomodulating Agents	NA	Dengue virus	16681		Focus forming assay	Decrease (41.1 %)	NA	30055216
DrugRepV_6035	Azelaic acid	Dermatologicals	Acne vulgaris	Dengue virus	16681		Focus forming assay	Decrease (36.6 %)	Approved	30055216
DrugRepV_6036	Mitoxantrone hydrochloride	Antineoplastic and Immunomodulating Agents	Multiple sclerosis	Dengue virus	16681		Focus forming assay	Decrease (53.8 %)	NA	30055216
DrugRepV_6037	Quinine sulfate	Antiparasitic products, Insectisides and Repellents	Malaria | Leg cramps	Dengue virus	16681		Focus forming assay	Decrease (81 %)	NA	30055216
DrugRepV_6038	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6039	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6040	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6041	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6042	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6043	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6044	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6045	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6046	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6047	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6048	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6049	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6050	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6051	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6052	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6053	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6054	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6055	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6056	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6057	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6058	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6059	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6060	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6061	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6062	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Dengue virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_6063	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Dengue virus	DENV-2 New guinea C		qRT-PCR	Decrease (90 %)	Phase I	27654301
DrugRepV_6064	N2-(4-fluorophenyl)-N3-(4-methyl-2-(3-methyl-1H-pyrazol- 5-yl)phenyl) pyrazine-2,3 dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6065	N2-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N3-(p- tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6066	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-2-yl)phenyl) pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6067	N2-(4-methyl-2-(thiophen-2-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6068	N2-(4-fluorophenyl)-N3-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6069	N2-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)-N3-(p- tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6070	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-3-yl) phenyl)pyrazine-2,3- dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6071	N2-(4-methyl-2-(thiophen-3-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6072	N2-(4-fluorophenyl)-N3-(2-(thiophen-3-yl)benzyl)pyrazine- 2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6073	N2-(2-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6074	N2-(4-fluorophenyl)-N3-(4-(thiophen-3-yl)benzyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6075	N2-(4-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6076	N2-(4-fluorophenyl)-N3-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)pyrazine-2,3-dicarboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6077	N2-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-di-carboxamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6078	N1-(4-fluorophenyl)-N2-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6079	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-2-yl) phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6080	N1-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6081	N1-(4-methyl-2-(thiophen-2-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6082	N1-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6083	N1-(4-fluorophenyl)-N2-(4-methyl-2-(5-methylthiophen-2- yl)phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6084	N1-(4-methyl-2-(thiophen-3-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6085	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-3-yl) phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6086	N1-(4-fluorophenyl)-N2-(2-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6087	N1-(2-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6088	N1-(4-fluorophenyl)-N2-(4-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6089	N1-(4-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6090	N1-(4-fluorophenyl)-N2-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6091	N1-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p-tolyl) phthalamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6092	2-(4-fluorobenzamido)-N-(4-methyl-2-(thiophen-3-yl) phenyl)benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6093	2-(4-fluorobenzamido)-N-(4-methyl-2-(5-methylthiophen- 2-yl)phenyl)benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6094	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-4-yl)phenyl) benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6095	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-3-yl)phenyl) benzamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_6096	Doxorubicin	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	Approved	20837762
DrugRepV_6097	SA-3	NA	NA	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6098	SA-11	NA	NA	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6099	SA-17	NA	NA	Dengue virus	New Guinea C (NGC)		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6100	SA-17	NA	NA	Dengue virus	New Guinea C		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_6101	CM-10-18	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6102	IHVR11029	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6103	IHVR17028	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6104	IHVR19029	NA	NA	Dengue virus	New Guinea C		MTT assay	Decrease (50 %)	NA	23578725
DrugRepV_6105	BCX4430	NA	Ebola virus	Dengue virus	New Guinea C		RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_6106	IHVR-19029	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	29253498
DrugRepV_6107	Coumarin A	NA	NA	Dengue virus	NG		RT-PCR	Decrease (50 %)	NA	28100218
DrugRepV_6108	Coumarin B	NA	NA	Dengue virus	NG		RT-PCR	Decrease (50 %)	NA	28100218
DrugRepV_6109	Lupeol Acetate 26SK001	NA	NA	Dengue virus	NG		RT-PCR	Decrease (50 %)	NA	28100218
DrugRepV_6110	Voacangine 26SK002	NA	NA	Dengue virus	NG		RT-PCR	Decrease (50 %)	NA	28100218
DrugRepV_6111	Coumarin A	NA	NA	Dengue virus	NG		RT-PCR	Decrease (37.1 %)	NA	28100218
DrugRepV_6112	Coumarin B	NA	NA	Dengue virus	NG		RT-PCR	Decrease (99.25 %)	NA	28100218
DrugRepV_6113	Lupeol Acetate 26SK001	NA	NA	Dengue virus	NG		RT-PCR	Decrease (23 %)	NA	28100218
DrugRepV_6114	Voacangine 26SK002	NA	NA	Dengue virus	NG		RT-PCR	Decrease (23 %)	NA	28100218
DrugRepV_6115	Favipiravir	Antiviral	Influenza virus	Dengue virus	hu/PHL/10-07		MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_6116	Favipiravir	Antiviral	Influenza virus	Dengue virus	hu/INDIA/09–74		MTT assay	Decrease (50 %)	Investigational	28236746
DrugRepV_6117	FGI-106	NA	NA	Dengue virus	NA		Flow cytometry	Decrease (50 %)	NA	19523489
DrugRepV_6118	FGI-106	NA	NA	Dengue virus	NA		Flow cytometry	Decrease (50 %)	NA	19523489
DrugRepV_6119	FGI-106	NA	NA	Dengue virus	NA		Flow cytometry	Decrease (50 %)	NA	19523489
DrugRepV_6120	FGI-106	NA	NA	Dengue virus	NA		Flow cytometry	Decrease (50 %)	NA	19523489
DrugRepV_6121	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	NA		Plaque assay	Decrease (50 %)	Investigational	27889529
DrugRepV_6122	Mefloquine	Antiparasitic products, Insectisides and Repellents	Malaria	Dengue virus	NA		Plaque assay	Decrease (50 %)	Approved, Investigational	27889529
DrugRepV_6123	GSK369796	NA	NA	Dengue virus	NA		Plaque assay	Decrease (50 %)	NA	27889529
DrugRepV_6124	Tomatidine	NA	NA	Dengue virus	16681		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6125	Tomatidine	NA	NA	Dengue virus	16007		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6126	Tomatidine	NA	NA	Dengue virus	H87		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6127	Tomatidine	NA	NA	Dengue virus	1036		MTT assay	Decrease (50 %)	NA	30468746
DrugRepV_6128	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C		NA	Decrease (50 %)	Approved	29890736
DrugRepV_6129	IFN-alpha	Antiviral	Hepatitis C virus | Leukemia | Melanoma	Dengue virus	New Guinea C		NA	Decrease (50 %)	Investigational	29890736
DrugRepV_6130	VGTI-A3	NA	NA	Dengue virus	New Guinea C		Focus forming assay	Decrease (90 %)	NA	29709563
DrugRepV_6131	VGTI-A3-03	NA	NA	Dengue virus	New Guinea C		Focus forming assay	Decrease (90 %)	NA	29709563
DrugRepV_6132	Ribavirin Nucleobase	NA	NA	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6133	Mizoribine Nucleobase	NA	NA	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6134	T-1105	NA	Zika virus	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6135	Diaminopurine	NA	NA	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6136	Favipiravir	Antiviral	Influenza virus	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	Investigational	29672522
DrugRepV_6137	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	Approved	29672522
DrugRepV_6138	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	Approved	29672522
DrugRepV_6139	Mizoribine	Immunosuppressant	Rheumatoid Arthritis	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	Investigational	29672522
DrugRepV_6140	T-1106	NA	Yellow Fever virus	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6141	Diaminopurine Riboside	NA	NA	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	NA	29672522
DrugRepV_6142	T-1105	NA	Zika virus	Dengue virus	New Guinea C		Titer reduction assay	Decrease (50 %)	NA	29672522
DrugRepV_6143	T-1106	NA	Yellow Fever virus	Dengue virus	New Guinea C		Titer reduction assay	Decrease (50 %)	NA	29672522
DrugRepV_6144	5,7-dichloro-2-(propan-2-yl)quinolin-8-ol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	29547522
DrugRepV_6145	5,7-dichloro-2-(2-methylpropyl)quinolin-8-ol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	29547522
DrugRepV_6146	Brefeldin A	Antibiotics	Bacterial infections	Dengue virus	NA		Virus titration assay	Decrease (50 %)	Experimental	29093640
DrugRepV_6147	Brefeldin A	Antibiotics	Bacterial infections	Dengue virus	NA		Virus titration assay	Decrease (50 %)	Experimental	29093640
DrugRepV_6148	Brefeldin A	Antibiotics	Bacterial infections	Dengue virus	NA		Virus titration assay	Decrease (50 %)	Experimental	29093640
DrugRepV_6149	Brefeldin A	Antibiotics	Bacterial infections	Dengue virus	NA		Virus titration assay	Decrease (50 %)	Experimental	29093640
DrugRepV_6150	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6151	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6152	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6153	AR-12	NA	Solid Tumors and Lymphoma	Dengue virus	NA		qRT-PCR	Decrease	Phase I	28666323
DrugRepV_6154	Schisandrin A	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	28338050
DrugRepV_6155	Schisandrin B	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	28338050
DrugRepV_6156	Schisandrin C	NA	NA	Dengue virus	NA		qRT-PCR	Decrease (50 %)	NA	28338050
DrugRepV_6157	Schisandrin A	NA	NA	Dengue virus	NA		Survival assay	Decrease	NA	28338050
DrugRepV_6158	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	16681		MTT assay	Decrease (50 %)	Approved	22068705
DrugRepV_6159	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	16681		MTT assay	Decrease (50 %)	Approved	22068705
DrugRepV_6160	5hydroxyl-6,7,3,4,5-pentamethoxyflavone	NA	NA	Dengue virus	16681		MTT assay	Decrease (50 %)	NA	22068705
DrugRepV_6161	5,3-dihydroxy-6,7,4,5-tetramethoxyflavone	NA	NA	Dengue virus	16681		MTT assay	Decrease (50 %)	NA	22068705
DrugRepV_6162	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (85 %)	NA	27490721
DrugRepV_6163	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (76 %)	NA	27490721
DrugRepV_6164	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (65 %)	NA	27490721
DrugRepV_6165	BZ-TRP-TSC	NA	NA	Dengue virus	NA		MTT assay	Decrease (76 %)	NA	27490721
DrugRepV_6166	Thiosemicarbazide	NA	NA	Dengue virus	NA		Immunoflourescence assay	Decrease	NA	27490721
DrugRepV_6167	Baicalin	Plant extract	Influenza	Dengue virus	NA		Focus forming reduction assay	Decrease	Phase II	24965553
DrugRepV_6168	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	02--20		Luciferase assay	Decrease (50 %)	Approved	24858611
DrugRepV_6169	4-{1-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl}-2-methoxyphenol	NA	NA	Dengue virus	NA		CPE reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6170	4-[1-(4-{[1,1-biphenyl]-4-yl}-1,3-thiazol-2-yl)-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl]phenol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6171	4-[1-(4-{[1,1-biphenyl]-4-yl}-1,3-thiazol-2-yl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]-2-methoxyphenol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6172	4-[1-(4-{[1,1-biphenyl]-4-yl}-1,3-thiazol-2-yl)-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl]phenol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6173	4-[(1E)-1-{2-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]hydrazin-1-ylidene}ethyl]phenol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6174	4-{[1,1-biphenyl]-4-yl}-2-[(2E)-2-[1-(4-methoxyphenyl)ethylidene]hydrazin-1-yl]-1,3-thiazole	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6175	4-{[1,1-biphenyl]-4-yl}-2-[(2E)-2-[1-(4-nitrophenyl)ethylidene]hydrazin-1-yl]-1,3-thiazole	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6176	4-{[1,1-biphenyl]-4-yl}-2-[(2E)-2-(phenylmethylidene)hydrazin-1-yl]-1,3-thiazole	NA	NA	Dengue virus	NA		CPE reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6177	4-[(E)-[2-(4-{[1,1-biphenyl]-4-yl}-1,3-thiazol-2-yl)hydrazin-1-ylidene]methyl]phenol	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	25791449
DrugRepV_6178	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	ThNH-7/93		Fluorescent focus-forming assay	Decrease (50 %)	Approved	22784856
DrugRepV_6179	(1S,2R,3S,4S)-3,4-dihydroxy-2-(hydroxymethyl)-1-[(2S,3S,4R,5R,6S)-2,4,5,6,7-pentahydroxy-3-(sulfonatooxy)heptyl]thiolan-1-ium	NA	NA	Dengue virus	ThNH-7/93		Fluorescent focus-forming assay	Decrease (50 %)	NA	22784856
DrugRepV_6180	(1R,2R,3S,4S)-1-[(2S,3S,4R,5R,6S)-2,3,4,5,6,7-hexahydroxyheptyl]-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium chloride	NA	NA	Dengue virus	ThNH-7/93		Fluorescent focus-forming assay	Decrease (50 %)	NA	22784856
DrugRepV_6181	2 -C-methyladenosine	NA	NA	Dengue virus	New Guinea C (NGC)		Cell proliferation assay	Decrease (50 %)	NA	17662475
DrugRepV_6182	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C (NGC)		Cell proliferation assay	Decrease (50 %)	Approved	17662475
DrugRepV_6183	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	New Guinea C (NGC)		Cell proliferation assay	Decrease (50 %)	Approved	17662475
DrugRepV_6184	UV-4B	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	26946111
DrugRepV_6185	UV-4B	NA	NA	Dengue virus	16681		Virus yield reduction assay	Decrease (50 %)	NA	26946111
DrugRepV_6186	UV-4B	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	26946111
DrugRepV_6187	UV-4B	NA	NA	Dengue virus	NA		Virus yield reduction assay	Decrease (50 %)	NA	26946111
DrugRepV_6188	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	02--20		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6189	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	16681		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6190	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	00-40		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6191	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	09--48		Plaque assay	Decrease (50 %)	Approved	27181378
DrugRepV_6192	Bromocriptine	Nervous System	Parkinson disease	Dengue virus	09--48		Survival assay	No significant effect	Approved	27181378
DrugRepV_6193	STK332077	NA	NA	Dengue virus	New Guinea C (NGC)		Virus yield reduction assay	Decrease (50 %)	NA	26807547
DrugRepV_6194	STK529754	NA	NA	Dengue virus	New Guinea C (NGC)		Virus yield reduction assay	Decrease (50 %)	NA	26807547
DrugRepV_6195	STK530661	NA	NA	Dengue virus	New Guinea C (NGC)		Virus yield reduction assay	Decrease (50 %)	NA	26807547
DrugRepV_6196	(2S)-6-amino-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-acetamido-5-[(prop-1-en-2-yl)amino]pentanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]hexanamido]-N-[(1S)-4-carbamimidamido-1-carbamoylbutyl]hexanamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.31 ± 0.06 Log PFU/ml)	NA	25823617
DrugRepV_6197	(E)-N-[(E)-({4-[(E)-{[(diaminomethylidene)amino]imino}methyl]phenyl}methylidene)amino]ethanimidamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.37 ± 0.15 Log PFU/ml)	NA	25823617
DrugRepV_6198	(2S)-6-amino-N-[(1S)-4-carbamimidamido-1-[(5-carbamimidamido-1-oxopentan-2-yl)carbamoyl]butyl]-2-[(2S)-2-(phenylformamido)propanamido]hexanamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.38 ± 0.10 Log PFU/ml)	NA	25823617
DrugRepV_6199	7-[(phenylamino)(pyridin-2-yl)methyl]quinolin-8-ol	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.34 ± 0.15 Log PFU/ml)	NA	25823617
DrugRepV_6200	1,8-dihydroxy-4,5-dinitro-9,10-dihydroanthracene-9,10-dione	NA	NA	Dengue virus	NA		Cell based assay	Decrease (50 %)	NA	25823617
DrugRepV_6201	4-carbamimidamidophenyl 4-carbamimidamidobenzoate	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.30 ± 0.10 Log PFU/ml)	NA	25823617
DrugRepV_6202	4-nitrophenyl 4-carbamimidamidobenzoate	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.41 ± 0.17 Log PFU/ml)	NA	25823617
DrugRepV_6203	(2E)-2-cyano-3-(4-hydroxyphenyl)prop-2-enamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.46 ± 0.15 Log PFU/ml)	NA	25823617
DrugRepV_6204	4-[2-(2,4-dinitrophenyl)diazen-1-yl]naphthalen-1-ol	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.49 ± 0.26 Log PFU/ml)	NA	25823617
DrugRepV_6205	1-ethyl-2-[(1E)-3-[(2Z)-1-ethyl-1H,2H-naphtho[1,2-d][1,3]oxazol-2-ylidene]prop-1-en-1-yl]naphtho[1,2-d][1,3]oxazol-1-ium	NA	NA	Dengue virus	NA		Cell based assay	Decrease (50 %)	NA	25823617
DrugRepV_6206	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-(phenylformamido)pentanamido]-N-[(1R)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.35 ± 0.21 Log PFU/ml)	NA	25823617
DrugRepV_6207	(4R,7S,10S,13S,16S,22R)-22-amino-10,16-bis(4-aminobutyl)-13-(3-carbamimidamidopropyl)-7-(hydroxymethyl)-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexaazacyclotricosane-4-carboxylic acid	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.46 ± 0.35 Log PFU/ml)	NA	25823617
DrugRepV_6208	1-[N-(2-ethylhexyl)carbamimidamido]-N-(6-{N-[N-(2-ethylhexyl)carbamimidoyl]carbamimidamido}hexyl)methanimidamide	NA	NA	Dengue virus	NA		Cell based assay	Decrease (5.62 ± 0.20 Log PFU/ml)	NA	25823617
DrugRepV_6209	(1R,2R,4S,5S,8R,10E,12S,13S,14E,16E,20R,21R,24S)-6-[(2S)-butan-2-yl]-21,24-dihydroxy-12-{[(2R,4S,6S)-5-{[(2S,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-5,11,13,22-tetramethyl-3,7,19-trioxaspiro[oxane-2,6-tet	NA	NA	Dengue virus	NA		Cell based assay	Decrease	NA	25823617
DrugRepV_6210	(1R,2R,4S,5S,6S,8R,10E,13S,14E,16E,20R,21E,24S)-6-cyclohexyl-24-hydroxy-12-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-21-(hydroxyimino)-5,11,13,22-tetramethyl-3,7,19-trioxaspiro[oxane-2,6-tetracyclo[15.6.1.14,8.0	NA	NA	Dengue virus	NA		Cell based assay	Decrease	NA	25823617
DrugRepV_6211	Mefenamic acid	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Dysmenorrhea, and mild to moderate pain, inflammation, and fever	Dengue virus	NA		Virus inhibition assay	Decrease (50 %)	Approved	24522138
DrugRepV_6212	Tolfenamic acid	Musculo-Skeletal System	Pain associated with the acute attack of migraines	Dengue virus	NA		Virus inhibition assay	Decrease (27.6 ± 3.7 %)	Approved, Investigational	24522138
DrugRepV_6213	Flufenamic Acid	Musculo-Skeletal System	Musculoskeletal | Joint disorders	Dengue virus	NA		Virus inhibition assay	Decrease (15.2 ± 1.1 %)	Approved	24522138
DrugRepV_6214	Meclofenamic acid	Musculo-Skeletal System	Pain | Primary dysmenorrhea	Dengue virus	NA		Virus inhibition assay	Decrease (19.4 ± 2.2 %)	Approved, Vet approved	24522138
DrugRepV_6215	Tetracycline	Antiinfectives For Systemic Use	Bacterial infections (Rocky Mountain spotted fever | Typhus fever | Tick fevers | Q fever | Rickettsialpox | Brill-Zinsser disease)	Dengue virus	NA		Virus inhibition assay	Decrease (23.6 ± 2.1 %)	Approved	24522138
DrugRepV_6216	Oxytetracycline	Antiinfectives For Systemic Use	Bacterial infections	Dengue virus	NA		Virus inhibition assay	Decrease (18.8 ± 2.1 %)	Approved, Investigational, Vet approved	24522138
DrugRepV_6217	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Dengue virus	NA		Virus inhibition assay	Decrease (50 %)	Approved	24522138
DrugRepV_6218	Rolitetracycline	Antiinfectives For Systemic Use	Bacterial infection	Dengue virus	NA		Virus inhibition assay	Decrease (32.8 ± 2.6 %)	Approved	24522138
DrugRepV_6219	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	NA		Virus inhibition assay	Decrease (50 %)	Approved	24522138
DrugRepV_6220	Baicalein	Plant extract	Influenza	Dengue virus	New Guinea C		Focus forming reduction assay	Decrease (50 %)	Phase II	23140177
DrugRepV_6221	2-chloro-10-(prop-2-en-1-yl)-9,10-dihydroacridin-9-one	NA	NA	Dengue virus	Hawaii		Virus yield inhibition assay	Decrease (50 %)	NA	25908170
DrugRepV_6222	2-chloro-10-(prop-2-en-1-yl)-9,10-dihydroacridin-9-one	NA	NA	Dengue virus	New Guinea C		Virus yield inhibition assay	Decrease (50 %)	NA	25908170
DrugRepV_6223	2-chloro-10-(prop-2-en-1-yl)-9,10-dihydroacridin-9-one	NA	NA	Dengue virus	H87		Virus yield inhibition assay	Decrease (50 %)	NA	25908170
DrugRepV_6224	2-chloro-10-(prop-2-en-1-yl)-9,10-dihydroacridin-9-one	NA	NA	Dengue virus	8124		Virus yield inhibition assay	Decrease (50 %)	NA	25908170
DrugRepV_6225	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	NGC		Plaque assay	Decrease (50 %)	Approved, Investigational	24583230
DrugRepV_6226	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	16681		Plaque assay	Decrease (1.75 * 105 pfu/ml)	Approved	7201778
DrugRepV_6227	6-MPTF	NA	NA	Dengue virus	16681		Plaque assay	Decrease (2.05 * 106 pfu/ml)	NA	7201778
DrugRepV_6228	Sinefungin	NA	NA	Dengue virus	NA		2-O-MTase assays	Decrease (50 %)	Experimental	23769894
DrugRepV_6229	AdoHcy	NA	NA	Dengue virus	NA		2-O-MTase assays	Decrease (50 %)	Experimental	23769894
DrugRepV_6230	Aurintricarboxylic acid	NA	NA	Dengue virus	NA		2-O-MTase assays	Decrease (50 %)	NA	23769894
DrugRepV_6231	5,50 -Methylene-disalicylic acid	NA	NA	Dengue virus	NA		2-O-MTase assays	Decrease (50 %)	NA	23769894
DrugRepV_6232	YK 51	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (92 %)	NA	20567498
DrugRepV_6233	YK 73	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (90 %)	NA	20567498
DrugRepV_6234	YK 73x	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (91 %)	NA	20567498
DrugRepV_6235	YK 101	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (94 %)	NA	20567498
DrugRepV_6236	YK 38	NA	NA	Dengue virus	New Guinea C		CPE inhibition assay	Decrease (83 %)	NA	20567498
DrugRepV_6237	YK 38	NA	NA	Dengue virus	New Guinea C		Virus plaque assay	Decrease (3.2 * 103 pfu/ml)	NA	20567498
DrugRepV_6238	YK 51	NA	NA	Dengue virus	New Guinea C		Virus plaque assay	Decrease (3.4 * 103 pfu/ml)	NA	20567498
DrugRepV_6239	YK 73	NA	NA	Dengue virus	New Guinea C		Virus plaque assay	Decrease (3.5 * 103 pfu/ml)	NA	20567498
DrugRepV_6240	YK 73x	NA	NA	Dengue virus	New Guinea C		Virus plaque assay	Decrease (2.8 * 103 pfu/ml)	NA	20567498
DrugRepV_6241	YK 101	NA	NA	Dengue virus	New Guinea C		Virus plaque assay	Decrease (2.6 * 103 pfu/ml)	NA	20567498
DrugRepV_6242	9-benzyl-6-[(1-methyl-4-nitro-4,5-dihydro-1H-imidazol-5-yl)methyl]-9H-purin-2-amine	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6243	2-{[(3-nitrophenyl)methyl]sulfanyl}-9H-purin-6-ol	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6244	2-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)aniline	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6245	1-(4-Bromophenyl)-2-(ethylamino)-2-methylpropyl hydrodisulfide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6246	N-[4-(4-aminobenzenesulfonyl)phenyl]pyridine-3-carboxamide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6247	2-(2-{2-[(2E,5E)-3-ethyl-4-oxo-5-[(phenylamino)methylidene]-1,3-thiazolidin-2-ylidene]hydrazin-1-yl}-1,3-thiazol-5-yl)-N-(2-methylphenyl)acetamide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6248	(2E)-3-(3,4-dichlorophenyl)-1-[2-(3,5-diphenyl-1H-pyrazol-1-yl)-4-methyl-1,3-thiazol-5-yl]prop-2-en-1-one	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6249	2-{[5-(4-{[(4-chlorophenyl)methylidene]amino}phenyl)-1,3,4-oxadiazol-2-yl]sulfanyl}-N-(2-nitrophenyl)acetamide	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6250	1,3-bis({4-[(1E)-1-(carbamimidamidoimino)ethyl]phenyl})urea	NA	NA	Dengue virus	NA		Luciferase assay	Decrease (50 %)	NA	19053243
DrugRepV_6251	3-{[(4-chlorophenyl)methyl]sulfanyl}-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-4-methyl-4H-1,2,4-triazole	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6252	2-({[5-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-1,2,4-oxadiazol-3-yl]methyl}sulfanyl)pyridin-1-ium-1-olate	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6253	1-(4-chlorophenyl)-2-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)ethan-1-one	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6254	1-(2-chlorophenyl)-3-{2-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3-thiazol-4-yl}urea	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6255	2-chloro-6-(4-chlorophenoxy)-4-{4-methyl-5-[(1E)-1-(2-phenylhydrazin-1-ylidene)ethyl]-1,3-thiazol-2-yl}pyridine	NA	NA	Dengue virus	NGC		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_6256	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	D1/Lao/03		Focus forming assay	Decrease (50 %)	Approved, Investigational	20851716
DrugRepV_6257	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	ThNH-7/93		Focus forming assay	Decrease (50 %)	Approved, Investigational	20851716
DrugRepV_6258	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	D3/BDH02-01		Focus forming assay	Decrease (50 %)	Approved, Investigational	20851716
DrugRepV_6259	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	ThD 17/97		Focus forming assay	Decrease (50 %)	Approved, Investigational	20851716
DrugRepV_6260	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6261	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6262	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6263	Dextran Sulphate	Blood and Blood Forming Organs	Antithrombotic	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	Phase I	19264337
DrugRepV_6264	Mannan	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6265	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6266	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6267	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6268	Dextran Sulphate	Blood and Blood Forming Organs	Antithrombotic	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	Phase I	19264337
DrugRepV_6269	Mannan	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6270	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6271	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6272	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6273	Dextran Sulphate	Blood and Blood Forming Organs	Antithrombotic	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	Phase I	19264337
DrugRepV_6274	Mannan	NA	NA	Dengue virus	New Guinea C (NGC)		Flow cytometry	Decrease (50 %)	NA	19264337
DrugRepV_6275	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6276	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6277	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6278	Dextran Sulphate	Blood and Blood Forming Organs	Antithrombotic	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	Phase I	19264337
DrugRepV_6279	Mannan	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	19264337
DrugRepV_6280	G3d	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6281	C2S-3	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6282	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	Approved, Investigational	15911027
DrugRepV_6283	DS8000	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6284	G3d	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6285	C2S-3	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6286	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	Approved, Investigational	15911027
DrugRepV_6287	DS8000	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6288	G3d	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6289	C2S-3	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6290	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	Approved, Investigational	15911027
DrugRepV_6291	DS8000	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6292	G3d	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6293	C2S-3	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6294	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	Approved, Investigational	15911027
DrugRepV_6295	DS8000	NA	NA	Dengue virus	NGC		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6296	G3d	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6297	C2S-3	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6298	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	Approved, Investigational	15911027
DrugRepV_6299	DS8000	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6300	G3d	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6301	C2S-3	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6302	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	Approved, Investigational	15911027
DrugRepV_6303	DS8000	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6304	G3d	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6305	C2S-3	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6306	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	Approved, Investigational	15911027
DrugRepV_6307	DS8000	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6308	G3d	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6309	C2S-3	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6310	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	Approved, Investigational	15911027
DrugRepV_6311	DS8000	NA	NA	Dengue virus	H87		Virus yield reduction assay	Decrease (50 %)	NA	15911027
DrugRepV_6312	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Dengue virus	NGC		Flow cytometry	Decrease (86 %)	Approved, Investigational	16309754
DrugRepV_6313	PI-88	NA	Hepatocellular carcinoma | Liver cancer | Melanoma | Multiple myeloma	Dengue virus	NGC		Flow cytometry	Decrease (53 %)	Investigational	16309754
DrugRepV_6314	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Dengue virus	NGC		Flow cytometry	Decrease (92 %)	Investigational	16309754
DrugRepV_6315	PPS	NA	NA	Dengue virus	NGC		Flow cytometry	Decrease (76 %)	NA	16309754
DrugRepV_6316	Lapachaone Alpha	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (98.84 %)	NA	22155902
DrugRepV_6317	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (92.38 %)	Approved	22155902
DrugRepV_6318	Lycorine Hydrochloride	Antiviral, Antimalarial, Anticancer and Antiinflammatory	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (50 %)	NA	22155902
DrugRepV_6319	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (84.62 %)	Approved, Investigational, Vet approved	22155902
DrugRepV_6320	C6 Ceramide	Dermatologicals	Skin disorder	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (84.06 %)	Approved	22155902
DrugRepV_6321	Anisomycin	Antibacterial	Bacterial infection	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (82.49 %)	Experimental	22155902
DrugRepV_6322	Shikonin	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (78.94 %)	NA	22155902
DrugRepV_6323	Cycloheximide	Antibacterial	Bacterial infections	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (78.71 %)	NA	22155902
DrugRepV_6324	Chelerythrine Chloride	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (73.36 %)	NA	22155902
DrugRepV_6325	Skimmianine	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (61.96 %)	NA	22155902
DrugRepV_6326	Actinomycin D	Antineoplastic and Immunomodulating Agents	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (59.6 %)	Approved	22155902
DrugRepV_6327	Narasin	Antibacterial	Parasitic and bacterial infections	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (50 %)	Experimental	22155902
DrugRepV_6328	Rapamycin	Antineoplastic and Immunomodulating Agents; Sensory Organ	Prophylaxis of organ rejection in patients receiving renal transplants	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (55.12 %)	Approved, Investigational	22155902
DrugRepV_6329	Tunicamycin B	NA	Bacterial infections	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (55.01 %)	Experimental	22155902
DrugRepV_6330	Acivicin	NA	Cancer	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (54.32 %)	Phase I	22155902
DrugRepV_6331	Cotinine	Nervous System	Psychosis	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (52.71 %)	Withdrawn	22155902
DrugRepV_6332	Cantharidin	Dermatologicals	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (51.87 %)	Approved	22155902
DrugRepV_6333	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (50.92 %)	Phase I	22155902
DrugRepV_6334	Gitoxigenin	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (49.01 %)	NA	22155902
DrugRepV_6335	Kainic acid	NA	Neuroexcitatory	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (48.87 %)	NA	22155902
DrugRepV_6336	Brefeldin A	Antibiotics	Bacterial infections	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (47.12 %)	Experimental	22155902
DrugRepV_6337	Dicoumarol	Blood and Blood Forming Organs	Coagulation disorders	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (45.99 %)	Approved	22155902
DrugRepV_6338	Diacetoxyscirpenol	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (45.55 %)	NA	22155902
DrugRepV_6339	Austricin	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (45.01 %)	NA	22155902
DrugRepV_6340	Valinomycin	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (43.34 %)	Experimental	22155902
DrugRepV_6341	Thapsigargin	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (42.9 %)	NA	22155902
DrugRepV_6342	Strophanthidin acetate	Others	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (50 %)	NA	22155902
DrugRepV_6343	Trimethylpsoralen, 4,5,8-	Dermatologicals	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (41.86 %)	NA	22155902
DrugRepV_6344	Echinomycin	NA	Bacterial infections	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (41.52 %)	NA	22155902
DrugRepV_6345	Chromomycin A3	NA	NA	Dengue virus	New Guinea C		Immunoflourescence assay	Decrease (40.87 %)	NA	22155902
DrugRepV_6346	AM404	NA	Pain and Fever	Dengue virus	New Guinea C (NGC)		NA	Decrease (50 %)	Phase IV	26856827
DrugRepV_6347	Paracetamol	Nervous System	Fever | Minor aches | Pains	Dengue virus	New Guinea C (NGC)		NA	Decrease (100 %)	Approved	26856827
DrugRepV_6348	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C (NGC)		NA	Decrease (50 %)	Approved	26856827
DrugRepV_6349	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-butyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6350	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclopentyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6351	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclohexyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6352	methyl 2-[(5Z)-5-[(4-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-carbamoylpentyl]carbamoyl}pentyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}phenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]hexanoate	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6353	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-benzyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6354	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-methylphenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6355	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-methoxyphenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6356	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-fluorophenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6357	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-chlorophenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6358	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-4-oxo-3-(2-phenylethyl)-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6359	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-butyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6360	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclopentyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6361	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclohexyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6362	2-[(5Z)-5-[(4-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-carbamoylpentyl]carbamoyl}pentyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}phenyl)methylidene]-2,4-dioxo-1,3-thiazolidin-3-yl]ethyl acetate	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6363	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-benzyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6364	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-methylphenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6365	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-methoxyphenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6366	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-fluorophenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6367	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-chlorophenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6368	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-2,4-dioxo-3-(2-phenylethyl)-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6369	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-6,7-dioxo-8-(phenylformamido)undecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6370	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-6,7-dioxo-8-[(thiophen-2-yl)formamido]undecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6371	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-({4-[(1E)-2-cyano-2-(cyclopropylcarbamoyl)eth-1-en-1-yl]phenyl}formamido)-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6372	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-({4-[(1E)-2-carbamoyleth-1-en-1-yl]phenyl}formamido)-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6373	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-6,7-dioxo-8-[(2E)-3-phenylprop-2-enamido]undecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Protease Assay	Decrease (50 %)	NA	24083834
DrugRepV_6374	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6375	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-methyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6376	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-butyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6377	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclopentyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6378	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclohexyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6379	methyl 2-[(5Z)-5-[(4-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-carbamoylpentyl]carbamoyl}pentyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}phenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]hexanoate	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6380	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-4-oxo-3-(prop-2-en-1-yl)-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6381	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-(2-hydroxyethyl)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6382	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-(4-methoxyphenyl)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6383	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-(4-chlorophenyl)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6384	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-methoxyphenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6385	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-chlorophenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6386	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-4-oxo-3-(2-phenylethyl)-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6387	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6388	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-butyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6389	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-cyclopentyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6390	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-(2-hydroxyethyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6391	(2S)-6-amino-2-[(2S)-2-[(4-{[(5Z)-3-benzyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-5-carbamimidamidopentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6392	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-3-[(4-chlorophenyl)methyl]-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6393	(2S)-6-amino-2-[(2S)-5-carbamimidamido-2-[(4-{[(5Z)-2,4-dioxo-3-(2-phenylethyl)-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]pentanamido]-N-[(1S)-1-carbamoylpentyl]hexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6394	(2S)-N-[(4S,7S)-1-amino-7-{[1-(4-{[(5Z)-3-benzyl-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl}phenyl)ethenyl]amino}-10-carbamimidamido-5,6-dioxodecan-4-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6395	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-6,7-dioxo-8-[(3-{[(5Z)-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]undecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6396	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-[(3-{[(5Z)-3-cyclopentyl-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]methyl}phenyl)formamido]-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6397	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-[(2S)-2-[(5Z)-5-[(3,4-dimethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]-3-phenylpropanamido]-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6398	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-(2-{3-[(4-methoxyphenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-yl}acetamido)-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6399	(2S)-N-[(5S,8S)-1-amino-11-carbamimidamido-8-{2-[(5Z)-3-[(4-methoxyphenyl)methyl]-4-oxo-2-sulfanylidene-1,3-thiazolidin-5-ylidene]acetamido}-6,7-dioxoundecan-5-yl]-2-hydrazinylhexanamide	NA	NA	Dengue virus	NA		Renilla luciferase assay	Decrease (50 %)	NA	24083834
DrugRepV_6400	HHA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6401	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6402	HHA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6403	HHA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6404	HHA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6405	HHA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6406	HHA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6407	HHA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6408	GNA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6409	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6410	GNA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6411	GNA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6412	GNA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6413	GNA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6414	GNA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6415	GNA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6416	UDA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6417	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6418	UDA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6419	UDA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6420	UDA	NA	NA	Dengue virus	D1/H/IMTSSA/98/606		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6421	UDA	NA	NA	Dengue virus	New Guinea C (NGC)		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6422	UDA	NA	NA	Dengue virus	H87		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6423	UDA	NA	NA	Dengue virus	Dak HD 34 460		RT-PCR	Decrease (50 %)	NA	21738755
DrugRepV_6424	Carbenoxolone disodium	NA	Digestive tract ulcers	Dengue virus	Hawaii		TCID50 assay	Decrease (500 Fold)	Experimental	27155198
DrugRepV_6425	Carbenoxolone disodium	NA	Digestive tract ulcers	Dengue virus	New Guinea C		TCID50 assay	Decrease (2000 Fold)	Experimental	27155198
DrugRepV_6426	Cdt yellow	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6427	Cdt white	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6428	Crotoxin	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6429	Crotapotin	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6430	Crotamin	NA	NA	Dengue virus	NGC		NA	Decrease (11 %)	NA	21723310
DrugRepV_6431	Convulxin	NA	NA	Dengue virus	NGC		NA	Decrease (5 %)	NA	21723310
DrugRepV_6432	PLA2-IC	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6433	PLA2-IC	NA	NA	Dengue virus	NGC		NA	Decrease (50 %)	NA	21723310
DrugRepV_6434	Cdt yellow	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6435	Cdt white	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6436	Crotoxin	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6437	Crotapotin	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6438	Crotamin	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (33 %)	NA	21723310
DrugRepV_6439	Convulxin	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (32 %)	NA	21723310
DrugRepV_6440	PLA2-IC	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6441	PLA2-IC	NA	NA	Dengue virus	NGC		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_6442	Cdt yellow	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6443	Cdt white	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6444	Crotoxin	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6445	Crotapotin	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6446	Crotamin	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (100 %)	NA	21723310
DrugRepV_6447	Convulxin	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (100 %)	NA	21723310
DrugRepV_6448	PLA2-IC	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6449	PLA2-IC	NA	NA	Dengue virus	NGC		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_6450	Cdt yellow	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_6451	Cdt white	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_6452	Crotoxin	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_6453	Crotapotin	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (41 %)	NA	21723310
DrugRepV_6454	Crotamin	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (46 %)	NA	21723310
DrugRepV_6455	Convulxin	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (2.3 %)	NA	21723310
DrugRepV_6456	PLA2-IC	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_6457	PLA2-IC	NA	NA	Dengue virus	NGC		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_6458	(3E)-N-tert-butyl-2-oxo-4-phenylbut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (26.3 %)	NA	21641807
DrugRepV_6459	(3E)-N-tert-butyl-3-methyl-2-oxo-4-phenylbut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (25.6 %)	NA	21641807
DrugRepV_6460	(3E)-N-tert-butyl-2-oxo-4-(thiophen-2-yl)but-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (27.6 %)	NA	21641807
DrugRepV_6461	(3E)-N-tert-butyl-4-(4-methoxyphenyl)-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (16.7 %)	NA	21641807
DrugRepV_6462	(3E)-N-tert-butyl-4-(3,4-dimethoxyphenyl)-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (36.1 %)	NA	21641807
DrugRepV_6463	(3E)-N-tert-butyl-4-(4-hydroxyphenyl)-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (37.6 %)	NA	21641807
DrugRepV_6464	(3E)-4-(4-aminophenyl)-N-tert-butyl-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (40.6 %)	NA	21641807
DrugRepV_6465	(3E)-N-tert-butyl-4-(4-chlorophenyl)-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (15.9 %)	NA	21641807
DrugRepV_6466	(3E)-N-tert-butyl-4-(1H-indol-3-yl)-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (39.1 %)	NA	21641807
DrugRepV_6467	(3E)-N-tert-butyl-4-[4-(dimethylamino)phenyl]-2-oxobut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (13.8 %)	NA	21641807
DrugRepV_6468	(3E)-N-cyclopropyl-2-oxo-4-phenylbut-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (31.2 %)	NA	21641807
DrugRepV_6469	2-[(3E)-2-oxo-4-phenylbut-3-enamido]ethyl acetate	NA	NA	Dengue virus	NA		Protease assay	Decrease (35.8 %)	NA	21641807
DrugRepV_6470	(3E)-2-oxo-4-phenyl-N-(1-phenylethyl)but-3-enamide	NA	NA	Dengue virus	NA		Protease assay	Decrease (0 %)	NA	21641807
DrugRepV_6471	methyl 3-hydroxy-2-[(3E)-2-oxo-4-phenylbut-3-enamido]propanoate	NA	NA	Dengue virus	NA		Protease assay	Decrease (35.1 %)	NA	21641807
DrugRepV_6472	Delphinidin Chloride	NA	NA	Dengue virus	NA		Plaque assay	Decrease	NA	28744282
DrugRepV_6473	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	Dengue virus	NA		Plaque assay	Decrease	Investigational	28744282
DrugRepV_6474	N-nonyl-deoxynojirimycin	NA	NA	Dengue virus	New Guinea C		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_6475	N-pentyl-(1-hydroxycyclohexyl)-DNJ	NA	NA	Dengue virus	New Guinea C		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_6476	N-Propylcyclohexyl-DNJ	NA	NA	Dengue virus	New Guinea C		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_6477	N-Butylcyclohexyl-DNJ	NA	NA	Dengue virus	New Guinea C		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_6478	Castanospermine	Antiviral	NA	Dengue virus	New Guinea C		Yield reduction assay	Decrease (50 %)	Experimental	17354651
DrugRepV_6479	N-acetyl cysteine	NA	Acetaminophen poisoning	Dengue virus	NA		Cell viability assay	Decrease (50 %)	Approved	30928439
DrugRepV_6480	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Dengue virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7003	Sunitinib	Antineoplastic and Immunomodulating Agents	Renal cell carcinoma | Gastrointestinal stromal tumor	West Nile virus	NY 99 3000.0259		Focus forming assay	Decrease (50 %)	Approved, Investigational	28240606
DrugRepV_7004	Nanchangmycin	Antibacterial; Antiviral	NA	West Nile virus	Kunjin		Real-time PCR	Decrease (95 %)	NA	28099856
DrugRepV_7005	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple Myeloma	Yellow fever virus	YF17D		Plaque assay	Decrease (50 %)	Approved	26565697
DrugRepV_7006	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	West Nile virus	3000.0259		Plaque assay	Decrease (100 pfu/ml)	Approved	12504563
DrugRepV_7007	Manidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	28814523
DrugRepV_7008	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (50 %)	Approved	28814523
DrugRepV_7009	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (50 %)	Approved	28814523
DrugRepV_7010	Pimecrolimus	Dermatologicals	Atopic dermatitis	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	28814523
DrugRepV_7011	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (50 %)	NA	28814523
DrugRepV_7012	Lacidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	28814523
DrugRepV_7013	Butoconazole Nitrate	Genito Urinary System and Sex Hormones	Vulvovaginal candidiasis	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (50 %)	Approved	28814523
DrugRepV_7014	Sulconazole Nitrate	Dermatologicals	Fungal infections (Tinea cruris and Tinea corporis)	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (50 %)	NA	28814523
DrugRepV_7015	Mitotane	Antineoplastic and Immunomodulating Agents	Adrenocortical tumours | Cushing's syndrome	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (50 %)	Approved	28814523
DrugRepV_7016	Manidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Plaque assay	Decrease (4 Logs)	Approved, Investigational	28814523
DrugRepV_7017	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Plaque assay	Decrease (4 Logs)	Approved	28814523
DrugRepV_7018	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Plaque assay	Decrease (4 Logs)	Approved	28814523
DrugRepV_7019	Pimecrolimus	Dermatologicals	Atopic dermatitis	Japanese encephalitis virus	AT31		Plaque assay	Decrease (5 Logs)	Approved, Investigational	28814523
DrugRepV_7020	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Plaque assay	Decrease (3 Logs)	NA	28814523
DrugRepV_7021	Manidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Real-time PCR	Decrease (0.01 %)	Approved, Investigational	28814523
DrugRepV_7022	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Real-time PCR	Decrease (0.01 %)	Approved	28814523
DrugRepV_7023	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Real-time PCR	Decrease (0.01 %)	Approved	28814523
DrugRepV_7024	Pimecrolimus	Dermatologicals	Atopic dermatitis	Japanese encephalitis virus	AT31		Real-time PCR	Decrease (0.01 %)	Approved, Investigational	28814523
DrugRepV_7025	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Real-time PCR	Decrease (0.1 %)	NA	28814523
DrugRepV_7026	Manidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (100 %)	Approved, Investigational	28814523
DrugRepV_7027	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (100 %)	Approved	28814523
DrugRepV_7028	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (100 %)	Approved	28814523
DrugRepV_7029	Pimecrolimus	Dermatologicals	Atopic dermatitis	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (100 %)	Approved, Investigational	28814523
DrugRepV_7030	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (100 %)	NA	28814523
DrugRepV_7031	Manidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (99 %)	Approved, Investigational	28814523
DrugRepV_7032	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (98 %)	Approved	28814523
DrugRepV_7033	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (96 %)	Approved	28814523
DrugRepV_7034	Pimecrolimus	Dermatologicals	Atopic dermatitis	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (100 %)	Approved, Investigational	28814523
DrugRepV_7035	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (70 %)	NA	28814523
DrugRepV_7036	Manidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (65 %)	Approved, Investigational	28814523
DrugRepV_7037	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (90 %)	Approved	28814523
DrugRepV_7038	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (95 %)	Approved	28814523
DrugRepV_7039	Pimecrolimus	Dermatologicals	Atopic dermatitis	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (95 %)	Approved, Investigational	28814523
DrugRepV_7040	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (100 %)	NA	28814523
DrugRepV_7041	Manidipine	Cardiovascular agents	Hypertension	West Nile virus	WNV replicon		Luciferase reporter assay	Decrease (55 %)	Approved, Investigational	28814523
DrugRepV_7042	Cilnidipine	Cardiovascular agents	Hypertension	West Nile virus	WNV replicon		Luciferase reporter assay	Decrease (90 %)	Approved	28814523
DrugRepV_7043	Benidipine Hydrochloride	Cardiovascular agents	Hypertension	West Nile virus	WNV replicon		Luciferase reporter assay	Decrease (90 %)	Approved	28814523
DrugRepV_7044	Pimecrolimus	Dermatologicals	Atopic dermatitis	West Nile virus	WNV replicon		Luciferase reporter assay	Decrease (88 %)	Approved, Investigational	28814523
DrugRepV_7045	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	WNV replicon		Luciferase reporter assay	Decrease (72 %)	NA	28814523
DrugRepV_7046	Verapamil	Cardiovascular agents	Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders).	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (45 %)	Approved	28814523
DrugRepV_7047	2-Aminobiphenyl borate	NA	NA	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (18 %)	NA	28814523
DrugRepV_7048	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (30 %)	Approved	28814523
DrugRepV_7049	1,2-bis-(o-aminophenoxy)-ethane-N,N,N,N-tetraacetic Acid	NA	NA	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (60 %)	NA	28814523
DrugRepV_7050	Verapamil	Cardiovascular agents	Hypertension (high blood pressure) | Angina (chest pain) | Arrhythmia (heart rhythm disorders).	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (35 %)	Approved	28814523
DrugRepV_7051	2-Aminobiphenyl borate	NA	NA	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (20 %)	NA	28814523
DrugRepV_7052	Cyclosporine	Antineoplastic and Immunomodulating Agents; Sensory Organ	Immune disorders	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (45 %)	Approved	28814523
DrugRepV_7053	1,2-bis-(o-aminophenoxy)-ethane-N,N,N,N-tetraacetic Acid	NA	NA	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (45 %)	NA	28814523
DrugRepV_7054	Manidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Survival assay	No significant effect	Approved, Investigational	28814523
DrugRepV_7055	Manidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	AT31		Plaque assay	No significant effect	Approved, Investigational	28814523
DrugRepV_7056	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	West Nile virus	NA		Plaque assay	Decrease (3 Logs)	Investigational	25313218
DrugRepV_7057	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	West Nile virus	NA		Real-time PCR	Decrease (2 Fold)	Investigational	25313218
DrugRepV_7059	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (98 %)	Approved	24680954
DrugRepV_7060	Primaquine	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (20 %)	Approved	24680954
DrugRepV_7061	Chloroquine ethyl phenyl Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (> 99 %)	NA	24680954
DrugRepV_7062	Chloroquine Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (> 99 %)	NA	24680954
DrugRepV_7063	Chloroquine Pamoate	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (10 %)	NA	24680954
DrugRepV_7064	Chloroquine Sulfate	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	No significant effect (0 %)	NA	24680954
DrugRepV_7065	Apoquinine	Antiparasitic	Malaria	West Nile virus	NA		Plaque assay	Decrease (56 %)	NA	24680954
DrugRepV_7066	Primaquine	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	No significant effect (0 %)	Approved	24680954
DrugRepV_7067	Quinine Hydrobromide Hydrate	Antiparasitic products, Insectisides and Repellents	Malaria | Leg cramps	West Nile virus	NA		Plaque assay	No significant effect (0 %)	NA	24680954
DrugRepV_7068	Quinacrine Mustard	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	West Nile virus	NA		Plaque assay	Decrease (> 99 %)	Experimental	24680954
DrugRepV_7069	Amodiaquine derivative (AQD1)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (98 %)	NA	24680954
DrugRepV_7070	Amodiaquine derivative (AQD2)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7071	Amodiaquine derivative (AQD3)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_7072	Amodiaquine derivative (AQD4)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_7073	Amodiaquine derivative (AQD5)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (80 %)	NA	24680954
DrugRepV_7074	Amodiaquine derivative (AQD6)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_7075	Amodiaquine derivative (AQD7)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (100 %)	NA	24680954
DrugRepV_7076	Amodiaquine derivative (AQD8)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (60 %)	NA	24680954
DrugRepV_7077	Amodiaquine	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	Approved	24680954
DrugRepV_7078	Amodiaquine derivative (AQD1)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7079	Amodiaquine derivative (AQD2)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7080	Amodiaquine derivative (AQD3)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7081	Amodiaquine derivative (AQD4)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7082	Amodiaquine derivative (AQD5)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7083	Amodiaquine derivative (AQD6)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7084	Amodiaquine derivative (AQD7)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7085	Amodiaquine derivative (AQD8)	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7086	Quinacrine Mustard	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	West Nile virus	NA		Plaque assay	Decrease (50 %)	Experimental	24680954
DrugRepV_7087	Chloroquine Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7088	Chloroquine ethyl phenyl Mustard	Antiparasitic products, Insectisides and Repellents	Malaria	West Nile virus	NA		Plaque assay	Decrease (50 %)	NA	24680954
DrugRepV_7090	NITD008	Antiviral	NA	West Nile virus	New York 3356		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_7091	NITD008	Antiviral	NA	Yellow fever virus	17D vaccine strain		Plaque assay	Decrease (50 %)	NA	19918064
DrugRepV_7092	Castanospermine	Antiviral	Dengue and Parainfluenza	West Nile virus	NY 1999-Replicon		Renilla luciferase assay	No significant difference	Experimental	15994763
DrugRepV_7093	Castanospermine	Antiviral	Dengue and Parainfluenza	West Nile virus	NY 1999-Replicon		Survival assay	Increase	Experimental	15994763
DrugRepV_7094	Castanospermine	Antiviral	Dengue and Parainfluenza	West Nile virus	NY 1999-Replicon		Survival assay	No significant difference	Experimental	15994763
DrugRepV_7095	Imipramine	Nervous System	Depression	West Nile virus	WT		Real-time PCR	Decrease (100 %)	Approved	28600536
DrugRepV_7096	Imipramine	Nervous System	Depression	West Nile virus	WT		Plaque assay	Decrease (100 %)	Approved	28600536
DrugRepV_7097	Abamectin	NA	Helmintic infection	Yellow fever virus	17D		Plaque assay	Decrease (5.3 Log)	Terminated	26752081
DrugRepV_7098	Berberine	NA	Parasitic and fungal infection	Yellow fever virus	17D		Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_7099	Bromocriptine	Nervous System	Parkinson disease	Yellow fever virus	17D		Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_7100	Cerivastatin	Cardiovascular agents	Rhabdomyolysis	Yellow fever virus	17D		Plaque assay	No significant effect (No significant effect Log)	Approved	26752081
DrugRepV_7101	Fenretinide	Anticancer	Prostate cancer | Breast cancer | Macular degeneration	Yellow fever virus	17D		Plaque assay	Decrease (3 Log)	Investigational	26752081
DrugRepV_7102	Ivermectin	Antiparasitic products, Insectisides and Repellents	Intestinal strongyloidiasis | Onchocerciasis	Yellow fever virus	17D		Plaque assay	Decrease (5.3 Log)	Approved, Investigational, Vet approved	26752081
DrugRepV_7108	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Immunoflourescence assay	Decrease (90 %)	NA	11907199
DrugRepV_7109	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Plaque assay	Decrease (3 Logs)	NA	11907199
DrugRepV_7110	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		LDH assay	No significant effect	NA	11907199
DrugRepV_7111	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Western blot	No significant effect (No significant effect Band Intensity)	NA	11907199
DrugRepV_7112	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Western blot	No significant effect (No significant effect Band Intensity)	NA	11907199
DrugRepV_7113	N-nonyl-deoxynojirimycin	NA	NA	Japanese encephalitis virus	RP-9		Survival assay	Increase	NA	11907199
DrugRepV_7114	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Japanese encephalitis virus	P3		Survival assay	Increase	Approved	30567313
DrugRepV_7115	4-(3,5-Diphenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7116	4-(5-(2-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7117	4-(5-(3-fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7118	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7119	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7120	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7121	4-(5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7122	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7123	4-(3-Phenyl-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7124	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7125	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7126	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7127	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7128	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7129	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7130	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7131	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7132	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7133	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7134	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7135	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7136	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7137	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7138	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7139	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7140	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7141	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7142	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7143	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7144	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	Yellow fever virus	17D		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7145	4-(5-(4-Fluorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7146	4-(5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7147	4-(5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7148	4-(3-Phenyl-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7149	4-(3-Phenyl-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7150	4-(3-(4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7151	4-(5-(2-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7152	4-(5-(3-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7153	4-(5-(4-fluorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7154	4-(5-(2-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7155	4-(5-(3-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7156	4-(5-(4-chlorophenyl)-3-(4-phenoxyphenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7157	4-(3-(4-phenoxyphenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7158	4-(3-(4-phenoxyphenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7159	4-(3-(4-phenoxyphenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7160	4-(3-(4-(benzyloxy)phenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7161	4-(3-(4-(benzyloxy)phenyl)-5-(2-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7162	4-(3-(4-(benzyloxy)phenyl)-5-(3-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7163	4-(3-(4-(benzyloxy)phenyl)-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7164	4-(3-(4-(benzyloxy)phenyl)-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7165	4-(3-(4-(benzyloxy)phenyl)-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7166	4-(3-(4-(benzyloxy)phenyl)-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7167	4-(3-(4-(benzyloxy)phenyl)-5-(o-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7168	4-(3-(4-(benzyloxy)phenyl)-5-(m-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7169	4-(3-(4-(benzyloxy)phenyl)-5-(p-tolyl)-4,5-dihydro-1H-pyrazol-1- yl)benzenesulfonamide	NA	NA	West Nile virus	Clinical isolate		MTT assay	Decrease (50 %)	NA	29028528
DrugRepV_7170	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	West Nile virus	KERN515 WN02		qRT-PCR	Decrease (50 %)	Phase I	27654301
DrugRepV_7171	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Japanese encephalitis virus	SA14		qRT-PCR	Decrease (50 %)	Phase I	27654301
DrugRepV_7172	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	Phase I	27654301
DrugRepV_7173	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-2-yl)phenyl) pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7174	N2-(4-fluorophenyl)-N3-(4-methyl-2-(thiophen-3-yl) phenyl)pyrazine-2,3- dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7175	N2-(4-methyl-2-(thiophen-3-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7176	N2-(4-fluorophenyl)-N3-(2-(thiophen-3-yl)benzyl)pyrazine- 2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7177	N2-(2-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7178	N2-(4-fluorophenyl)-N3-(4-(thiophen-3-yl)benzyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7179	N2-(4-(thiophen-3-yl)benzyl)-N3-(p-tolyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7180	N2-(4-fluorophenyl)-N3-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)pyrazine-2,3-dicarboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7181	N2-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N3-(p-tolyl) pyrazine-2,3-di-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7182	N1-(4-fluorophenyl)-N2-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7183	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-2-yl) phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7184	N1-(4-methyl-2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7185	N1-(4-methyl-2-(thiophen-2-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7186	N1-(4-methyl-2-(5-methylthiophen-2-yl)phenyl)-N2-(p- tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7187	N1-(4-fluorophenyl)-N2-(4-methyl-2-(5-methylthiophen-2- yl)phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7188	N1-(4-methyl-2-(thiophen-3-yl)phenyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7189	N1-(4-fluorophenyl)-N2-(4-methyl-2-(thiophen-3-yl) phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7190	N1-(4-fluorophenyl)-N2-(2-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7191	N1-(2-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7192	N1-(4-fluorophenyl)-N2-(4-(thiophen-3-yl)benzyl) phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7193	N1-(4-(thiophen-3-yl)benzyl)-N2-(p-tolyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7194	N1-(4-fluorophenyl)-N2-(2-(3-methyl-1H-pyrazol-5-yl) phenyl)phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7195	N1-(2-(3-methyl-1H-pyrazol-5-yl)phenyl)-N2-(p-tolyl) phthalamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7196	2-(4-fluorobenzamido)-N-(4-methyl-2-(thiophen-3-yl) phenyl)benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7197	2-(4-fluorobenzamido)-N-(4-methyl-2-(5-methylthiophen- 2-yl)phenyl)benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7198	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-4-yl)phenyl) benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7199	2-(4-fluorobenzamido)-N-(4-methyl-2-(pyridin-3-yl)phenyl) benzamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	27240271
DrugRepV_7200	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7201	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7202	CCG-3925	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7203	CCG-7648	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7204	CCG-6269	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7205	CCG-3374	NA	NA	Yellow fever virus	YFV 17D		HTS assay	Decrease (50 %)	NA	19651907
DrugRepV_7206	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		qRT-PCR	Decrease (20 Fold)	NA	19651907
DrugRepV_7207	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		qRT-PCR	Decrease (15 Fold)	NA	19651907
DrugRepV_7208	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Immunoflourescence assay	Decrease	NA	19651907
DrugRepV_7209	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		Immunoflourescence assay	Decrease	NA	19651907
DrugRepV_7210	CCG-6269	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (87 %)	NA	19651907
DrugRepV_7211	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (92 %)	NA	19651907
DrugRepV_7212	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (90 %)	NA	19651907
DrugRepV_7213	CCG-3394	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (38 %)	NA	19651907
DrugRepV_7214	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (48 %)	NA	19651907
DrugRepV_7215	CCG-4088	NA	NA	Yellow fever virus	YFV 17D		Luciferase assay	Decrease (42 %)	NA	19651907
DrugRepV_7216	Doxorubicin	Antineoplastic and Immunomodulating Agents	Cancer	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	Approved	20837762
DrugRepV_7217	SA-3	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7218	SA-11	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7219	SA-17	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7220	SA-17	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	20837762
DrugRepV_7221	2-(3-chlorophenoxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Plaque reduction assay	Decrease (60 %)	NA	28068627
DrugRepV_7222	2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Plaque reduction assay	Decrease (78 %)	NA	28068627
DrugRepV_7223	2-(2,3-dichlorophenoxy) acetaldehyde thiosemicarbazone	NA	NA	Yellow fever virus	NA		Plaque reduction assay	Decrease (70 %)	NA	28068627
DrugRepV_7224	2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Plaque reduction assay	Decrease (40 %)	NA	28068627
DrugRepV_7225	2-(4-(4-chlorophenyl) thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Plaque reduction assay	Decrease (55 %)	NA	28068627
DrugRepV_7226	2-(3-chlorophenoxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Decrease (17 %)	NA	28068627
DrugRepV_7227	2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Decrease (22 %)	NA	28068627
DrugRepV_7228	2-(2,3-dichlorophenoxy) acetaldehyde thiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Decrease (14 %)	NA	28068627
DrugRepV_7229	2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Flow cytometry	Decrease (10 %)	NA	28068627
DrugRepV_7230	2-(4-(4-chlorophenyl) thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Flow cytometry	Decrease (3 %)	NA	28068627
DrugRepV_7231	2-(3-chlorophenoxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Increase	NA	28068627
DrugRepV_7232	2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Increase	NA	28068627
DrugRepV_7233	2-(2,3-dichlorophenoxy) acetaldehyde thiosemicarbazone	NA	NA	Yellow fever virus	NA		Flow cytometry	Increase	NA	28068627
DrugRepV_7234	2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Flow cytometry	Increase	NA	28068627
DrugRepV_7235	2-(4-(4-chlorophenyl) thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione	NA	NA	Yellow fever virus	NA		Flow cytometry	Increase	NA	28068627
DrugRepV_7236	2-(3-chlorophenoxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Immunoflourescence assay	Decrease	NA	28068627
DrugRepV_7237	2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone	NA	NA	Yellow fever virus	NA		Immunoflourescence assay	Decrease	NA	28068627
DrugRepV_7239	BCX4430	NA	Ebola virus	Yellow fever virus	17D		RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_7240	BCX4430	NA	Ebola virus	Japanese encephalitis virus	SA14		RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_7241	Favipiravir	Antiviral	Influenza virus	Yellow fever virus	17D		Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	27736754
DrugRepV_7242	IHVR-19029	NA	NA	Yellow fever virus	17D		qRT-PCR	Decrease (50 %)	NA	29253498
DrugRepV_7243	BCX4430	NA	Ebola virus	Yellow fever virus	17D		NA	Decrease (50 %)	Investigational	27095300
DrugRepV_7244	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,4-triazole-3-carboxamide	NA	NA	West Nile virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7245	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,4-triazole-3-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7246	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-imidazole-4-carboxamide	NA	NA	West Nile virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7247	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-imidazole-4-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7248	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,3-triazole-4-carboxamide	NA	NA	West Nile virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7249	1-[4,5-dihydroxy-3-(hydroxymethyl)cyclopent-2-en-1-yl]-1H-1,2,3-triazole-4-carboxamide	NA	NA	Yellow fever virus	NA		NA	Decrease (50 %)	NA	16451078
DrugRepV_7250	Brefeldin A	Antibiotics	Bacterial infections	Japanese encephalitis virus	NA		Virus titration assay	Decrease (50 %)	Experimental	29093640
DrugRepV_7251	3-{[(4-chlorophenyl)methyl]sulfanyl}-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-4-methyl-4H-1,2,4-triazole	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7252	2-({[5-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-1,2,4-oxadiazol-3-yl]methyl}sulfanyl)pyridin-1-ium-1-olate	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7253	1-(4-chlorophenyl)-2-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)ethan-1-one	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7254	1-(2-chlorophenyl)-3-{2-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3-thiazol-4-yl}urea	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7255	2-chloro-6-(4-chlorophenoxy)-4-{4-methyl-5-[(1E)-1-(2-phenylhydrazin-1-ylidene)ethyl]-1,3-thiazol-2-yl}pyridine	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7256	3-{[(4-chlorophenyl)methyl]sulfanyl}-5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-4-methyl-4H-1,2,4-triazole	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7257	2-({[5-(5-methyl-3-phenyl-1,2-oxazol-4-yl)-1,2,4-oxadiazol-3-yl]methyl}sulfanyl)pyridin-1-ium-1-olate	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7258	1-(4-chlorophenyl)-2-({5-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3,4-oxadiazol-2-yl}sulfanyl)ethan-1-one	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7259	1-(2-chlorophenyl)-3-{2-[(4,5-dichloro-1H-imidazol-1-yl)methyl]-1,3-thiazol-4-yl}urea	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7260	2-chloro-6-(4-chlorophenoxy)-4-{4-methyl-5-[(1E)-1-(2-phenylhydrazin-1-ylidene)ethyl]-1,3-thiazol-2-yl}pyridine	NA	NA	Yellow fever virus	17D		Plaque assay	Decrease (50 %)	NA	19781577
DrugRepV_7261	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Japanese encephalitis virus	JaOArS982		Focus forming assay	Decrease (50 %)	Approved, Investigational	20851716
DrugRepV_7262	Heparin	Blood and Blood Forming Organs	Venous thrombosis	Japanese encephalitis virus	Nakayama		Flow cytometry	Decrease (70 %)	Approved, Investigational	16309754
DrugRepV_7263	PI-88	NA	Hepatocellular carcinoma | Liver cancer | Melanoma | Multiple myeloma	Japanese encephalitis virus	Nakayama		Flow cytometry	Decrease (66 %)	Investigational	16309754
DrugRepV_7264	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	Japanese encephalitis virus	Nakayama		Flow cytometry	Decrease (85 %)	Investigational	16309754
DrugRepV_7265	PPS	NA	NA	Japanese encephalitis virus	Nakayama		Flow cytometry	Decrease (70 %)	NA	16309754
DrugRepV_7266	PI-88	NA	Hepatocellular carcinoma | Liver cancer | Melanoma | Multiple myeloma	West Nile virus	NY-99		Flow cytometry	Decrease (66 %)	Investigational	16309754
DrugRepV_7267	Cdt yellow	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7268	Cdt white	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7269	Crotoxin	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7270	Crotapotin	NA	NA	Yellow fever virus	17D		NA	Decrease (43 %)	NA	21723310
DrugRepV_7271	Crotamin	NA	NA	Yellow fever virus	17D		NA	Decrease (20 %)	NA	21723310
DrugRepV_7272	Convulxin	NA	NA	Yellow fever virus	17D		NA	Decrease (22 %)	NA	21723310
DrugRepV_7273	PLA2-IC	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7274	PLA2-IC	NA	NA	Yellow fever virus	17D		NA	Decrease (50 %)	NA	21723310
DrugRepV_7275	Cdt yellow	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7276	Cdt white	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7277	Crotoxin	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7278	Crotapotin	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7279	Crotamin	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (14.34 %)	NA	21723310
DrugRepV_7280	Convulxin	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (25.5 %)	NA	21723310
DrugRepV_7281	PLA2-IC	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7282	PLA2-IC	NA	NA	Yellow fever virus	17D		Virucidal assay	Decrease (50 %)	NA	21723310
DrugRepV_7283	Cdt yellow	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7284	Cdt white	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7285	Crotoxin	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7286	Crotapotin	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7287	Crotamin	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7288	Convulxin	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7289	PLA2-IC	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7290	PLA2-IC	NA	NA	Yellow fever virus	17D		Adsorption assay	Decrease (50 %)	NA	21723310
DrugRepV_7291	Cdt yellow	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_7292	Cdt white	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_7293	Crotoxin	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_7294	Crotapotin	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_7295	Crotamin	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (32 %)	NA	21723310
DrugRepV_7296	Convulxin	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (-70 %)	NA	21723310
DrugRepV_7297	PLA2-IC	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (50 %)	NA	21723310
DrugRepV_7298	PLA2-IC	NA	NA	Yellow fever virus	17D		Internalization assay	Decrease (46 %)	NA	21723310
DrugRepV_7299	(3E)-N-tert-butyl-2-oxo-4-phenylbut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (20 %)	NA	21641807
DrugRepV_7300	(3E)-N-tert-butyl-3-methyl-2-oxo-4-phenylbut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (0 %)	NA	21641807
DrugRepV_7301	(3E)-N-tert-butyl-2-oxo-4-(thiophen-2-yl)but-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (20.3 %)	NA	21641807
DrugRepV_7302	(3E)-N-tert-butyl-4-(4-methoxyphenyl)-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (27.3 %)	NA	21641807
DrugRepV_7303	(3E)-N-tert-butyl-4-(3,4-dimethoxyphenyl)-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (31 %)	NA	21641807
DrugRepV_7304	(3E)-N-tert-butyl-4-(4-hydroxyphenyl)-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (31.4 %)	NA	21641807
DrugRepV_7305	(3E)-4-(4-aminophenyl)-N-tert-butyl-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (39.5 %)	NA	21641807
DrugRepV_7306	(3E)-N-tert-butyl-4-(4-chlorophenyl)-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (6.3 %)	NA	21641807
DrugRepV_7307	(3E)-N-tert-butyl-4-(1H-indol-3-yl)-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (40.6 %)	NA	21641807
DrugRepV_7308	(3E)-N-tert-butyl-4-[4-(dimethylamino)phenyl]-2-oxobut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (33.9 %)	NA	21641807
DrugRepV_7309	(3E)-N-cyclopropyl-2-oxo-4-phenylbut-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (20 %)	NA	21641807
DrugRepV_7310	2-[(3E)-2-oxo-4-phenylbut-3-enamido]ethyl acetate	NA	NA	West Nile virus	NA		Protease assay	Decrease (29.8 %)	NA	21641807
DrugRepV_7311	(3E)-2-oxo-4-phenyl-N-(1-phenylethyl)but-3-enamide	NA	NA	West Nile virus	NA		Protease assay	Decrease (12.2 %)	NA	21641807
DrugRepV_7312	methyl 3-hydroxy-2-[(3E)-2-oxo-4-phenylbut-3-enamido]propanoate	NA	NA	West Nile virus	NA		Protease assay	Decrease (27.5 %)	NA	21641807
DrugRepV_7313	CW-33A	NA	NA	Japanese encephalitis virus	T1P1		Virus yield reduction assay	Decrease (50 %)	NA	30413749
DrugRepV_7314	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Virus yield reduction assay	Decrease (50 %)	NA	30413749
DrugRepV_7315	CW-33A	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	30413749
DrugRepV_7316	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	30413749
DrugRepV_7317	NITD008	Antiviral	NA	Japanese encephalitis virus	JEV?Pac?Rluc?Rep		Luciferase assay	Decrease (50 %)	NA	28779235
DrugRepV_7318	NITD008	Antiviral	NA	Japanese encephalitis virus	JEV?Pac?Rluc?Rep		Western blot	Decrease (NA %)	NA	28779235
DrugRepV_7319	MJ-47	NA	NA	Japanese encephalitis virus	JEVSRIP		Flow cytometry	Decrease (50 %)	NA	28394283
DrugRepV_7320	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	NS3 helicase		Flow cytometry	Decrease (79 %)	NA	27679979
DrugRepV_7321	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	NS3 helicase		Flow cytometry	Decrease (73 %)	NA	27679979
DrugRepV_7322	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	P3		Western blot	Decrease (70.1 %)	NA	27679979
DrugRepV_7323	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	P3		Western blot	Decrease (94.8 %)	NA	27679979
DrugRepV_7324	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	P3		Immunoflourescence assay	Decrease (86.71 %)	NA	27679979
DrugRepV_7325	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	P3		Immunoflourescence assay	Decrease (89.3 %)	NA	27679979
DrugRepV_7326	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log pfu/ml)	NA	27679979
DrugRepV_7327	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log pfu/ml)	NA	27679979
DrugRepV_7328	N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide	NA	NA	Japanese encephalitis virus	P3		Cell viability assay	Decrease (50 %)	NA	27679979
DrugRepV_7329	N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide	NA	NA	Japanese encephalitis virus	P3		Cell viability assay	Decrease (50 %)	NA	27679979
DrugRepV_7330	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Cytopathic effect (CPE) assay	Decrease	NA	27563890
DrugRepV_7331	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Cytopathic effect (CPE) assay	Decrease	NA	27563890
DrugRepV_7332	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (5 times pfu/ml)	NA	27563890
DrugRepV_7333	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (3 times pfu/ml)	NA	27563890
DrugRepV_7334	CW-33	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	27563890
DrugRepV_7335	FGIN-1-27	NA	NA	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log %)	NA	24348901
DrugRepV_7336	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log %)	Investigational	24348901
DrugRepV_7337	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Japanese encephalitis virus	P3		Plaque assay	Decrease (2 log %)	Approved	24348901
DrugRepV_7338	FGIN-1-27	NA	NA	Japanese encephalitis virus	P3		Immunoflourescence assay	Decrease (80 %)	NA	24348901
DrugRepV_7339	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	P3		Immunoflourescence assay	Decrease (60 %)	Investigational	24348901
DrugRepV_7340	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Japanese encephalitis virus	P3		Immunoflourescence assay	Decrease (30 %)	Approved	24348901
DrugRepV_7341	FGIN-1-27	NA	NA	Japanese encephalitis virus	P3		Luminescence assay	Decrease (50 %)	NA	24348901
DrugRepV_7342	Cilnidipine	Cardiovascular agents	Hypertension	Japanese encephalitis virus	P3		Luminescence assay	Decrease (50 %)	Investigational	24348901
DrugRepV_7343	Niclosamide	Antiparasitic products, Insectisides and Repellents	Tapeworm and intestinal fluke infections | Helminthiasis	Japanese encephalitis virus	P3		Luminescence assay	Decrease (50 %)	Approved	24348901
DrugRepV_7344	Baicalein	Plant extract	Influenza	Japanese encephalitis virus	HE861351		Focus forming reduction assay	Decrease (50 %)	Phase II	23222683
DrugRepV_7345	Quercetin	Antioxidant	NA	Japanese encephalitis virus	HE861351		Focus forming reduction assay	Decrease (50 %)	Experimental, Investigational	23222683
DrugRepV_7346	Baicalein	Plant extract	Influenza	Japanese encephalitis virus	HE861351		Real-time PCR	Decrease (68.46 ± 1.19 %)	Phase II	23222683
DrugRepV_7347	Quercetin	Antioxidant	NA	Japanese encephalitis virus	HE861351		Real-time PCR	Decrease (9.1 ± 0.2 %)	Experimental, Investigational	23222683
DrugRepV_7348	Indigo	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	22911608
DrugRepV_7349	Indirubin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Investigational	22911608
DrugRepV_7350	Indirubin	NA	NA	Japanese encephalitis virus	Beijing-1		Survival assay	Increase	Investigational	22911608
DrugRepV_7351	NG-monomethyl-L-arginine	NA	Obesity | Type 2 Diabetes | Ocular Physiology | Regional Blood Flow	Japanese encephalitis virus	78668A		Survival assay	Decrease	Approved, Investigational	10762444
DrugRepV_7352	N-nitro-L-arginine methyl ester	NA	NA	Japanese encephalitis virus	RP-9		Survival assay	Decrease	NA	9188590
DrugRepV_7353	S-nitroso-N-acetylpenicillamine	NA	NA	Japanese encephalitis virus	NT109		Plaque assay	Decrease (3 log pfu/ml)	NA	9188590
DrugRepV_7354	Glycine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (16.37 %)	NA	14011545
DrugRepV_7355	DL-Phenylalanine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	No significant effect (3.63 %)	NA	14011545
DrugRepV_7356	L-Leucine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	No significant effect (3.63 %)	NA	14011545
DrugRepV_7357	DL-Aspartic acid -Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Decrease (23.63 %)	NA	14011545
DrugRepV_7358	DL-Asparagine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Decrease (36.36 %)	NA	14011545
DrugRepV_7359	DL-Alanine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (9 %)	NA	14011545
DrugRepV_7360	L-Cysteine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Decrease (18.18 %)	NA	14011545
DrugRepV_7361	DL-Lysine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (9 %)	NA	14011545
DrugRepV_7362	L-Tyrosine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	No significant effect (10 %)	NA	14011545
DrugRepV_7363	DL-Methionine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (20 %)	NA	14011545
DrugRepV_7364	2-Picolinic acid-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (0.45 %)	NA	14011545
DrugRepV_7365	Guanidine-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (9.5 %)	NA	14011545
DrugRepV_7366	Diethyl Dithiocarbamic Acid-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (27.72 %)	NA	14011545
DrugRepV_7367	Diphenylthiocarbazone-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (12.14 %)	NA	14011545
DrugRepV_7368	8-Hydroxyquinoline-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	No significant effect (8.6 %)	NA	14011545
DrugRepV_7369	3,4-Dimercaptotoluene-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Increase (10 %)	NA	14011545
DrugRepV_7370	1,10-Phenanthroline-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	No significant effect (5 %)	NA	14011545
DrugRepV_7371	1,10-Phenanthroline-3,4-dimercaptotoluene-Zn	NA	NA	Japanese encephalitis virus	Nakayama		Paralysis	Decrease (35 %)	NA	14011545
DrugRepV_7372	Luteolin	NA	NA	Japanese encephalitis virus	SX09S01		Plaque assay	Decrease (50 %)	NA	27126774
DrugRepV_7373	Luteolin	NA	NA	Japanese encephalitis virus	SX09S01		Plaque assay	Decrease (2 log Log PFU/ml)	NA	27126774
DrugRepV_7374	Luteolin	NA	NA	Japanese encephalitis virus	SX09S01		Western blot	Decrease	NA	27126774
DrugRepV_7375	Chrysophanol	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	24395532
DrugRepV_7376	Aloe-emodin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	24395532
DrugRepV_7377	Aloe-emodin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7378	Aloe-emodin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7379	Shikonin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7380	Shikonin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	NA	18701259
DrugRepV_7381	Arecoline	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Experimental	18701259
DrugRepV_7382	Arecoline	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Experimental	18701259
DrugRepV_7383	Hesperetin	NA	NA	Japanese encephalitis virus	T1P1		Plaque assay	Decrease (50 %)	Experimental	18701259
DrugRepV_7384	Dehydroepiandrosterone	NA	Schizophrenia	Japanese encephalitis virus	NT113		Plaque assay	Decrease	Approved	16099910
DrugRepV_7385	Dehydroepiandrosterone	NA	Schizophrenia	Japanese encephalitis virus	NT113		Slot Blot analysis	Decrease	Approved	16099910
DrugRepV_7386	Dehydroepiandrosterone	NA	Schizophrenia	Japanese encephalitis virus	NT113		Western blot	Decrease	Approved	16099910
DrugRepV_7387	SCH16-Ribavirin	NA	NA	Japanese encephalitis virus	P20778		Cytopathic effect (CPE) assay	Decrease	NA	22738253
DrugRepV_7388	SCH16-Mycophenolic acid	NA	NA	Japanese encephalitis virus	P20778		Cytopathic effect (CPE) assay	Decrease	NA	22738253
DrugRepV_7389	Delphinidin Chloride	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (O.6 Log)	NA	28744282
DrugRepV_7390	Cyanidin Chloride	NA	NA	West Nile virus	NY-99		Plaque assay	No significant effect (No significant effect Log)	NA	28744282
DrugRepV_7391	Catechin	Antioxidant	NA	West Nile virus	NY-99		Plaque assay	No significant effect (No significant effect Log)	NA	28744282
DrugRepV_7392	Epicatechin	NA	Pre-diabetes	West Nile virus	NY-99		Plaque assay	No significant effect (No significant effect Log)	Investigational	28744282
DrugRepV_7393	Epigallocatechin	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (0.5 Log)	Experimental	28744282
DrugRepV_7394	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	West Nile virus	NY-99		Plaque assay	Decrease (1.1 Log)	Investigational	28744282
DrugRepV_7395	Delphinidin Chloride	NA	NA	West Nile virus	NY-99		RT-PCR	Decrease (0.7 Copies/cell)	NA	28744282
DrugRepV_7396	Epigallocatechin Gallate	Cardiovascular agents	Hypertension and Diabetic Nephropathy	West Nile virus	NY-99		RT-PCR	Decrease (0.7 Copies/cell)	Investigational	28744282
DrugRepV_7397	Nordihydroguaiaretic Acid	NA	Actinic keratoses	West Nile virus	NY-99		Plaque assay	Decrease (50 %)	Approved, Investigational	28507114
DrugRepV_7398	Nordihydroguaiaretic Acid	NA	Actinic keratoses	West Nile virus	NY-99		Plaque assay	Decrease (50 %)	Approved, Investigational	28507114
DrugRepV_7399	Resveratrol	Anticancer	Herpes labialis infections (cold sores)	West Nile virus	NY-99		Plaque assay	Decrease (0.6 Log)	Approved, Experimental, Investigational	28507114
DrugRepV_7400	PF-429242	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (0.4 Log)	NA	28507114
DrugRepV_7401	Fatostatin	NA	NA	West Nile virus	NY-99		Plaque assay	Decrease (0.7 Log)	NA	28507114
DrugRepV_7402	Zileuton	NA	Asthma	West Nile virus	NY-99		Plaque assay	No significant change (No significant change Log)	Approved / Withdrawn	28507114
DrugRepV_7403	BCX4430	NA	Ebola virus	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Investigational	28336346
DrugRepV_7404	BCX4430 Hydrochloride	NA	Ebola virus	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Investigational	28336346
DrugRepV_7405	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7406	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7407	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7408	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7409	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7410	L-Neplanocin A	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7411	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7412	(1S,2R,3S)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7413	Cyclopentenyl nucleosides	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7414	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl] hypoxanthine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7415	(1R,2S,3R)-9-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]guanine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7416	(1S,2R,3S)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]uracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7417	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]thymine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7418	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorouracil	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7419	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]cytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7420	(1R,2S,3R)-1-[2,3-Dihydroxy-4-hydroxymethyl-4-cyclopenten-1-yl]-5-fluorocytosine	NA	NA	West Nile virus	New York isolate		CPE inhibition assay	Decrease (50 %)	NA	11689085
DrugRepV_7421	N-nonyl-deoxynojirimycin	NA	NA	West Nile virus	NA		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_7422	N-pentyl-(1-hydroxycyclohexyl)-DNJ	NA	NA	West Nile virus	NA		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_7423	N-Propylcyclohexyl-DNJ	NA	NA	West Nile virus	NA		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_7424	N-Butylcyclohexyl-DNJ	NA	NA	West Nile virus	NA		Yield reduction assay	Decrease (50 %)	NA	17354651
DrugRepV_7425	Castanospermine	Antiviral	NA	West Nile virus	NA		Yield reduction assay	Decrease (50 %)	Experimental	17354651
DrugRepV_7426	6-Azauridine	NA	Cancer	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7427	6-Azauridine	NA	Cancer	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7428	6-Azauridine triacetate	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7429	6-Azauridine triacetate	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7430	Pyrazofurin	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7431	Pyrazofurin	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7432	2-Thio-6-azauridine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7433	2-Thio-6-azauridine	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7434	6-Azauridine	NA	Cancer	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7435	6-Azauridine	NA	Cancer	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7436	6-Azauridine triacetate	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7437	6-Azauridine triacetate	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7438	Pyrazofurin	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7439	Pyrazofurin	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7440	2-Thio-6-azauridine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7441	2-Thio-6-azauridine	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7442	3-Deazaguanosine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7443	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	West Nile virus	New York		Visual assay	Decrease (50 %)	Approved	12076755
DrugRepV_7444	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	Approved	12076755
DrugRepV_7445	Ribamidine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7446	Ribamidine	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7447	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	New York		Visual assay	Decrease (50 %)	Approved	12076755
DrugRepV_7448	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	Approved	12076755
DrugRepV_7449	Selenazofurin	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7450	Selenazofurin	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7451	Tiazofurin	Antineoplastic and Immunomodulating Agents	Cancer	West Nile virus	New York		Visual assay	Decrease (50 %)	Experimental	12076755
DrugRepV_7452	beta-Methylene TAD	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7453	beta-Methylene TAD	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7454	3-Deazaguanosine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7455	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	West Nile virus	New York		NR assay	Decrease (50 %)	Approved	12076755
DrugRepV_7456	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	Approved	12076755
DrugRepV_7457	Ribamidine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7458	Ribamidine	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7459	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	New York		NR assay	Decrease (50 %)	Approved	12076755
DrugRepV_7460	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	Approved	12076755
DrugRepV_7461	Selenazofurin	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7462	Selenazofurin	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7463	Tiazofurin	Antineoplastic and Immunomodulating Agents	Cancer	West Nile virus	New York		NR assay	Decrease (50 %)	Experimental	12076755
DrugRepV_7464	beta-Methylene TAD	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7465	beta-Methylene TAD	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7466	3-Deazauridine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7467	3-Deazauridine	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7468	Cyclopentenylcytosine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7469	Cyclopentenylcytosine	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7470	3-Deazauridine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7471	3-Deazauridine	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7472	Cyclopentenylcytosine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7473	Cyclopentenylcytosine	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7474	Hypericin	Anticancer	Cutaneous T-cell Lymphoma	West Nile virus	New York		Visual assay	Decrease (50 %)	Investigational	12076755
DrugRepV_7475	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	West Nile virus	New York		Visual assay	Decrease (50 %)	Investigational	12076755
DrugRepV_7476	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	Investigational	12076755
DrugRepV_7477	Hypericin	Anticancer	Cutaneous T-cell Lymphoma	West Nile virus	New York		NR assay	Decrease (50 %)	Investigational	12076755
DrugRepV_7478	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	West Nile virus	New York		NR assay	Decrease (50 %)	Investigational	12076755
DrugRepV_7479	Suramin	Antiparasitic products, Insectisides and Repellents	Sleeping sickness | Onchocerciasis	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	Investigational	12076755
DrugRepV_7480	5-fluorouridine	NA	Cancer	West Nile virus	New York		Visual assay	Decrease (50 %)	Experimental	12076755
DrugRepV_7481	5-fluorouridine	NA	Cancer	West Nile virus	New York		NR assay	Decrease (50 %)	Experimental	12076755
DrugRepV_7482	(S )-DHPA	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7483	(S )-DHPA	NA	NA	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7484	3-Deazaneplanocin A	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7485	(S )-DHPA	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7486	(S )-DHPA	NA	NA	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7487	3-Deazaneplanocin A	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7488	6-Bromotoyocamycin	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7489	Formycin B	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	Experimental	12076755
DrugRepV_7490	6-Bromotoyocamycin	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7491	Formycin B	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	Experimental	12076755
DrugRepV_7492	2-Thiouracil	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7493	5-Azacytidine	Antineoplastic and Immunomodulating Agents	Anemia	West Nile virus	New York		Visual assay	Decrease (50 %)	Approved	12076755
DrugRepV_7494	Cyclopentyluracil	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7495	Dihydro-5-azacytidine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7496	Uridine 2,3-dialdehyde	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7497	2-Thiouracil	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7498	5-Azacytidine	Antineoplastic and Immunomodulating Agents	Anemia	West Nile virus	New York		NR assay	Decrease (50 %)	Approved	12076755
DrugRepV_7499	Cyclopentyluracil	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7500	Dihydro-5-azacytidine	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7501	Uridine 2,3-dialdehyde	NA	NA	West Nile virus	New York		NR assay	Decrease (50 %)	NA	12076755
DrugRepV_7502	6-Azauridine	NA	Cancer	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7503	6-Azauridine triacetate	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7504	Pyrazofurin	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7505	Selenazofurin	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7506	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	New York		Visual assay	Decrease (50 %)	Approved	12076755
DrugRepV_7507	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	West Nile virus	New York		Visual assay	Decrease (50 %)	Approved	12076755
DrugRepV_7508	Cyclopentenylcytosine	NA	NA	West Nile virus	New York		Visual assay	Decrease (50 %)	NA	12076755
DrugRepV_7509	6-Azauridine	NA	Cancer	West Nile virus	New York		Virus yield reduction assay	Decrease (90 %)	NA	12076755
DrugRepV_7510	Pyrazofurin	NA	NA	West Nile virus	New York		Virus yield reduction assay	Decrease (90 %)	NA	12076755
DrugRepV_7511	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	New York		Virus yield reduction assay	Decrease (90 %)	Approved	12076755
DrugRepV_7512	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	West Nile virus	New York		Virus yield reduction assay	Decrease (90 %)	Approved	12076755
DrugRepV_7513	Cyclopentenylcytosine	NA	NA	West Nile virus	New York		Virus yield reduction assay	Decrease (90 %)	NA	12076755
DrugRepV_7515	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	West Nile virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7516	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Yellow fever virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_7897	Ouabain	Cardiovascular agents	Atrial fibrillation and flutter | Heart failure	Japanese encephalitis virus	NA		NA	Decrease (50 %)	Approved	31871089
DrugRepV_7898	Digoxin	Cardiovascular agents	Arrhythmia	Japanese encephalitis virus	NA		NA	Decrease (50 %)	Approved	31871089
DrugRepV_7899	Lycorine	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7900	Cephalotaxlen	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7901	Schisandrin B	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7902	Procyanidin	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7903	Emodin	NA	Polycystic Kidney	Japanese encephalitis virus	NA		NA	Decrease (50 %)	Investigational	31871089
DrugRepV_7904	Schisandrin B	NA	NA	Japanese encephalitis virus	NA		NA	Decrease (50 %)	NA	31871089
DrugRepV_7905	RK-33	NA	NA	Dengue virus	New Guinea C		Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_7906	RK-33	NA	NA	Zika virus	Asian/Cook Islands/2014	NA	Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_7907	RK-33	NA	NA	West Nile virus	Kunjin		Plaque assay	Decrease (50 %)	NA	31936642
DrugRepV_8275	Digoxin	Cardiovascular agents	Arrhythmia	Zika virus	NA	NA	qRT-PCR	Decrease (50 %)	Approved	32669655
DrugRepV_8276	Ouabain	Cardiovascular agents	Atrial fibrillation and flutter | Heart failure	Zika virus	NA	NA	qRT-PCR	Decrease (50 %)	Approved	32669655
DrugRepV_8277	Asunaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	MTT assay	Decrease (50 %)	Phase III	32488021
DrugRepV_8278	Simeprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	MTT assay	Decrease (50 %)	Approved	32488021
DrugRepV_8282	1-(2-fluorophenyl)-3-(4-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8283	1-(3-fluorophenyl)-3-(4-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8284	1-(4-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl)-3-(3-fluorophenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8285	1-(3-fluorophenyl)-3-(4-(4-(3-oxobutyl)-1H-1,2,3-triazol-1-yl)phenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8286	1-(4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl)-3-(3-fluorophenyl)urea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8287	N-(2-(3-(4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl)ureido)phenyl)methanesulfonamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8288	1-(4-(4-isopentyl-1H-1,2,3-triazol-1-yl)phenyl)-3-o-tolylurea	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8289	1-(4-(4-hexyl-1H-1,2,3-triazol-1-yl)phenyl)-3-(2-(trifluoromethyl)phenyl)urea)	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8290	3-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)-N-(2-morpholinophenyl)benzenesulfonamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8291	ethyl 3-((3-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl)sulfonamido)benzoate	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8292	3-((3-(4-(ethoxymethyl)-1H-1,2,3-triazol-1-yl)phenyl)sulfonamido)benzoic acid	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8293	3-(4-butyl-1H-1,2,3-triazol-1-yl)-N-(2-(methylsulfonamido)phenyl)benzenesulfonamide	NA	NA	Dengue virus	NA		NA	Decrease (50 %)	NA	32435411
DrugRepV_8299	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	Paraiba_01	NA	Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8300	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MR-766	NA	Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8301	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8302	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	13-104		Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8303	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	Paraiba_01	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8304	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MR-766	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8305	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8306	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	13-104		Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8307	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Paraiba_01	NA	Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8308	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MR-766	NA	Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8309	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8310	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	13-104		Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8451	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Yellow fever virus	YFV17D		NA	Decrease (50 %)	Approved	30699122
DrugRepV_8456	Berberine Chloride	NA	NA	Zika virus	NA	NA	NA	Decrease (50 %)	NA	29844387
DrugRepV_8458	Emodin	NA	Polycystic Kidney	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Investigational	30641880